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Chapter 1
Introduction and outline of the thesis
Corine H. GeurtsvanKessel and Bart N. Lambrecht
Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
Department of Virology, Erasmus University Medical Centre, Rotterdam, The Netherlands
Laboratory of Immunoregulation and Mucosal Immunology, University Hospital Gent, Gent, Belgium
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8Influenza virus infection
 
Influenza disease, often referred to as “flu”, is caused by the influenza viruses. 
These viruses are most only responsible for epidemics of variable severity almost 
every winter (1-3) but occasionally cause major pandemic outbreaks. The term 
“influenza” has been derived from the Italian astrologers in the mid-1300s, who 
thought the flu was due to the “influence” of the heavenly bodies. Yet, the aetiology 
of the disease and the explanation for it’s peculiar behavior remained elusive. At 
the turn of the 19th century, influenza was thought to be due to a bacterial infection 
with Haemophilus influenzae. It was not until 1931 that Richard Shope showed 
that the causative agent was a virus (4). A few years later, Smith and co-workers for 
the first time isolated an influenza virus from humans with respiratory illness (5).
 The burden of influenza virus for the society, not only from a clinical 
but also from an economic perspective, is often underestimated (6). This relates 
particularly to the recurring annual winter epidemics. Fortunately, since the virus 
was first discovered, efficient means to contain the infection have been developed. 
Vaccination is the primary method for the prevention of influenza. However, due 
to the continuous genetic and antigenic variation that influenza viruses undergo, 
a constant global surveillance is required to identify and select new variants with 
epidemic or pandemic potential. Therefore, improvement of vaccination strategies 
against epidemic influenza and development of effective vaccines against potential 
pandemic viruses are a public health priority. New strategies for influenza vaccines 
include altering the dose, site or method of delivery of inactivated vaccines, the use 
of adjuvants or immunomodulators to enhance immune responses, or targeting of 
viral proteins that may promote broader, cross protective responses (7).
 In order to develop novel intervention strategies, profound knowledge 
of both the influenza virus and the immunological response of the host to the 
virus are essential. Influenza viruses belong to the family of Orthomyxoviridae, 
and are enveloped, single stranded negative-sense RNA viruses with a segmented 
genome. There are three types of influenza viruses (A, B and C), which can be 
distinguished on the basis of antigenic characteristics of the internal proteins. The 
8 RNA segments of influenza viruses A and B and seven segments of influenza 
C are independently encapsidated by the viral nucleoprotein (NP) and associated 
with polymerase proteins to form a ribonucleoprotein complex (RNP). The RNP 
complexes are located inside a shell of matrix protein (M1), which lines the viral 
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1envelope and provides rigidity to the viral structure. The envelope of influenza 
viruses is derived from the plasma membrane of the host cell in which the virus 
has replicated. Influenza A and B viruses have two surface glycoproteins, the 
hemagglutinin (HA) and neuraminidase (NA), which form a typical layer of spikes 
radiating outward from the lipid envelope and that respectively mediate cell entry 
and release of virus particles. Influenza C virus exhibits a single multi-functional 
glycoprotein. The matrix protein M2 functions as an ion channel and together with 
HA and NA interacts with the internal M1 protein (figure 1).
 In the initial phase of influenza virus infection, the HA on the influenza 
virus envelope binds to sialic acid-containing receptors on the host cells (figure 
2 and ref 8,9). Upon binding, the virus particle becomes endocytosed by the cell 
and internalized. Human influenza A viruses preferentially bind sialic acid residues 
attached to galactose by an α2,6 linkage, whereas avian influenza viruses prefer 
sialic acid attached by an α2,3 linkage (10, 11).The low pH in the endosome causes 
an acidification of the interior of the virus resulting in a dissociation of the M1 from 
the RNP, allowing the release of RNP. The acid pH also triggers a structural change 
in the HA, which induces fusion of the viral envelope with the membrane of the 
endosome, resulting in uncoating and entry of the viral RNP into the cytoplasm and 
Figure 1: Schematic representation of an influenza A virus particle.
Adapted from Smolinski et al., Microbial Threats to Health: The Threat of Pandemic Influenza (ISBN:0-0309-09717-7) 
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subsequent transport of the RNPs into the nucleus. In the nucleus, the viral RNA is 
transcribed into messenger RNA for the translation of viral proteins and copy RNA 
that serves as a template for viral RNA synthesis. The newly synthesized viral RNA 
forms RNPs with the newly translated polymerase proteins and NP, which are then 
transported to the cell membrane. Together with the other structural proteins that 
have assembled there, the RNPs are packaged into new virions, which bud from the 
cell surface. The efficient release of the viral particles is facilitated by the NA surface 
glycoprotein that cleaves sialic acid residues from the cell surface thereby allowing 
virion detachment from the cell and preventing virion aggregation. The enzym 
responsible for cleavage of the HA precursor molecule is a trypsin-like protease, 
which is released from cells in the respiratory epithelium. Due to the limited 
distribution of this enzyme, influenza virus infection is normally restricted to the 
respiratory tract. Progeny virus can infect other cells or can be transmitted to new 
individuals. The entire process of viral infection seriously disrupts the normal cell 
physiology, eventually leading to cell death. However, this cytopathic effect does 
not occur until the cell has produced many thousands of new virus particles.
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Figure 2: Schematic representation of the replication cycle of influenza A virus. 
Adapted from http://www.reactome.org/figures/influenza_life_cycle_overview
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1 Since influenza A viruses are responsible for all pandemic and most epidemic 
outbreaks, studies described in this these are restricted to influenza A virus. The 
clinical outcome of influenza A virus infection causing upper and lower respiratory 
tract infection, is mainly determined by the way in which the innate and adaptive 
immune system initially recognizes and deals with the replicating virus (12-16). The 
innate immune response is a rapid response, generally regarded as predetermined 
and directed towards a broad range of pathogens. This rapid innate response leads 
to high-level production of type I interferons by infected lung epithelial cells, 
alveolar macrophages and natural interferon producing cells (also known as pre-
pDCs).  Innate chemokines promote the recruitment of neutrophils, natural killer 
(NK) cells and dendritic cells (DCs) (17, 18). Following this innate response, the 
adaptive immune response will be activated. This is an acquired response, relying 
on specific viral recognition and reactivity. The adaptive response can be divided 
into a humoral antibody-mediated response and a cellular T-lymphocyte-mediated 
response. Neutralizing anibodies are secreted by B-lymphocytes, and bind to virus 
particles and infected cells that present virus proteins on their membranes, thereby 
blocking virus-entry into host cells and promoting phagocytosis by macrophages 
(19, 20). The T-lymphocyte mediated response consists of two distinct populations 
of CD3+ T cells, the CD8+ cytotoxic T-lymphocytes (CTL) and the CD4+ T helper 
lymphocytes. Upon recognition of antigen presented by DCs, naïve CD8+ T 
lymphocytes differentiate and expand clonally into mature activated effector cells, 
which subsequently migrate from the lymphe nodes or spleen into blood circulation 
and intercellular fluids. These CTL act via secretory and cell contact-dependent 
pathways by T cell receptor (TCR) contact. The TCR recognizes infected cells via 
foreign peptides presented by MHC class-I molecules. Although virus-specific 
CTL cannot prevent infection of host cell, like virus neutralizing antibodies, they 
promote viral clearance and accelerate recovery from infection by eliminating 
virus infected cells, thereby limiting the production of progeny virus (21-23). The 
CD4+ T helper lymphocytes have an immune response promoting and regulating 
function. By secreting cytokines and interferons they facilitate proliferation and 
differentiation of CTL and B-lymphocytes.
 In both innate and adaptive immune responses DCs have been described to 
either induce or mediate the response and thereby have a function beyond just CTL 
activation. With the studies described in this thesis we have focussed on the role of 
the different lung DC subsets during influenza virus infection. 
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Introducing DC heterogeneity
Dendritic cells have been described by Steinman 25 years ago, as a population of 
cells with antigen presenting capacity found in the spleen and lymph nodes of mice. 
It was initially thought that these cells represented a unique population of cells that 
could be isolated based on physical characteristics (low density in comparison with 
other cells, formation of long dendrites), expression of cell surface molecules like 
the integrin CD11c, and the functional characteristic of being able to stimulate 
naïve T cell proliferation(18). In the decades following initial discovery, there has 
been an explosion of papers describing the precise surface phenotype of DCs in 
various tissues, the ways in which these cells can be generated in vitro, as well as the 
various ways in which these cells contribute to disease pathogenesis.  This has lead 
to a seemingly endless list of papers describing the surface marker expression of 
DCs. Only recently there have been attempts to try to streamline this information 
into a general paradigm on how we can subdivide DC subsets that is comprehensive 
to a novice to the field of DC biology (24, 25). At least in murine central lymphoid 
organs, there is a broad division into conventional DCs (cDCs) and plasmacytoid 
DCs (pDCs). The interested reader is referred to specialized literature on this 
topic, but broadly speaking, there are at least 3 subsets of CD11chi cDCs (CD8α+, 
CD4+ and CD8α-CD4-) and 1 population of CD11cint pDC in the spleen, whereas 
in the skin draining lymph nodes, there are at least 5 subsets of cells, the extra one 
representing skin derived Langerhans cells (26). In contrast to cDCs, mouse pDCs 
uniquely express the endocytic receptor Siglec-H (recognized by the moAb 440c)
(27), the bone-marrow stromal antigen-1 (the latter is recognized by the monoclonal 
antibodies mPDCA-1 or 120G8) and the B cell marker B220.  Plasmacytoid DCs 
also express high levels of L-selectin and Ly6C, recognized by the Gr1 antibody 
(anti-Ly6C/Ly6G) which also marks granulocytes and subsets of monocytes (28). 
In mice both cDC and pDC subsets can express MHCII, CD80, CD86, CD40 and 
OX40L and should therefore both be capable of antigen presentation to T cells(29). 
It is however clear now that different subsets of DCs perform different tasks, 
some subsets of cDCs being better at crosspresentation of antigen to CD8 cells 
on MHCI molecules and others better at presenting endocytosed antigen to CD4 
T cells on MHCII molecules (30) (31) (32) (33). These differences might relate 
to intrinsic differences between DC subsets in expression of endocytic receptors 
that target their cargo to well defined intracellular processing compartments (30), 
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1or to intrinsic differences in the expression levels of MHC processing machinery 
proteins in various subsets(32).
Heterogeneity of mouse lung DC subsets
The subject of lung DC heterogeneity has been appreciated from the very starting 
point when lung DCs were being unravelled in the mouse and rat, and it has since 
become clear that different DC subsets exert different functions (34-36). Here, we 
will mainly discuss the DC subsets of murine lung (see figure 3), as this  species is 
the most studied in various animal models of disease.  
 In mouse lungs, DCs are found in most tissue compartments, including 
the large extrathoracic and intrathoracic conducting airways, the lung parenchyma 
accessible by lung tissue digestion, the alveolar compartment accessible by 
bronchoalveolar lavage, the pleura, the perivascular space, as well marginating 
inside the pulmonary lung vessels (37, 38). Although the lung is not a central 
Figure 3. Dendritic cell subsets in the airways.
The conducting airways are composed of airway epithelial cells, which act as a molecular sieve excluding inhaled 
antigens and pathogens. Two populations of resident DCs are located underneath the epithelial layer. Mucosal 
CD11b- DCs are situated in the basolateral space, and can extend their processes between epithelial cells directly 
into the airway lumen. This “periscope” function provides a mechanism for continuous immune surveillance of the 
airway luminal surface. CD11b+ resident DCs and pDCs are located underneath the basal membrane. In the alveolar 
space alveolar DCs and macrophages are located. Upon inflammatory conditions like respiratory viral infections, an 
activated population of inflammatory DCs expressing CD11b and Ly6C can be found in the lung tissue as well as the 
interferon producing killer DCs (IKDC).
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lymphoid organ, most recent papers now also broadly subdivide lung DCs into cDCs 
and pDCs (13, 14, 39), while the denominators ‘lymphoid’ and ‘myeloid’ are best 
abandoned. All cDCs in the mouse express high levels of the integrin CD11c, and 
these cells can be further subdivided into CD11b+ or CD11b- (40-42). The trachea 
and large conducting airways have a well-developed network of intraepithelial 
DCs, even in steady-state conditions (43). These cells resemble skin Langerhans 
cells, and have been shown to express langerin and CD103 but not CD11b (14,40). 
In the submucosa of the conducting airways, CD103-CD11b+CD11c+ cDCs can be 
found, and these cells are particularly suited for priming and restimulating effector 
CD4+ T cells in the lung (44, 45). 
 The lung interstitium, which is accessible by enzymatic digestion, also 
contains CD11b+ and CD11b- cDCs that access the alveolar lumen (41, 42,46). It 
should be noted that this population of cells also comprises DCs that line the small 
intrapulmonary bronchioles, as well as those that line the vessel walls. Intravascular 
DCs are also highly enriched in the lung capillaries and most authors studying lung 
DCs try to eliminate this subset prior to enzymatic digestion of the lung by rinsing 
the right heart circulation via the pulmonary artery (37). In the nearby alveolar 
lumen, autofluorescent CD11bloCD11chi alveolar macrophages and alveolar CD11bhi 
CD11chi DCs can be found. One needs to be particularly carefull not to confuse 
CD11bloCD11chi alveolar macrophages with CD11blo cDCs, as macrophages can 
profoundly suppress functional characteristics of lung DCs (47). Therefore, 
protocols that solely rely on purification of lung DCs by CD11c magnetic beads 
are confounded. We and others commonly use the characteristic autofluorescence 
of alveolar macrophages to discriminate the two when performing flow-cytometry 
based sorting experiments on lung DCs (48-50). Lung plasmacytoid DCs in steady 
state only represent a minor population of CD11cint cells that also express bone 
marrow stromal antigen-1 (recognized by moAb 120G8 and mPDCA-1), Siglec-H, 
Ly6C, and B220 (51-53) and can be found in large conducting airways and lung 
interstitium (41). 
 Under inflammatory conditions, things become even more complicated. 
Inflammatory stimuli like TLR ligands, virus or bacterial infection, or environmental 
exposure to pollutants like cigarette smoke or ozone trigger the production of 
chemokines that attrack monocytes and other inflammatory cells to the lungs in a 
CCR2 and/or CCR5 dependent manner (13, 14, 54-56).  These CCR2+ monocytes 
can be the immediate precursors to so-called inflammatory CD11bhi CD11chi DCs, 
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1that still express high levels of Ly6C as a remnant of their monocytic descent (56). 
Under some conditions, these DCs have been called TIP-DCs for TNF-producing 
iNOS-producing DCs (57), and in some conditions lung iDCs have been shown 
to produce iNOS(56). These inflammatory DCs closely resemble the steady state 
CD11b+ cDCs and therefore some authors have suggested that cDCs ‘mature’ or alter 
phenotype or even proliferate under inflammatory conditions (39,58). A second 
confounder when studying DC subsets under inflammatory conditions, particularly 
when high levels of IFNα are being produced during viral infection, is the fact 
that the bone marrow stromal Ag-1 and B220 is also induced on inflammatory 
type CD11b+ DCs, considerably confounding the discrimination beween pDCs 
and cDCs if the characteristics of size and expression of Siglec-H is not taken into 
account (GeurtsvanKessel, unpublished).  This has led to the misinterpretation that 
pDCs can differentiate to cDCs and vice versa, or that pDCs become myeloid-like 
(13, 59, 60). Finally, a recently described population of NK cells with high MHCII 
and intermediate CD11c was discovered and named IKDC (61). We have recently 
observed that this subset is also found inside the lungs following inflammatory 
stimuli (see chapter 3).  As it has a CD11cdim, B220dim, MHCIIdim CD11b-, CD19-, 
CD3- phenotype, it is easy to confuse this subset with pDCs if one does not use 
Siglec-H or a specific NK marker like NK1.1 or NKp46  to discriminate the two.
Origin of lung DC subsets
Studies performed by Holt’s group in the rat and mouse have suggested that the 
turnover rate of tracheal DCs is in the order of 2-3 days, whereas interstitial lung 
DCs are much more long lived (42, 62). Both studies suggested repopulation of 
DC subsets by a circulating precursor cell derived from the bone-marrow.  Recent 
studies performed to elaborate on the origin of the two main cDC populations, 
CD11b-CD103+ DCs and CD11b+CD103- DCs, have demonstrated an origin from 
distinct circulating monocyte precursors, even in steady state conditions(63). Two 
distinct monocyte populations have been described in the mouse. A population 
of Ly-6ChighCCR2high (Gr-1high) monocytes are characterized as the more classical 
monocytes that readily emigrate to sites of ongoing inflammation (64, 65), whereas 
Ly-6ClowCCR2low (Gr-1low) monocytes expressing high levels of CX3CR1 do not 
robustly emigrate to many tissues, but do migrate well to lung even in absence 
of inflammation(64). Randolph and colleagues revealed that CD103+CD11b- 
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DCs preferentially derived from CCR2hi monocytes, whereas CD11bhigh cDC 
preferentially arise from CCR2lo monocytes, thus lending proof to the concept 
that subsets of monocytes recruited to the same tissue undergo differential 
differentiation pathways within the DC lineage. Others working on lung DC 
ontogeny have however refuted this idea (56, 66). Studies have been performed 
in which a spleen-resident precursor of steady state cDCs was identified. These 
cells were not monocytes but could nevertheless generate DCs with relatively high 
efficiency (67, 68) and therefore were named pre-DC. The equivalent of these pre-
DCs were also found in BM and other lymphoid organs (67) (69), implicating that 
DCs can arise from a precursor that is resident within the lymphoid organ itself and 
was preprogrammed in the bone marrow as a macrophage-DC precursor (MDP)
Figure 4. Antigen uptake and presentation by dendritic cells in the airways. 
Dendritic cells are released from the bloodstream and give rise to CD11b- cDCs (Ly6Chi) or CD11b+ cDCs (Ly6Clo). 
CD11b- DCs can directly recognize viral particles in the airway lumen by sensing with their processes. In contrast, 
CD11b+ DCs and pDCs are located underneath the basal membrane and do not pass the epithelial barrier with 
their processes but pickup antigen which has passed the basal membrane. The different DC populations migrate to 
the lymphe nodes by afferent lymphatics and exert their specific functions. Whereas the migrated CD11b- DCs can 
present their antigen to both CD4 and CD8 T cells, the resident lymphe node population of CD8α+ DCs only presents 
to CD8 T cells. These resident DCs might obtain their antigen from the migrated CD11b+ DCs or pDCs which present 
antigen less efficiently themselves.
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1(24). It remains to be determined whether a MDP or pre-DC population can also 
be found in the lungs. 
Function of lung DC subsets
The general paradigm of DC function states that DCs reside in an immature state in 
the periphery of the lung, where they sample the inhaled air for incoming antigen (see 
figure 4). Upon triggering of pattern recognition receptors like Toll like receptors, 
the cells migrate via the afferent lymphatics to the T cell area where they select 
and activate naïve T cells and differentiate them into either tolerizing Treg cells or 
cytokine secreting T effector cells. Considerable progress has recently been made 
to suggest that different lung DC subsets perform various aspects of this paradigm 
differentially.  The conducting airways are lined with a mucociliary blanket and 
composed of airway epithelial cells that are connected by tight junctions and zonula 
adherens. The epithelial-cell layer acts as a molecular sieve that excludes inhaled 
antigens and pathogens based on their molecular weight. Intraepithelial CD11b- 
DCs are situated in the basolateral space, only separated from the inhaled air by 
the epithelium tight-junction barrier. In the airways, as well as in the gut, DCs can 
extend their processes between epithelial cells directly into the airway lumen. This 
‘periscope’ function is constitutively active in the airway mucosal DC population, 
providing a mechanism for continuous immune surveillance of the airway luminal 
surface (70-72). At least in mouse lungs, intraepithelial CD103+ DCs express 
the tight junction proteins claudin-1, claudin-7 and zonula-2, which form tight 
junctions with airway epithelial cells, thereby explaining how DCs can sample the 
content of the airway lumen while keeping the epithelium barrier function intact 
(40). Following sampling of airway luminal contents, there is transport of antigen 
to the mediastinal nodes. When large fluorescently labelled antigens are injected 
into the lungs of mice, different subsets of DCs become antigen positive in the 
draining mediastinal lymph nodes as early as 12 hours after antigen administration 
(41, 50). 
 There are several mechanisms by which the inhaled antigen could reach 
the lymph nodes (for more detailed discussion on this topic see (41). Most of the 
experimental evidence suggest that antigen is taken up by DCs in the lung that then 
migrate in a CC-chemokine receptor 7 (CCR7)- and CCR8-dependent manner to 
the draining mediastinal lymph nodes, which is analogous to the directed migration 
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of skin DCs (41, 73). It is still unclear exactly where and by which DC subset the 
inhaled antigen is sampled from the airways, as both mucosal cDCs that line the 
conducting airways and cDCs that are situated in the alveolar wall are exposed to 
inhaled antigens, and have the potential to migrate to the lymph nodes (53,41,46, 
74). Similarly, only one paper briefly showed that also pDCs might migrate from 
the periphery of the lung to the mediastinal node during viral infection (39).
 In addition to cell-mediated transport, the tight junction barrier might act 
as a molecular sieve that allows the passive leakage of smaller antigens into the 
afferent lymph vessels.  Antigen sampled in such a passive manner might gain access 
to resident DCs in the draining lymph node, such as CD8α+ DCs or plasmacytoid 
DCs (pDCs)(53).  Although there is indeed evidence for the passive transfer of 
fluorescently labelled molecules to the mediastinal lymph nodes, no studies to date 
have demonstrated that antigen that reaches the resident DCs in this way can result 
in the induction of T-cell division (41, 50, 53). The final and most important aspect 
of DC function is the capacity of these cells to program T cell responses.  Regarding 
functional differences in DC populations from airway mucosa versus parenchymal 
tissue von Garnier et al (41, 42) demonstrated that airway mucosal cDC were more 
endocytic and presented peptide to naive CD4+ T cells more efficiently than their 
lung counterparts. However, only DCs matured in vitro or after migration to lymphe 
nodes in vivo could present whole protein to T cells and induce T cell activation. 
This finding indicates a mechanism in which DC function is regulated at the level 
of protein processing, rather than peptide loading.
 It has been shown that inhalation of harmless antigen leads to T cell 
unresponsiveness in process that is accompanied by DC-driven T cell proliferation 
and formation of Tregs (75, 76). Whether this is a function of particular lung DC 
subsets still remains a matter of debate. We and others have shown that inhalation 
tolerance clearly depends on the presence of pDCs that take up inhaled harmless 
antigen and lead to formation of Treg cells (51-53).  Others have shown that this 
process also required cDCs that depend on CCR7 for migration to the mediastinal 
nodes (45, 73). In this regard, del Rio suggested that CD103+CD11b- cDCs 
were specialized in crosstolerizing CD8 responses, whereas CD11bhi cDCs were 
specialized in tolerizing CD4 T cell responses to inhaled harmless antigen. 
 Antigen encountered in the lung by DCs as part of a respiratory pathogen, 
or model protein antigens administered together with different TLR ligands can 
induce different types of effector T helper responses (77). A detailed description on 
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1how T cell effector responses are programmed is beyond the scope of this article, but 
suffice it to say that cytokines and costimulatory molecules are the most important 
factors that will determine the outcome of a pulmonary immune response driven 
by lung DCs.  Stumbles (78) and Dodge (79) have demonstrated that lung DCs 
are biased towards inducing Th2 responses, through production of IL-6, but it is 
not yet clear whether this property could be linked to the distinct properties of a 
particular cDC subset in a particular location.  In any case, depending on the type 
of inflammatory stimulus, lung DCs can induce CTL responses, and Th1, Th2 or 
Th17 Th effector responses.  In the coming chapters we will illustrate how a better 
understanding of DC subsets of the lungs has provided novel insights into how 
effector T cell responses are induced in the lung.
Outline of the thesis
As this introduction has pointed out, the emerging field of DC research has 
recently focused on seemingly antagonistic ideas on the role of DC subsets. 
Functional specialization of DC subsets, plasticity (multitasking) and crosstalk 
between functionally distinct DC subsets has been described, but the situation in 
inflammatory conditions remained to be unraveled. With the studies described 
in this thesis we aimed to unravel the complexity of the DC system during 
influenza virus infection, and provide a conceptual framework to understand 
how cooperation between functionally distinct DC subsets can shape immunity 
and immunological memory to pathogens. To start, chapter 2 gives an extensive 
description of the various DC subsets in the airways of influenza-infected mice 
by using 10-color flow cytometry. Migration patterns of these subsets and their 
antigen presenting capacity were demonstrated. To study distinct functions during 
infection, we depleted specific DC subsets by using either transgenic mouse models 
or antibody depletion. In chapter 3 we demonstrate a recently described DC subset 
in the lungs of influenza virus infected mice, called interferon-killer DC (IKDC). 
Both antigen presenting capacity and killer potential was demonstrated in this cell 
population and they thereby resembled conventional NK cells. Chapter 4 shows a 
previously unappreciated role of inflammatory DCs (iDC) after influenza virus has 
been cleared from the lungs. iDCs controlled the maintenance of local lymphoid 
structures in the lung following influenza virus infection, the so called inducible 
bronchus associated lymphoid tissue (iBALT). IBALT following influenza virus 
20
infection did not only contribute to local immunity, but was also a source of virus 
specific plasma cells migrating to the bone marrow. In chapter 5 we elaborate on 
antigen presenting capacities of bone-marrow cultured DC subsets during in vitro 
influenza virus infection and demonstrated differences in antigen processing. 
Finally, the findings presented in this thesis are evaluated in a summarizing 
discussion (chapter 6). 
21Introduction and outine of the thesis
Ch
ap
te
r 
1References
Beveridge, W.I. 1991. The chronicle of influenza epidemics. 1. Hist Philos Life Sci 13:223-234.
Ghendon, Y. 1994. Introduction to pandemic influenza through history. 2. Eur J Epidemiol 10:451-453.
Patterson, K.D. 1985. Pandemic and epidemic influenza, 1830-1848. 3. Soc Sci Med 21:571-580.
Shope, R.E. 1931. The Etiology of Swine Influenza. 4. Science 73:214-215.
Smith W., A.C., Laidlaw P. 1933. A virus obtained from influenza patients. 5. Lancet 2:66-68.
Nicholson, K.G., J.M. Wood, and M. Zambon. 2003. Influenza. 6. Lancet 362:1733-1745.
Katz JM, G.S., Sambhara S. 2006. Influenza vaccines: current and future strategies. 7. Influenza Virology- Current 
Topics 203-228.
Weis, W., J.H. Brown, S. Cusack, J.C. Paulson, J.J. Skehel, and D.C. Wiley. 1988. Structure of the influenza virus 8. 
haemagglutinin complexed with its receptor, sialic acid. Nature 333:426-431.
Wiley, D.C., and J.J. Skehel. 1987. The structure and function of the hemagglutinin membrane glycoprotein of 9. 
influenza virus. Annu Rev Biochem 56:365-394.
Connor, R.J., Y. Kawaoka, R.G. Webster, and J.C. Paulson. 1994. Receptor specificity in human, avian, and 10. 
equine H2 and H3 influenza virus isolates. Virology 205:17-23.
van Riel, D., V.J. Munster, E. de Wit, G.F. Rimmelzwaan, R.A. Fouchier, A.D. Osterhaus, and T. Kuiken. 2006. 11. 
H5N1 Virus Attachment to Lower Respiratory Tract. Science 312:399.
Eichelberger, M., W. Allan, M. Zijlstra, R. Jaenisch, and P.C. Doherty. 1991. Clearance of influenza virus 12. 
respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. The 
Journal of experimental medicine 174:875-880.
McGill, J., N. Van Rooijen, and K.L. Legge. 2008. Protective influenza-specific CD8 T cell responses require 13. 
interactions with dendritic cells in the lungs. The Journal of experimental medicine 205:1635-1646.
GeurtsvanKessel, C.H., M.A. Willart, L.S. van Rijt, F. Muskens, M. Kool, C. Baas, K. Thielemans, C. Bennett, 14. 
B.E. Clausen, H.C. Hoogsteden, A.D. Osterhaus, G.F. Rimmelzwaan, and B.N. Lambrecht. 2008. Clearance of 
influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. 
The Journal of experimental medicine 205:1621-1634.
Pichlmair, A., O. Schulz, C.P. Tan, T.I. Naslund, P. Liljestrom, F. Weber, and C. Reis e Sousa. 2006. RIG-I-15. 
mediated antiviral responses to single-stranded RNA bearing 5’-phosphates. Science 314:997-1001.
Belz, G.T., N.S. Wilson, C.M. Smith, A.M. Mount, F.R. Carbone, and W.R. Heath. 2006. Bone marrow-derived 16. 
cells expand memory CD8+ T cells in response to viral infections of the lung and skin. European journal of 
immunology 36:327-335.
Kumagai, Y., O. Takeuchi, H. Kato, H. Kumar, K. Matsui, E. Morii, K. Aozasa, T. Kawai, and S. Akira. 2007. 17. 
Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. 
Immunity 27:240-252.
Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. 18. Nature 392:245-252.
Yarchoan, R., B.R. Murphy, W. Strober, H.S. Schneider, and D.L. Nelson. 1981. Specific anti-influenza virus 19. 
antibody production in vitro by human peripheral blood mononuclear cells. J Immunol 127:2588-2594.
Murphy, B.R., J.A. Kasel, and R.M. Chanock. 1972. Association of serum anti-neuraminidase antibody with 20. 
resistance to influenza in man. The New England journal of medicine 286:1329-1332.
Bender, B.S., T. Croghan, L. Zhang, and P.A. Small, Jr. 1992. Transgenic mice lacking class I major 21. 
histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after 
influenza virus challenge. The Journal of experimental medicine 175:1143-1145.
McMichael, A.J., F.M. Gotch, G.R. Noble, and P.A. Beare. 1983. Cytotoxic T-cell immunity to influenza. 22. The 
New England journal of medicine 309:13-17.
McMichael, A. 1994. Cytotoxic T lymphocytes specific for influenza virus. 23. Curr Top Microbiol Immunol 
189:75-91.
Naik, S.H. 2008. Demystifying the development of dendritic cell subtypes, a little. 24. Immunol Cell Biol 86:439-
452.
Shortman, K., and Y.J. Liu. 2002. Mouse and human dendritic cell subtypes. 25. Nature Rev Immunol 2:151-161.
Henri, S., D. Vremec, A. Kamath, J. Waithman, S. Williams, C. Benoist, K. Burnham, S. Saeland, E. Handman, 26. 
and K. Shortman. 2001. The dendritic cell populations of mouse lymph nodes. J. Immunol. 167:741-748.
Blasius, A., W. Vermi, A. Krug, F. Facchetti, M. Cella, and M. Colonna. 2004. A cell-surface molecule 27. 
selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. 
Blood 103:4201-4206.
22
Nakano, H., M. Yanagita, and M.D. Gunn. 2001. CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and 28. 
spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194:1171-1178.
Boonstra, A., C. Asselin-Paturel, M. Gilliet, C. Crain, G. Trinchieri, Y.J. Liu, and A. O’Garra. 2003. Flexibility of 29. 
mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: 
dependency on antigen dose and differential toll-like receptor ligation. The Journal of experimental medicine 
197:101-109.
Burgdorf, S., A. Kautz, V. Bohnert, P.A. Knolle, and C. Kurts. 2007. Distinct pathways of antigen uptake and 30. 
intracellular routing in CD4 and CD8 T cell activation. Science 316:612-616.
Burgdorf, S., C. Scholz, A. Kautz, R. Tampe, and C. Kurts. 2008. Spatial and mechanistic separation of cross-31. 
presentation and endogenous antigen presentation. Nature immunology 9:558-566.
Dudziak, D., A.O. Kamphorst, G.F. Heidkamp, V.R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. 32. 
Liu, H.W. Lee, C.G. Park, R.M. Steinman, and M.C. Nussenzweig. 2007. Differential antigen processing by 
dendritic cell subsets in vivo. Science 315:107-111.
Sancho, D., D. Mourao-Sa, O.P. Joffre, O. Schulz, N.C. Rogers, D.J. Pennington, J.R. Carlyle, and C. Reis e 33. 
Sousa. 2008. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. The Journal 
of clinical investigation 118:2098-2110.
Xia, W.J., E.E. Schneeberger, K. McCarthy, and R.L. Kradin. 1991. Accessory cells of the lung. 34. II. Ia+ pulmonary 
dendritic cells display cell surface antigen heterogeneity. Am J Respir Cell Mol Biol 5:276-283.
Kradin, R.L., W. Xia, K.M. Mc Carthy, and E.E. Schneeberger. 1993. FcR+/- subsets of Ia+ pulmonary dendritic 35. 
cells in the rat display differences in their abilities to provide accessory co-stimulation for naive (Ox-22+) and 
sensitized (Ox-22-) T cells. Am.J.Pathol. 142:811-819.
Schon-Hegrad, M.A., J. Oliver, P.G. McMenamin, and P.G. Holt. 1991. Studies on the density, distribution and 36. 
surface phenotype of intraepithelial class II major histocompatibility complex antigen (Ia)-bearing dendritic 
cells (DC) in the conducting airways. J. Exp. Med. 173:1345-1356.
Suda, T., K. McCarthy, Q. Vu, J. McCormack, and E.E. Schneeberger. 1998. Dendritic cell precursors are 37. 
enriched in the vascular compartment of the lung. Am. J. Respir. Cell Mol. Biol.. 19:728-737.
Sertl, K., T. Takemura, E. Tschachler, V.J. Ferrans, M.A. Kaliner, and E.M. Shevach. 1986. Dendritic cells with 38. 
antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura. J. Exp. Med. 
163:436-451.
Grayson, M.H., M.S. Ramos, M.M. Rohlfing, R. Kitchens, H.D. Wang, A. Gould, E. Agapov, and M.J. Holtzman. 39. 
2007. Controls for lung dendritic cell maturation and migration during respiratory viral infection. J Immunol 
179:1438-1448.
Sung, S.S., S.M. Fu, C.E. Rose, Jr., F. Gaskin, S.T. Ju, and S.R. Beaty. 2006. A major lung CD103 (alphaE)-40. 
beta7 integrin-positive epithelial dendritic cell population expressing Langerin and tight junction proteins. J 
Immunol 176:2161-2172.
Wikstrom, M.E., and P.A. Stumbles. 2007. Mouse respiratory tract dendritic cell subsets and the immunological 41. 
fate of inhaled antigens. Immunol Cell Biol 85:182-188.
von Garnier, C., L. Filgueira, M. Wikstrom, M. Smith, J.A. Thomas, D.H. Strickland, P.G. Holt, and P.A. 42. 
Stumbles. 2005. Anatomical location determines the distribution and function of dendritic cells and other 
APCs in the respiratory tract. J Immunol 175:1609-1618.
Lambrecht, B.N., B. Salomon, D. Klatzmann, and R.A. Pauwels. 1998. Dendritic cells are required for the 43. 
development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. 
J. Immunol. 160:4090-4097.
van Rijt, L.S., S. Jung, A. Kleinjan, N. Vos, M. Willart, C. Duez, H.C. Hoogsteden, and B.N. Lambrecht. 2005. 44. 
In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features 
of asthma. The Journal of experimental medicine 201:981-991.
del Rio, M.-L., J.-I. Rodriguez-Barbosa, E. Kremmer, and R. Forster. 2007. CD103- and CD103+ bronchial 45. 
lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and 
CD8+ T cells. J Immunol 178:6861-6866.
Cleret, A., A. Quesnel-Hellmann, A. Vallon-Eberhard, B. Verrier, S. Jung, D. Vidal, J. Mathieu, and J.N. 46. 
Tournier. 2007. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J 
Immunol 178:7994-8001.
Holt, P.G., M.A. Schon-Hegrad, and J. Oliver. 1988. MHC class II antigen-bearing dendritic cells in pulmonary 47. 
tissues of the rat (regulation of antigen presentation activity by endogenous macrophage populations). J. Exp. 
23Introduction and outine of the thesis
Ch
ap
te
r 
1Med. 167:262-274.
Vermaelen, K., and R. Pauwels. 2004. Accurate and simple discrimination of mouse pulmonary dendritic cell 48. 
and macrophage populations by flow cytometry: methodology and new insights. Cytometry A 61A:170-177.
Van Rijt, L.S., H. Kuipers, N. Vos, D. Hijdra, H.C. Hoogsteden, and B.N. Lambrecht. 2004. A rapid flow 49. 
cytometric method for determining the cellular composition of bronchoalveolar lavage fluid cells in mouse 
models of asthma. Journal of immunological methods 288:111-121.
Vermaelen, K.Y., I. Carro-Muino, B.N. Lambrecht, and R.A. Pauwels. 2001. Specific migratory dendritic cells 50. 
rapidly transport antigen from the airways to the thoracic lymph nodes. J.Exp.Med. 193:51-60.
Xanthou, G., T. Alissafi, M. Semitekolou, D.C. Simoes, E. Economidou, M. Gaga, B.N. Lambrecht, C.M. Lloyd, 51. 
and V. Panoutsakopoulou. 2007. Osteopontin has a crucial role in allergic airway disease through regulation 
of dendritic cell subsets. Nat Med 13:570-578.
Oriss, T.B., M. Ostroukhova, C. Seguin-Devaux, B. Dixon-McCarthy, D.B. Stolz, S.C. Watkins, B. Pillemer, P. 52. 
Ray, and A. Ray. 2005. Dynamics of dendritic cell phenotype and interactions with CD4+ T cells in airway 
inflammation and tolerance. J Immunol 174:854-863.
De Heer, H.J., H. Hammad, T. Soullie, D. Hijdra, N. Vos, M.A. Willart, H.C. Hoogsteden, and B.N. Lambrecht. 53. 
2004. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled 
antigen. The Journal of experimental medicine 200:89-98.
Robays, L.J., T. Maes, S. Lebecque, S.A. Lira, W.A. Kuziel, G.G. Brusselle, G.F. Joos, and K.V. Vermaelen. 2007. 54. 
Chemokine receptor CCR2 but not CCR5 or CCR6 mediates the increase in pulmonary dendritic cells during 
allergic airway inflammation. J Immunol 178:5305-5311.
Osterholzer, J.J., T. Ames, T. Polak, J. Sonstein, B.B. Moore, S.W. Chensue, G.B. Toews, and J.L. Curtis. 2005. 55. 
CCR2 and CCR6, but not endothelial selectins, mediate the accumulation of immature dendritic cells within 
the lungs of mice in response to particulate antigen. J Immunol 175:874-883.
Lin, K.L., Y. Suzuki, H. Nakano, E. Ramsburg, and M.D. Gunn. 2008. CCR2+ monocyte-derived dendritic 56. 
cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J 
Immunol 180:2562-2572.
Serbina, N.V., T.P. Salazar-Mather, C.A. Biron, W.A. Kuziel, and E.G. Pamer. 2003. TNF/iNOS-producing 57. 
dendritic cells mediate innate immune defense against bacterial infection. Immunity 19:59-70.
Wang, H., N. Peters, V. Laza-Stanca, N. Nawroly, S.L. Johnston, and J. Schwarze. 2006. Local CD11c+ MHC 58. 
class II- precursors generate lung dendritic cells during respiratory viral infection, but are depleted in the 
process. J Immunol 177:2536-2542.
Zuniga, E.I., D.B. McGavern, J.L. Pruneda-Paz, C. Teng, and M.B. Oldstone. 2004. Bone marrow plasmacytoid 59. 
dendritic cells can differentiate into myeloid dendritic cells upon virus infection. Nature immunology 5:1227-
1234.
Comeau, M.R., A.R. Van Der Vuurst De Vries, C.R. Maliszewski, and L. Galibert. 2002. CD123(bright) 60. 
Plasmacytoid Predendritic Cells: Progenitors Undergoing Cell Fate Conversion? J Immunol 169:75-83.
Taieb, J., N. Chaput, C. Menard, L. Apetoh, E. Ullrich, M. Bonmort, M. Pequignot, N. Casares, M. Terme, C. 61. 
Flament, P. Opolon, Y. Lecluse, D. Metivier, E. Tomasello, E. Vivier, F. Ghiringhelli, F. Martin, D. Klatzmann, 
T. Poynard, T. Tursz, G. Raposo, H. Yagita, B. Ryffel, G. Kroemer, and L. Zitvogel. 2006. A novel dendritic cell 
subset involved in tumor immunosurveillance. Nat Med 12:214-219.
Holt, P.G., S. Haining, D.J. Nelson, and J.D. Sedgwick. 1994. Origin and steady-state turnover of class II MHC-62. 
bearing dendritic cells in the epithelium of the conducting airways. J. Immunol. 153:256-261.
Jakubzick, C., F. Tacke, F. Ginhoux, A.J. Wagers, N. van Rooijen, M. Mack, M. Merad, and G.J. Randolph. 2008. 63. 
Blood monocyte subsets differentially give rise to CD103+ and CD103- pulmonary dendritic cell populations. 
J Immunol 180:3019-3027.
Geissmann, F., S. Jung, and D.R. Littman. 2003. Blood monocytes consist of two principal subsets wih distinct 64. 
migratory properties. Immunity 19:71-82.
Le Borgne, M., N. Etchart, A. Goubier, S.A. Lira, J.C. Sirard, N. van Rooijen, C. Caux, S. Ait-Yahia, A. Vicari, 65. 
D. Kaiserlian, and B. Dubois. 2006. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 
are responsible for CD8+ T cell crosspriming in vivo. Immunity 24:191-201.
Landsman, L., C. Varol, and S. Jung. 2007. Distinct differentiation potential of blood monocyte subsets in the 66. 
lung. J Immunol 178:2000-2007.
Diao, J., E. Winter, C. Cantin, W. Chen, L. Xu, D. Kelvin, J. Phillips, and M.S. Cattral. 2006. In situ replication 67. 
of immediate dendritic cell (DC) precursors contributes to conventional DC homeostasis in lymphoid tissue. 
24
J Immunol 176:7196-7206.
Naik, S.H., P. Sathe, H.Y. Park, D. Metcalf, A.I. Proietto, A. Dakic, S. Carotta, M. O’Keeffe, M. Bahlo, A. 68. 
Papenfuss, J.Y. Kwak, L. Wu, and K. Shortman. 2007. Development of plasmacytoid and conventional dendritic 
cell subtypes from single precursor cells derived in vitro and in vivo. Nature immunology 8:1217-1226.
Diao, J., E. Winter, W. Chen, C. Cantin, and M.S. Cattral. 2004. Characterization of Distinct Conventional and 69. 
Plasmacytoid Dendritic Cell-Committed Precursors in Murine Bone Marrow. J Immunol 173:1826-1833.
Jahnsen, F.L., D.H. Strickland, J.A. Thomas, I.T. Tobagus, S. Napoli, G.R. Zosky, D.J. Turner, P.D. Sly, P.A. 70. 
Stumbles, and P.G. Holt. 2006. Accelerated antigen sampling and transport by airway mucosal dendritic cells 
following inhalation of a bacterial stimulus. J Immunol 177:5861-5867.
Asokananthan, N., P.T. Graham, D.J. Stewart, A.J. Bakker, K.A. Eidne, P.J. Thompson, and G.A. Stewart. 2002. 71. 
House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine 
protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. J Immunol 
169:4572-4578.
Chieppa, M., M. Rescigno, A.Y. Huang, and R.N. Germain. 2006. Dynamic imaging of dendritic cell extension 72. 
into the small bowel lumen in response to epithelial cell TLR engagement. The Journal of experimental medicine 
203:2841-2852.
Hintzen, G., L. Ohl, M.L. del Rio, J.I. Rodriguez-Barbosa, O. Pabst, J.R. Kocks, J. Krege, S. Hardtke, and R. 73. 
Forster. 2006. Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-
mediated antigen transport to the bronchial lymph node. J Immunol 177:7346-7354.
von Garnier, C., M.E. Wikstrom, G. Zosky, D.J. Turner, P.D. Sly, M. Smith, J.A. Thomas, S.R. Judd, D.H. 74. 
Strickland, P.G. Holt, and P.A. Stumbles. 2007. Allergic airways disease develops after an increase in allergen 
capture and processing in the airway mucosa. J Immunol 179:5748-5759.
Stock, P., O. Akbari, G. Berry, G.J. Freeman, R.H. Dekruyff, and D.T. Umetsu. 2004. Induction of T helper 75. 
type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nature immunology 
5:1149-1156.
Akbari, O., G.J. Freeman, E.H. Meyer, E.A. Greenfield, T.T. Chang, A.H. Sharpe, G. Berry, R.H. DeKruyff, and 76. 
D.T. Umetsu. 2002. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit 
allergen-induced airway hyperreactivity. Nat Med 8:1024-1032.
Kuipers, H., D. Hijdra, V.C. De Vries, H. Hammad, J.B. Prins, A.J. Coyle, H.C. Hoogsteden, and B.N. Lambrecht. 77. 
2003. Lipopolysaccharide-Induced Suppression of Airway Th2 Responses Does Not Require IL-12 Production 
by Dendritic Cells. J Immunol 171:3645-3654.
Stumbles, P.A., J.A. Thomas, C.L. Pimm, P.T. Lee, T.J. Venaille, S. Proksch, and P.G. Holt. 1998. Resting 78. 
respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require 
obligatory cytokine signals for induction of Th1 immunity. J. Exp. Med. 188:2019-2031.
Dodge, I.L., M.W. Carr, M. Cernadas, and M.B. Brenner. 2003. IL-6 production by pulmonary dendritic cells 79. 
impedes Th1 immune responses. J Immunol 170:4457-4464.
Clearance of influenza virus from the lung 
depends on langerin+CD11b- but not 
plasmacytoid dendritic cells
Corine H. GeurtsvanKessel, Monique A.M. Willart, Leonie S. van Rijt, Femke Muskens, 
Mirjam Kool, Chantal Baas, Kris Thielemans, Clare Bennett, Bjorn E. Clausen, Henk C. 
Hoogsteden, Albert D.M.E. Osterhaus, Guus F. Rimmelzwaan* and Bart N. Lambrecht*
Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
Department of Virology, Erasmus University Medical Centre, Rotterdam, The Netherlands
Department of Physiology, Free University Brussels, Belgium
Department of Cell Biology and Histology, University of Amsterdam, The Netherlands
Department of Respiratory Diseases, Laboratory of Immunoregulation and Mucosal Immunology, University Hospital Gent, Gent, Belgium
 
Journal of Experimental Med. 2008 Jul 7;205(7):1621-34
* both authors contributed equally
Chapter 2
26
ABSTRACT
Although dendritic cells (DCs) play an important role in mediating protection against 
influenza virus, the precise role of lung DC subsets such as CD11b- and CD11b+ conventional 
DCs or plasmacytoid DCs in different lung compartments is currently unknown. Early 
after intranasal infection, tracheal CD11b-CD11chi DCs migrated to the mediastinal LN, 
acquiring costimulatory molecules in the process.  This emigration from the lung was 
followed by an accumulation of CD11b+CD11chi DCs into the trachea and lung interstitium. 
In the mediastinal nodes, the CD11b+ DCs contained viral nucleoprotein abundantly, but 
these cells failed to present antigen to CD4 or CD8 T cells, whereas resident CD11b-CD8a+ 
DCs presented to CD8 cells and migratory CD11b-CD8a- DCs presented to CD4 and CD8 
T cells. When lung CD11chi DCs and macrophages or langerin+CD11b-CD11chi DCs were 
depleted using either CD11c-DTR or langerin-DTR mice, the development of virus specific 
CD8+ T cells was severely delayed, which correlated with increased clinical severity and a 
delayed viral clearance. Plasmacytoid 120G8+ CD11cint DCs also accumulated in the lung 
and lymph nodes carrying viral nucleoprotein but in their induced absence, there was 
no effect on viral clearance or clinical severity.  Rather, in pDC-depleted mice, there was 
a reduction in antiviral antibody production following lung clearance of the virus.  This 
suggests that multiple DCs are endowed with different tasks in mediating protection 
against influenza virus.
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INTRODUCTION
Influenza type A is a cytolytic virus that causes acute respiratory infection of which 
the clinical outcome can vary greatly. The way in which the innate and adaptive 
immune system initially recognizes and deals with replicating virus could be 
decisive in determining outcome of infection, as this might heavily influence the 
kinetics of viral clearance (1-3).  Little is known about the initial recognition event 
of Influenza virus by the lung immune system in vivo.
 In immediate response to viral infection, innate defence mechanisms 
consist of high level production of type I interferons by infected epithelial cells, 
alveolar macrophages and natural interferon producing cells (also known as pre-
plasmacytoid DCs), as well as recruitment of conventional (c)DCs, neutrophils and 
NK cells (4, 5). By expressing a wide array of microbial pattern recognition receptors 
shared with cells of the innate immune response and at the same time displaying 
the potential to process and present antigen to naive T cells, DCs bridge innate and 
adaptive immunity. After recognizing foreign antigen in the periphery of the body, 
DCs migrate via afferent lymphatics into the draining LN, where they can induce 
antigen-specific protective CD8 cytotoxic T lymphocyte (CTL) responses as well as 
CD4 T helper cells that enforce cellular and humoral immunity (6). 
 In the lung, DCs are situated in immediate proximity to the respiratory 
epithelial cells where they form an elaborate network that rapidly reacts to all kinds 
of foreign antigens and inflammatory stimuli, including respiratory viruses (7-10). 
Different DC subsets can be found in the lung, each with functional specialization 
(11-15). In the mouse, all DC subsets express the integrin CD11c and subsets are 
further defined based on the expression of the marker CD11b, as well as anatomical 
location (11, 13, 16).  The trachea and large conducting airways have a well developed 
network of intraepithelial DCs, even in steady state conditions (17, 18).  These cells 
have been shown to express langerin and CD103 while lacking expression of CD11b 
(10, 13, 15). In the submucosa of the conducting airways, CD103-CD11b+CD11c+ 
conventional DCs can be found, particularly under conditions of inflammation, and 
these cells might be particularly suited for priming and restimulating effector CD4 
cells in the lung in response to protein antigens (15, 19, 20). The lung interstitium 
that is accessible by enzymatic digestion also contains CD11b+ and CD11b- DCs that 
access the alveolar lumen and migrate to the MLN (11, 14). In the nearby alveolar 
lumen, CD11chi alveolar macrophages control the function of these interstitial DCs 
28
(21). Plasmacytoid DCs are CD11b-CD11cint cells expressing SiglecH and bone 
marrow stromal Ag-2 (recognized by the moAbs mPDCA-1 or 120G8) (22, 23). In 
the lungs, pDCs are predominantly found in the lung interstitium and produce large 
amounts of IFN-a in response to triggering by CpG motifs or viral infection ex vivo 
(5, 24).  Under particular conditions, lung pDCs can prevent immunopathology in 
response to inhalation of harmless antigens or in response to respiratory syncitial 
virus (RSV) (24-26)
 Several investigators have studied the involvement of antigen presenting 
cells such as DCs, macrophages and B cells in mediating protective immunity 
to Influenza virus (27). It was shown that a mouse adapted strain of influenza 
virus induced the in vivo maturation of CD11c+ DCs in the lung (28) and their 
migration to the mediastinal LNs (2, 8, 29).  Dendritic cells isolated ex vivo from 
the mediastinal LN of influenza infected mice presented viral nucleoprotein derived 
peptides to virus specific CD8 T cells in vitro for at least 10 days, a peak occuring 
around 72 h post infection (27, 29-32).  In humans, both monocyte derived DCs 
and plasmacytoid DCs were shown to be capable of activating already primed 
influenza specific T cells in vitro (33, 34) and upon adoptive transfer in vivo (35).
 Although these studies certainly suggest the strong involvement of DCs 
in mediating protective immunity to influenza A virus, direct description of the 
functional in vivo involvement of the now well described DC subsets in the different 
compartments of the lung during early infection is lacking.  Here, using 8 colour flow 
cytometry, we have carefully studied the kinetics of reaction of different DC subsets 
and alveolar macrophages in different lung compartments, to intranasal infection 
with influenza virus X-31 (H3N2), focusing particularly on CD11b+ and CD11b- 
subsets as well as on pDCs, describing which subsets carry viral nucleoprotein to 
the nodes, and carefully dissecting which subsets present antigen to specific CD8 
and CD4 T cells. Using genetic cell specific targeting techniques, CD11chi DCs 
and macrophages or langerin+CD11chi DCs could be depleted in CD11c-DTR or 
langerin-DTR mice carrying a diphteria toxin receptor (36, 37) and pDCs could be 
depleted using moAbs. Together, our results demonstrate that different DC subsets 
perform specialized tasks during primary encounter with influenza virus in the 
lung. 
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RESULTS
Lung dendritic cell subtypes and alveolar macrophages respond to 
influenza virus infection differentially 
As expected following intranasal inoculation with 5x105 TCID50 influenza A virus 
X-31 (H3N2), there was induction of a vigorous innate and adaptive immune 
response in the lung. The innate cellular immune response was already present 
1 dpi and peaked at 4 dpi, exemplified by a strong increase in neutrophils. B 
lymphocytes (CD19+) cells were present in the lung by day 4 and peaked around 
day 10.  Total CD8+ cells in the lung peaked around day 10 (see suppl. figure 1). 
To investigate the number  of DC subsets and macrophages after influenza virus 
infection, enzymatically digested lungs (from which the large conducting airways 
were dissected) were analysed at different time points after infection by 8 color flow-
cytometry. Digested lung cells were first gated for live leukocytes and expression 
of the pan-leukocyte marker CD45. Conventional DCs were characterised as low 
fluorescent cells, with a CD45hi, MHCIIhiCD11chi phenotype (suppl. figure 2A), and 
further subdivided into CD11b+ or CD11b- (11, 13, 15, 30). As previously described, 
pDCs were small, low autofluorescent cells expressing a CD45hi, CD11blo, MHCint 
CD11cint mPDCA-1+ phenotype (Suppl. figure 2B).  Alveolar macrophages were 
identified in the BAL fluid as highly fluorescent cells with a CD11chi, CD11blo, 
MHCIIlo, F4/80hi phenotype (Suppl. figure 2C). The use of CD11c and CD11b 
expression in combination with autofluorescence typically seen in alveolar 
macrophages adequately discriminated alveolar DCs from macrophages, as has 
been described (11, 38, 39). 
 In the mock situation, 65% of CD11chi DCs were CD11b- and 35% were 
CD11b+. Following infection with influenza virus X-31, a significant increase in 
both CD11b+ (figure 1A) and CD11b- (figure 1B) lung DCs was seen from 2 dpi and 
these DC subsets remained increased up to at least 10 dpi. The DCs expressed high 
levels of MHCII and upregulated maturation markers such as CD86 (figure 1A,B), 
CD40, CD80 and ICAM-1 (data not shown). The increase in the expression level of 
these markers peaked shortly after inoculation (2 days) and gradually returned back 
to the levels seen in mock infected mice (see bar diagrams). In contrast, the number 
of pDCs peaked shortly after infection (2 dpi) and then returned back to base-line 
condition (figure 1C). This increased recruitment of pDCs was accompanied by a 
30
distinct but very transient upregulation of maturation markers (CD86 is shown). 
Alveolar macrophages were studied in the BAL fluid accessible by broncho alveolar 
lavage. This compartment contains a large amount of resident alveolar macrophages 
in mock situation.  Following influenza virus infection there was a non-significant 
trend of increase in alveolar macrophage number at 4 dpi (figure 1D), accompanied 
by a temporary increase in CD86 and more continue increase in MHCII expression 
(average MFI of 820 in mock to 2769 at 10 dpi).
Figure 1: Number and surface phenotype of mouse lung CD11b+ and CD11b- DCs, pDCs and alveolar 
macrophages following influenza infection.
Populations were gated as shown in supplementary figure 2, and indicated by gate in left column of each panel. (A) 
CD11b+ DCs significantly increased after infection and remained increased up to 10 dpi (left panel); CD86 expression 
was plotted in histograms in the right panel with an average MFI in the lower graph. (B) The increase in CD11b- DCs 
demonstrated in flowcytometric plots in left panel, with absolute numbers in the lower graph. CD86 expression 
was upregulated and plotted as average MFI (mean fluorescence intensity) in the lower graph (C) pDCs increased 
significantly at 2 dpi and then returned back to base-line. Recruitment of pDCs was accompanied by upregulation of 
CD86 (right panel).  (D) Alveolar macrophages slightly increased in number, but CD86 expression was not increased. 
Grey histograms represent isotype controls and were measured on 4 dpi. The values are representative of 5 mice/
group and expressed as mean ± SEM.  Similar results were obtained from at least 3 separate experiments. * p<0,05 
**p<0,01
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Response of DC subsets in the large conducting airways to influenza virus 
infection
To examine the DC network in the large conducting airways, we stained in vivo fixed 
and permeabilized tracheal whole mounts with a monoclonal antibody to MHCII 
revealing the presence of a highly developed network of DCs demonstrating delicate 
dendritic processes in between bronchial epithelial cells (figure 2A).  Following 
infection, there was an increase in MHCII+ cells at 2 dpi and cells had a more rounded 
appearance, making it difficult to quantify DC density. At 4 dpi there was a strong 
decrease in density of cells staining for MHCII, followed by a restoration to baseline 
density and morphology by 10 dpi.  To quantify these changes better, 8-colour 
flow cytometry was performed on tracheal digests, demonstrating considerable 
heterogeneity in DCs at various time points post infection (figure 2B).In the mock 
situation, all CD45+ MHCII+ cells expressed CD11c, identifying them as DCs.  The 
majority of these cells (appr. 75%) were CD11b negative and expressed the mucosal 
aE-integrin marker CD103 (figure 2C). At 2 dpi, this subset was depleted from the 
tracheal digest and a majority of cells now expressed CD11b but lacked CD103, 
most consistent with the phenotype of a freshly recruited monocyte derived DC 
(figure 2B&C). A temporary increase in the expression level of CD86 was found 
on these CD11b+ DCs at day 2 (figure 2B). At 10 dpi, the subset balance between 
CD11b+ and CD11b- DCs was almost restored to baseline, and cells again showed 
a highly dendritic morphology and CD86 expression level returned to baseline 
levels.  As reported before by others, we detected a minor percentage (0.35% of 
live tracheal CD45+ leukocytes) of mPDCA-1+ pDCs in tracheal digests of mock 
infected mice (figure 2D) (11).  Again, pDCs increased following influenza  virus 
infection and temporarily upregulated their expression of costimulatory molecules 
(figure  2E). 
Influenza virus infection increases DC subsets in MLN 
Upon recognition of antigen, lung DCs are known to migrate to the mediastinal 
LN. We followed the kinetics of increase and expression of maturation markers on 
various DC subsets within this node. Conventional DC subsets were CD11c+MHCII+ 
cells (figure 3A) that were further discriminated based on expression of the myeloid 
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Figure 2: Dendritic cell subtypes in tracheal tissue following influenza infection.
(A) Tracheal whole mount sections stained for MHCII expression were performed at various days pi. Scale bar 
represents 35 mm. (B) Flow cytometric analysis of DCs in tracheal cell suspensions stained for CD45, CD11c, CD11b, 
F4/80 and CD103. CD11c+ cells contained two subsets, one CD11b-, the other CD11b+. Histograms represent CD86 
expression on both subsets. The dotted line indicates the MFI at mock situation. (C) Absolute numbers of the two 
subsets following influenza infection.  Histograms represent CD103 expression on both subsets. (D) Plasmacytoid 
DCs were identified as CD11cintPDCA-1+ cells representing a minor percentage of CD45+ leukocytes in tracheal 
cell suspensions, and only temporarily expressing CD86 (histogram). (E) Absolute number of pDCs at various days 
following infection. * p<0,05 ** p<0,01
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marker CD11b (figure 3B).  
 Following infection, there was an increase in the absolute amount of 
CD11c+MHCII+CD11b- as well as CD11c+MHCII+CD11b+ DCs, starting at 2dpi 
and the increase was more pronounced in the CD11b+ subset. Within the CD11b-
CD11chi cells, there was a clear increase in cells co-expressing langerin and CD103 
(30 x 104at 4 dpi vs 2 x 104 in mock infected mice).  Belz et al. previously suggested 
that a resident subset of CD11b-CD8a+ DCs was responsible for generating virus 
specific CD8 CTLs, while the population of CD11b-CD11c+ cells transported antigen 
from the periphery (30).  Therefore, cells were further discriminated based on 
CD8a (figure  3C).  Compared with mock, at 4 dpi there was a generalized increase 
in all CD8a- subsets (CD11b- and CD11b+) while the resident CD8a+CD11b- DCs 
were not increased. Following infection, CD11c+MHCII+ cells had higher levels of 
the CD86 maturation marker compared with mock infected mice, consistent with 
their potential to prime CD8 T cell responses (figure 3D), and this was found in all 
subsets of DCs. 
 To test the antigen-presenting potential of the various DC subsets in the 
MLN, mice were infected with influenza virus encoding either the immunodominant 
OVA257-264 Kb restricted MHCI epitope recognized by the OT-I TCR-transgenic 
strain (40) or carrying the OVA323-339 MHCII epitope recognized by the OT-II TCR 
transgenic strain (41), allowing us to probe presentation of sorted lung DC subsets 
to naive OVA-specific CD8 and CD4 T cells directly ex vivo. To have an indication 
about the uptake of viral antigen or virally infected apoptotic cells, preparations 
of sorted DC subsets from the MLN were also stained for the presence of viral 
nucleoprotein using a specific Ab (figure  3E), and confirmed using 8 color flow 
cytometric staining on permeabilized cells (figure  3F). Viral nucleoprotein was 
found particularly in the CD11b+CD8a- subset as well as abundantly in the pDC 
subset, and was practically absent from the CD11b- subsets (figure  3F). When DC 
subsets were sorted and cocultured with OVA-specific OTI cells (figure  3G, top 
panels) or OTII cells (figure 3G, lower panels), the CD11b-CD8a- subset presented 
antigen to both CD8 and CD4 T cells, whereas the CD11b-CD8a+ resident DCs 
presented exclusively to CD8 cells.  Despite the fact that these cells had seen viral 
antigens (see nucleoprotein staining, figure  3E&F), the CD11b+ DCs and the pDCs 
did not present antigen to naive CD4 or CD8 T cells. As a control, OT-I or OT-II 
T cells incubated with total MLN DCs obtained from mice infected with the virus 
containing the OVA-MHCII or –MHCI epitope respectively, failed to proliferate.
34
Conditional depletion of lung CD11chi cells aggravates features of 
infection 
DCs are extremely potent APCs that are uniquely suited to prime naïve T cells. 
To study the immune response against Influenza virus infection with and without 
CD11chi DCs, CD11c-DTR mice were treated with DT intratracheally 1 day prior to 
infection with influenza virus X-31. By this localized treatment, lung CD11chi DCs 
(both CD11b+ and CD11b-) and alveolar macrophages were efficiently depleted 
from the lungs (figure 4A). In the trachea, the localized treatment with DT led to a 
reduction of CD11b+ DCs, but not to depletion of CD11b- DCs (suppl. figure 3A) 
or pDCs (data not shown).  In the mediastinal LN all DC subsets were partially 
depleted after DT treatment with the biggest depletion occurring in the resident 
CD11b-CD8a+ DCs (suppl. figure 3B and (19, 37)). On the contrary, CD11chi cells 
in the spleen or non-draining LNs were not affected (data not shown) (19, 37). 
At different time-points post-infection the clinical, immune response and viral 
replication were analyzed. First, clinical severity of infection was determined by 
measuring body weight. In general, mice show a maximal 10 % weight loss after a 
mild X-31 infection, and rapidly regain weight once virus has been cleared from 
the lungs. When CD11c-DTR Tg mice were treated with DT prior to infection the 
clinical severity of infection dramatically increased and mice lost up to 20% weight, 
representing a sublethal infection. This weight loss could not be contributed to DT 
treatment, as the control group, treated with DT prior to Mock infection, did not 
loose weight (figure  4B). As weight loss might be related to initial severity of infection 
or failure of the immune system to clear infectious particles from the lung, we next 
studied the generation of an efficient immune response in CD11chi depleted mice. 
For efficient lung clearance of a primary influenza virus infection, CD8+ CTLs play 
an important role. We therefore measured the number of nucleoprotein (NP)366-
374 peptide/H-2Db specific CTL cells using tetramer reagents and correlated their 
numbers  to viral clearance. In DT treated and infected animals, the number of virus 
specific CTL cells was significantly reduced in lung, spleen (figure 4C) and MLN 
(data not shown). In addition to the measurement of CTL, CD3-stimulated IFNg 
production by CD4 and CD8 T cells from MLN was determined and dramatically 
suppressed in the absence of DCs (figure 4D). As induction of virus-specific CTL 
responses is necessary for viral clearance from the lung, we measured viral titers in 
the lungs. In this mild infection model, virus is normally cleared completely at 8 dpi 
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Figure 3: DC subsets in MLN following influenza virus infection. 
(A) kinetics of CD11c+MHCII+ DCs demonstrating almost 4-fold increase following infection (B) expression of CD11b 
by CD11c+ DCs gated in A. Black bar represents CD11b+ population and the white bar CD11b-. (C) CD8a expression 
on different DC subsets demonstrated in combination with CD11b, with percentages of the different populations 
plotted in the graph. (D) CD86 expression on different MLN subsets. (E) Sorted DC subsets were stained for 
intracellular NP. Uninfected cells stain dull red due to evans blue in the solution, the green fluorescence indicates NP. 
Scale bar represents 20 mm. (F) Flowcytometric analysis of total detectable amount of intracellular NP in DC subsets, 
as a percentage of total live LN cells per DC subset. (G) Plots represent CFSE labeled T cell proliferation 4 days after 
co-culture with different sorted DC populations obtained from pooled LNs of 20 influenza-infected mice. Top row 
shows CD8+ T cells, lower graphs show CD4+ T cell proliferation. Numbers in left corner of the plot represent the % of 
cells recruited into cell division. All figures are representative of at least 5 mice/group and expressed as mean ± SEM. 
Similar results were obtained from at least two separate experiments. * p<0,05
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Figure 4: Infection parameters after conditional depletion of CD11chi cells in a CD11c-DTR transgenic mouse 
model.CD11c-DTR transgenic mice received an i.t. injection of DT on day -1, followed by X-31 intranasal infection. 
(A) Efficient depletion of lung CD11chi cells by DT treatment compared to PBS treatment. Right plots demonstrate 
flowcytometry data, numbers indicate % of live cells within the gate (B) Body weight following influenza infection.
(C) Virus specific CTL response in spleen and lung measured by Flupeptide/H-2Db tetramer (TM) staining. (D) IFN-a 
levels in supernatants of MLN cell cultures re-stimulated with anti-CD3 Ab. (E) Viral titers measured in lung tissue 
following influenza X-31 infection. N.d. signifies non-detectable (F) IFNIFa levels in BAL fluid.  (G) Adoptive transfer of 
wild type DCs and alveolar macs into DT treated CD11c-DTR Tg mice prior to viral infection. CD11c-DTR Tg mice were 
either treated with PBS or diphteria toxin (DT) and received either DCs or macrophages prior to influenza infection. 
Numbers of Flupeptide/H-2Db specific CTL in spleen suspensions (left graph) and viral titer in lung tissue (right graph). 
The values are representative of 5 mice/group and expressed as mean ± SEM.  Similar results were obtained from at 
least 2 separate experiments. * p<0,05 **p<0,01.
(figure  4E and (42)). However, in the absence of lung CD11chi cells and mediastinal 
CD8a+CD11chi cells, the virus had not been cleared at this time. A delay in viral 
clearance could be due to a direct defect in CTL priming, but could also result 
from a less efficient innate response consisting mainly of type I IFN production. 
IFN-a has been described as an important anti-viral cytokine, mainly produced by 
epithelial cells and alveolar macrophages, but also by pDCs and even cDCs following 
influenza infection in vitro (3, 5). We therefore determined the IFN-a production 
in the BAL fluid at different time points after infection in CD11chi depleted mice. 
In vivo, IFN-a was produced in the lungs following X-31 infection, but levels were 
not affected by CD11chi cell depletion (figure  4F).
 The above data show that lung CD11chi cells are required for an efficient 
immune response against influenza virus infection. However, as CD11c is also 
highly expressed by alveolar macrophages and these cells are also depleted by local 
i.t. administration of DT we performed adoptive transfer reconstitution experiments 
(19, 37). Tg mice depleted of CD11chi cells therefore received i.t. unpulsed wild 
type CD11chi DCs or alveolar macrophages at the moment of infection. DCs were 
capable of restoring the CTL response (figure 4G) and as a consequence viral 
clearance from the lung was complete by day 8 (figure 4G, right panel). Alveolar 
macrophages were not capable of restoring anti-viral immunity or viral clearance. 
These experiments demonstrated that CD11chi DCs are sufficient for inducing an 
adequate immune response against influenza virus infection.
Depletion of lung langerin+ DCs aggravates infection parameters
The conditional depletion of CD11chi cells in CD11c-DTR mice did not allow us 
to address the contribution of tracheal CD11b-CD11chi DCs as tracheal CD11b-
38
CD11chi DCs nor their CD11b- progeny in the MLN were depleted in CD11c-DTR 
mice. Therefore we performed experiments in langerin-DTR mice. When DT was 
intratracheally administered to these mice, there was a strong reduction in CD11b-
CD11chi DCs in the trachea, whereas tracheal CD11b+ DCs were unaffected. 
In the lungs, CD11chi DCs were depleted whereas alveolar macrophages were 
unaffected.  The CD8a+CD11b- resident MLN cDC subset do not express langerin, 
and consequently, lung administration of DT to these mice only led to reduction 
in the lung-derived CD11b-CD8a- migratory DC (see suppl figure 3). Depletion of 
langerin+ DCs resulted in a severe weight loss in the mice until 8 dpi (figure 5B) 
and this was correlated with a significant decrease in CTL response (figure 5C) and 
a deficient viral clearance at 8 dpi (figure 5D). 
Figure 5: Effect of conditional depletion of Langerin+ DCs cells during influenza infection.
Langerin-DTR transgenic mice received an i.t. injection of DT on day -1, followed by X-31 intranasal infection. (A) 
Efficient depletion of MHCII+CD11c+ DCs in Lung after DT treatment. Stated number indicates % of live cells within the 
gate (B) Body weight following influenza infection. More than twenty % weight loss represents a sublethal infection. 
(C) Virus specific CTL response in spleen and lung measured by Flupeptide/H-2Db tetramer (TM) staining. (D) Viral titers 
measured in lung tissue following influenza X-31 infection. Virus is normally cleared completely at 8 dpi. N.d. signifies 
non-detectable. The values are representative of 5 mice/group and expressed as mean ± SEM.  Similar results were 
obtained from at least 2 separate experiments. * p<0,05 **p<0,01.
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Figure 6: Infection parameters following influenza in mice depleted of pDC. 
Mice received three i.p injections of depleting moAb 120G8 prior to infection with influenza on day 0. (A) Efficient 
depletion of lung pDCs after 3 days of 120G8 i.p. treatment compared with PBS treatment. (B) Body weight following 
infection (C) Virus specific CTL response in spleen and lung cell suspensions measured by Flupeptide/H-2Db tetramer 
staining (D) IFNg levels in supernatants of MLN cell cultures re-stimulated with anti-CD3 Ab (E) Viral titers in lung 
following influenza infection. (F) IFN-a levels in BAL fluid. The values are representative of 5 mice/group and expressed 
as mean ± SEM.  Similar results were obtained from at least 2 separate experiments. *p<0,05 **p<0,01.
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Depletion of pDCs did not alter the course of infection
The experiments using CD11cDTR and langerin-DTR mice mainly depleted 
CD11chi cells, whereas CD11cint pDCs are globally not affected by this targeting 
strategy (43). To additionally address the role of pDCs, we performed experiments 
in which pDCs were depleted by injection of the 120G8 monoclonal Ab (22). Using 
this antibody, an effective depletion of pDCs to less than 10% of baseline numbers 
was achieved in the lung (figure 6A), as measured using Abs directed against both 
bone marrow stromal Ag and Siglec-H (24). Surprisingly, this efficient depletion of 
pDCs did not affect any of the infection parameters and virus was cleared efficiently 
by 8 dpi (figure 6B-E). As pDCs have been described as main IFN-a producing 
cells in response to a viral infection (44) it was similarly striking that there was no 
reduction in the protein level of IFN-a in the BAL fluid or in the mRNA level for 
IFN-a in lung tissue following depletion of pDCs (figure 6F).
The production of hemagglutinin specific antibodies depends on pDCs 
and not on CD11chi DCs. 
The induction of antiviral CD8 T cell responses is only one aspect of adaptive 
immunity to influenza.  We also measured the production of serum hemaglutinin 
Figure 7: Virus specific serum antibodies of influenza virus infected mice after DC subset depletion. 
(A) Virus specific antibodies in serum of C57BL/6 mice after i.p. treatment with 120G8 depleting Ab or PBS. (B) or 
in serum of CD11c-DTR mice after i.t. treatment with DT or PBS, measured at 8 dpi and 1 month p.i. The values are 
representative of at least 5 mice/group and expressed as geometric  mean titre (GMT) of hemagglutinin inhibition 
(HI) ± SEM.  The differences in HI titer can be explained by the background of the mice. CD11c-DTR mice were F1 
(Balb/c x C57Bl/6) animals and developed less high viral titers and HI titers then the pure C57BL/6 mice that were 
used in 120G8 depletion experiments. Similar results were obtained from at least 2 separate experiments. * p<0,05 
**p<0,01.
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specific antibodies at 8 dpi and 28 dpi, by measuring hemaglutinin inhibition titers. 
Whereas there was no effect on induction of CD8 responses following 120G8-
mediated pDC depletion, virus specific antibody titers measured at both time 
points were significantly reduced (figure 7A). We found no evidence for 120G8 
staining on lung B-cells, making it unlikely that this would be a depleting effect of 
120G8 on B cells directly (data not shown). Antibody responses were maintained 
in mice depleted of CD11chi DCs by DT treatment of CD11cDTR mice one day 
prior to infection in CD11c-DTR mice (figure 7B). 
DISCUSSION
Belz et al. have elegantly described that following influenza infection, both 
CD11b-CD8a+ resident mediastinal LN DCs as well as CD11b-CD8a- lung derived 
migratory DC subset presented Ag to naïve CD8+ T cells ex vivo (30, 32). However, 
these authors have not described in detail where exactly in the lung these CD11b- 
migratory DCs originated from, whether any of the DCs would also present to CD4+ 
T cells nor have they studied in detail the precise contribution of inflammatory 
CD11b+ or pDCs that are recruited to inflamed lungs. 
 Our studies on the various anatomical lung compartments suggest that a 
predominant source of CD11b- DCs arriving in the mediastinal nodes are from 
the network of highly dendritic shaped CD103+ intraepithelial DCs that line the 
large conducting airways (see figure 1 and (13, 18).  There was a marked decrease 
in this subset of highly dendriform tracheal CD11b-CD103+ DCs at 2dpi, at a time 
that the langerin+CD103+CD11b-CD8a- DCs started to accumulate in the MLN. 
The disappearance of CD11b-CD11c+ tracheal DCs was accompanied by a new 
influx of CD11b+CD11c+ DCs into the trachea (present as more rounded cells at 
day 2 pi on whole mounts) and into the lung interstitium.  These cells most likely 
differentiate from recruited Ly6C+ monocytes that give rise to inflammatory-type 
DCs (16, 45), or arrose from local proliferation and differentiation of a myeloid 
precursor population that also generates alveolar macrophages (46). An identical 
subset of CD11b+CD11c+ DCs was found to be increased in the MLN from day 2-4 
onwards, suggesting again migration from the lungs to the MLN.  It was striking 
that there were several subsets of DCs found to be recruited and/or activated in 
the mediastinal LN, following influenza infection, strongly suggesting the division 
of labor between various APCs.  Recently, several papers have shown that the 
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cross presentation of exogenous harmless or viral antigen to CD8+ lymphocytes or 
presentation of exogenous antigen to CD4 T cells is a mutually exclusive function of 
CD8a+ or CD8a- DC subsets respectively (47-49). We therefore performed a head-
to-head comparison of the potential to present viral antigen to naïve CD4 or CD8 
T cells, taking advantage of influenza virus encoding either the MHCI or MHCII 
ovalbumin immunodominant epitope. 
 As previously described by Belz et al, CD8a+CD11b- resident DCs 
presented viral antigen to naïve CD8 cells, supported by the fact that these cells had 
upregulated costimulatory molecules.  Strikingly, the population of airway derived 
CD11b-CD8a- DCs also upregulated costimulatory molecules and presented not 
only to CD8 T cells but as well to CD4 T cells. This suggests that processing for 
and presentation on both MHCI and MHCII molecules can occur in a single cell 
population in vivo in the lung, contrary to what was shown for the spleen or lymph 
nodes (30). Vermaelen et al. also previously demonstrated that Ag presentation of 
harmless antigen to naive CD4 T cells in the MLN was an exclusive function of a 
migratory DC population (50).  Despite the fact that both CD8a+ and CD8a-CD11b- 
DCs presented antigen to naïve T cells, the strength of viral NP staining was not 
abundant.  This could be explained by the fact that viral NP was digested in these 
subsets as part of an antigen processing step, leading to a loss of immunoreactivity 
towards the NP-specific antibody.  Alternatively, Belz previously suggested that 
resident CD8a+ cells acquired the antigen from another migratory APC, proposedly 
the CD11b-CD8a- lung derived DCs, although this was never directly demonstrated 
(30).  Our data on viral NP staining suggest that the CD11b+ DCs as well as the pDCs 
were abundantly positive for viral antigen in the mediastinal LN, and therefore 
could be the most important source for providing viral antigens to resident CD8a+ 
DCs. 
 Another striking observation was the fact that the CD11b+CD11c+ subset 
found to be increased in the trachea, lung and mediastinal LN following influenza 
infection hardly presented any viral antigen to CD4 or CD8 T cells. Clearly, the 
CD11b+ DCs had seen viral antigens (either directly or through phagocytosis of 
virally infected apoptotic epithelial cells) as they carried an abundant amount of 
viral nucleoprotein in their cytoplasm. The absence of APC function by this subset 
is in striking contrast to the situation when harmless non-inflammatory antigen is 
inhaled (15).  What could be the purpose of recruitment of a different DC subset, in 
addition to CD11b-DCs, if these cells do not present antigen to naïve T cells? First, 
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as these cells have been shown to massively produce inflammatory chemokines, 
CD11b+ DCs might be crucial in attracking effector CD4 and CD8 cells that have 
been generated in the LN back to the lung and trachea, where they would mediate 
effector function (51). Secondly, CD11b+ DCs might have direct innate antiviral 
activity by producing TNFa and iNOS dependent NO, analogous to the situation 
seen with Listera monocytogenes infection (52, 53).  Thirdly, recruited CD11b+ 
DCs might also stimulate the innate antiviral activity of NK cells. The important 
function of inflammatory DCs in initiating the innate response is supported by the 
fact that influenza produces the non-structural protein-1 (NS-1), with a specific 
aim to subvert the innate immune function of the CD11b+ DC subset (3, 54). 
Future studies in our laboratory will have to address the direct or indirect innate 
and adaptive functions of inflammatory CD11b+ DCs in influenza infection.  
 Another way to study the function of lung DC subsets is to deplete them 
using various cell specific genetic targeting strategies employing the expression of the 
diphteria toxin receptor under control of a specific promotor and administration of 
the diphteria toxin via the airways (19).  In CD11c-DTR mice, there is a predominant 
depletion of lung CD11chi DCs, of tracheal CD11b+CD11chi DCs and of resident 
mediastinal LN CD8a+CD11chi DCs. As CD11b-CD11chi migratory tracheal DCs are 
not depleted in these mice, we consequently observed no decrease in MLN CD11b-
CD8a- DCs.  In CD11c-DTR mice given DT, we noticed that generation of virus 
specific CD8+ CTLs as well as production of effector cytokines (IFNg) by MLN cells 
was severely diminished. Based on our antigen presentation studies and based on 
previous work of Belz et al, we propose that this is due to depletion of the resident 
CD8a+CD11chi DCs or to the depletion of chemokine producing lung CD11b+ DCs. 
In CD11c-DTR mice, CD11chi alveolar macrophages are also depleted, although it 
is unlikely that this contributed to a decrease in antiviral immunity as adoptive 
transfer of wild type DCs but not macrophages restored immunity.  
 To address the specific role of migratory tracheal CD11b-DCs, we 
performed experiments in langerin-DTR mice (36).  Langerin was found to be 
present particularly on mucosal CD11b-CD103+ DCs in the lung (13), a population 
of cells that strictly relies on CCR7 to migrate to the mediastinal LN (15). In 
accordance, we also found increased numbers of langerin+CD103+CD11b-CD11c+ 
DCs in the mediastinal LN following influenza infection. Following intratracheal 
administration of DT, there was a selective depletion of CD11b-CD8a- migratory 
DCs in the trachea and MLN, while leaving the CD8a+ resident LN population or 
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alveolar macrophages unaffected. In the absence of the migratory langerin+ CD11b- 
DC population, influenza ran a particularly severe course. Strikingly, these data 
also suggest that the langerin+ DCs of the lung are much more immunogenic than 
their langerin+ Langerhans’ cell counterparts in the skin (36, 55, 56).
 Finally, we also addressed the in vivo function of lung plasmacytoid DCs, 
previously known as natural IFN-a producing cells (44).  In humans, these cells 
produce copious amounts of IFN-a  when exposed to influenza virus in vitro (57) 
and have been shown to stimulate already primed influenza-specifc CD4 and 
CD8 T cells (34). It has therefore been suggested that upon proper stimulation, 
plasmacytoid DCs develop into bona fide APCs that stimulate primarily antiviral 
immune response (58). To address the antigen presenting function of pDCs, we 
sorted pDCs from the mediastinal nodes of infected mice, and found no evidence 
for presentation to either CD4 or CD8 T cells ex vivo, despite the fact that the 
cells contained copious amounts of viral NP intracelullarly. Previous studies with 
other respiratory viruses have suggested that pDCs have a more immunoregulatory 
role, crucial for preventing excessive immune activation and immunopathology 
(12, 24, 25).  Although pDCs were attracted to the lungs and tracheal wall during 
influenza infection, their confirmed depletion using 120G8 Ab did not affect viral 
titers, generation of virus specific T cells, or severity of infection, arguing against 
a predominant role for pDCs as APCs, immunoregulatory cells or innate immune 
cells in this mild infection model. It was similarly striking to see that there was no 
effect on IFN-a production when pDCs were effectively depleted.  Infections in 
epithelial surfaces that bathe in IFN-a  (produced by epthelial cells) might be less 
dependent on IFN-a  production by plasmacytoid DCs. Akira’s group demonstrated 
recently that during lung infection with RNA viruses, alveolar macrophages are 
a predominant source of type I interferon, and that pDCs only start producing 
IFN-a when macrophages are depleted from the lungs (5).  The only effect of 
treatment with the 120G8 antibody was a significant reduction of the titer of virus-
specific HI antibodies at 8 dpi and 28 dpi, signifying a possible role for pDCs in 
stimulating humoral antiviral immunity, as previously suggested (59). Although we 
found no evidence for 120G8 staining on lung B cells following influenza infection, 
treatment with 120G8 Ab could also deplete plasma cells directly and in this way 
reduce HI Ab titers. Therefore we are awaiting more specific (e.g. genetic) pDC 
targeting strategies to address this point further. 
 In conclusion, our paper demonstrates a division of labor between 
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different DC subsets during pulmonary influenza infection, knowledge that 
might be employed for the design of better influenza vaccines and could increase 
understanding why particular strains of influenza are more pathogenic than 
others.
MATERIALS AND METHODS
Mice
C57BL/6 mice (6-8 weeks) were purchased from Harlan (Zeist, The Netherlands). The generation and 
screening of CD11c-DTR Tg mice has been reported previously (37). Male Balb/c background CD11c-
DTR Tg (H2-Dd) were crossed to C57BL/6 (H2-Db) to obtain F1 progeny, to allow detection of H2-Db 
tetramer. CD11chi cells were depleted in CD11c-DTR x C57BL/6 Tg mice by i.t. injection of 50 ng DT, 
a dose previously determined by titration (15) . PDCs were depleted by i.p. injection of pDC-selective 
depleting 120G8 antibody (22). All experiments were approved by an independent animal ethics committee 
of Erasmus MC Rotterdam, the Netherlands.
Influenza virus infection 
Influenza virus X-31 (MRC, Cambridge, England) were inoculated in the allantoic cavity of 11-day-old 
embryonated chicken eggs. The allantoic fluid was harvested after 2 days. Infectious virus titers were 
determined in Madin-Darby Canine Kidney (MDCK) cells (ATCC: Product CCL-34 (NBL-2) as described 
previously (60). Virus titers were obtained at day 4 and 8 post infection. Lungs were stored at -70 C. Lungs 
were homogenized with a Polytron homogenizer (Kinematica AG, Littau-Lucerne, Switzerland) in infection 
medium (Eagles Minimal Essential Medium (EMEM), Bovine serum albumin (fraction V 0,3 %), 4 mg/ml 
trypsin, 2mM l-glutamin, 100 U/ml penicillin, 100 mg/ml streptomycin, 0,15% NaHCO3, 20mM Hepes, 
non essential amino acids 0,1 mM). Ten-fold serial dilutions of these samples were used in eight-fold to 
determine the virus titers in MDCK cells as described previously (60). For antigen presentation assays of 
lymph node DCs, mice were infected with WSN influenza virus encoding OVA257-264 Kb restricted MHC 
I epitope in the neuraminidase (40) and X-31 influenza virus encoding OVA323-339 MHC II epitope in 
hemagglutinin of the virus (41) The OVA viruses were kindly provided by Dr. R. Webby (St. Jude Children’s 
Hospital, Memphis,USA).
Flow cytometry
For detection and phenotyping of DCs at day 2, 4 and 10 post infection, single cell suspensions of MLN and 
lung samples were prepared as described previously (24). Trachea was digested in collagenase solution for 1 
hour at 37˚C to promote release of DCs. Cells were subsequently stained with moAbs directed against MHCII 
FITC, intracellular NP FITC, CD86 PE, CD11c PE Texas Red, CD45 PECy5, CD103 PECy7, intracellular 
Langerin APC, mPDCA-1 APC, F4/80 APC Cy7, CD11b Pacific Blue and a fixable live/dead marker in 
Aqua (Molecular Probes). Acquisition of 8-9 colour samples was on a FacsAria cytometer equipped with 
FacsDIVA software. Final analysis and graphical output were performed using FlowJo software (Treestar, 
Costa Mesa, CA).  Cell sorting of DC subsets from MLN was performed on a FacsAria cytometer. Purity of 
sorted populations was > 95%.
Immunofluorescence on sorted DC subsets
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Sorted cell populations were spotted on microscope slides, dried and fixed in acetone. Subsequently, the 
slides were incubated with FITC labelled influenza A nucleoprotein specific antibody (IMAGENTM 
Influenza virus, DakoCytomation Diagnostics) at 37 ˚C for 15 minutes.  The slides were washed with PBS 
twice and once with distilled water, dried and embedded into a glycerol–PBS solution (Citifluor, UKC 
Chemlab, Canterbury). Uninfected cells stain dull red due to the Evan’s blue in the solution.  Green and 
yellow signal indicates the presence of NP. Fluorescence was scored using a fluorescence microscope (Carl 
Zeiss Jena, Jena, Germany).
Analysis of T cell proliferation
OT-1 and OT-2 transgenic T cells were isolated from spleens and LNs of respective mice, enriched by 
MACS cell sorting with anti-CD8 or -CD4 antibodies according to manufacturer’s protocol (Miltenyi Biotec 
GmbH) and labelled with CFSE (61). Sorted DC subsets were co-cultured with T cells in v-bottom plate at 
1/10 ratio for 4 days. T cell divisions were measured by flow cytometry. The percentage of cells recruited 
into cell division was calculated by dividing the number of individed cells by CFSE content as described 
previously using the formula 100 x {1 - [n0/(n0 + n1/2 + n2/4 + n3/8 + n4/16 + n5/32 + n6/64 + n7/128)]} 
to correct for the multiplying effect of division (61)
Tracheal whole mount staining
Animals were anesthetized with a lethal dose of Nembutal and perfused in vivo with 1 % paraformaldehyde 
fixative in PBS (pH7.4) for 2 minutes through the ascending aorta (18). Tracheas were removed, opened by 
a midline incision and pinned flat on silicone-coated petri dishes. After permeabilization in PBS containing 
0,3 % Triton X-100(Sigma), tissues were preblocked with rabbit serum, incubated with M5/114 mAb (rat 
IgG2, anti-I-A, and I-Eb,d,k, Boehringer Mannheim, Indianapolis, IN), for 36 hours at room temperature, 
washed, incubated with peroxidase conjugated rabbit-anti-rat IgG, followed by incubation for 20 minutes in 
0,05 % diaminobenzidine (DAB)in Tris-buffered saline (pH7,6). Tissues were dehydrated in serial alcohol 
steps and cleared in toluene. The entire trachea was mounted in D.P.X. mounting medium.
Detection of virus-specific CTL by tetramer-staining
Single cell suspensions of lung and spleen samples were prepared as described previously (24). Red blood 
cells were removed using erythrocyte lysis buffer (Roche, Almere, the Netherlands). The cells were washed 
with 0.5% BSA in PBS and stained 20 minutes at room temperature with antibodies: CD3e-PerCP, CD8b.2-
FITC (PharMingen, San Diego, United States), ToPro 3-APC (Molecular Probes,Eugene, United States) and 
PE labeled H-2Db tetramer with the NP366–374 epitope ASNENMETM (62) (Sanquin Research, Amsterdam, 
The Netherlands) 
Effector cytokine production
On 4 dpi, single cell suspensions of lung-draining lymph nodes were prepared. Cells were cultured in RPMI 
1640 medium (RPMI 1640 with 5% FCS) at a concentration of 2 x 106 cells/ml in the presence of either 
1 µg/ml plate-bound anti-CD3 (BD Biosciences) or medium alone and incubated at 37°C. After 4 days, 
supernatants were collected and stored at –20°C until ELISA for IFNg (BD Biosciences) was performed. 
IFN-a ELISA (PBL Biomedical laboratories) was performed on BAL fluid on several dpi. QRT-PCR for 
IFN-a was performed on homogenised lung on 4 dpi (Applied Biosystems, Assay-On-Demand).
Generation of BM-DCs
Bone marrow cells were cultured for 9 days in DC medium (DC-CM; RPMI 1640 containing glutamax-I 
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(Invitrogen, Carlbad, CA) supplemented with 5% (v/v) FCS (Sigma-Aldrich), 50 mM 2-Mercaptoethanol 
(Sigma-Aldrich), 50 mg/ml gentamicin (Invitrogen), and 20 ng/ml recombinant mouse GM-CSF, as 
described (15).
Adoptive transfer
Adoptive transfer reconstitution experiments were performed in DT treated CD11c-DTR x C57BL/6 mice. 
At the moment of infection they were treated with 2 x 106 i.t. bone-marrow –derived DCs and 2 x 105 
alveolar macrophages, as previously described (19). 
Detection of virus specific antibodies in serum
After treatment with cholera filtrate and heat inactivation at 56°C, the serum samples were tested for the 
presence of anti-HA antibodies. For this purpose, a hemagglutination inhibition (HI) assay was used 
following a standard protocol of 1% turkey erythrocytes and 4 HA U of H3N2 influenza virus (63).
Statistical analysis
All experiments were performed using 5-10 animals per group. The difference between groups was calculated 
using the Mann-Whitney U test for unpaired data (GraphPad Prism version 4.0; GraphPad, San Diego, CA 
Differences were considered significant when p<0,05.
Online Supplemental Materials
Figure S1 shows time kinetics of neutrophils, B cells and CD8+ T cells in the lung following influenza 
infection. Figure S2 shows the gating strategy for cDCs (A), pDCs (B) and alveolar macrophages (C). Figure 
S3 shows depletion of DC subsets in trachea (A) and MLN (B) in CD11c-DTR (left column) and Langerin-
DTR (right column). The online version of this article is available at http://www.jem.org/cgi/content/full/
jem20071365.
Acknowledgements
Corine H. Geurts van Kessel is supported by a VIRGO grant of the Dutch Organisation for Scientific 
Research. Leonie S. van Rijt is supported by a EUR Fellowship grant and Bart N. Lambrecht by a VIDI and 
VIRGO grant of the Dutch Organisation for Scientific Research, and by an Odysseus Grant of the Flemish 
Governement. Mirjam Kool is supported by a grant from the Dutch Asthma foundation. Björn E Clausen 
is the recipient of a VIDI grant and a career development grant of the Landsteiner Foundation for blood 
transfusion Research (LSBR). The authors have no conflicting financial interests.
48
References
Eichelberger, M., W. Allan, M. Zijlstra, R. Jaenisch, and P.C. Doherty. 1991. Clearance of influenza virus 1. 
respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp 
Med 174:875-880.
Legge, K.L., and T.J. Braciale. 2005. Lymph node dendritic cells control CD8+ T cell responses through 2. 
regulated FasL expression. Immunity 23:649-659.
Pichlmair, A., O. Schulz, C.P. Tan, T.I. Naslund, P. Liljestrom, F. Weber, and C. Reis e Sousa. 2006. RIG-I-3. 
mediated antiviral responses to single-stranded RNA bearing 5’-phosphates. Science 314:997-1001.
Tecle, T., M.R. White, and K.L. Hartshorn. 2005. Innate Immunity to Influenza A virus infection. 4. Current 
Respir Med Rev 1:127-145.
Kumagai, Y., O. Takeuchi, H. Kato, H. Kumar, K. Matsui, E. Morii, K. Aozasa, T. Kawai, and S. Akira. 2007. 5. 
Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. 
Immunity 27:240-252.
Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. 6. Nature 392:245-252.
McWilliam, A.S., D.J. Nelson, J.A. Thomas, and P.G. Holt. 1994. Rapid dendritic cell recruitment is a hallmark 7. 
of the acute inflammatory response at mucosal surfaces. J. Exp. Med. 179:1331-1336.
Legge, K.L., and T.J. Braciale. 2003. Accelerated migration of respiratory dendritic cells to the regional lymph 8. 
nodes is limited to the early phase of pulmonary infection. Immunity 18:265-277.
Lambrecht, B.N., J.B. Prins, and H.C. Hoogsteden. 2001. Lung dendritic cells and host immunity to infection. 9. 
Eur Respir J 18:692-704.
Vermaelen, K., and R. Pauwels. 2005. Pulmonary dendritic cells. 10. Am J Respir Crit Care Med 172:530-551.
von Garnier, C., L. Filgueira, M. Wikstrom, M. Smith, J.A. Thomas, D.H. Strickland, P.G. Holt, and P.A. 11. 
Stumbles. 2005. Anatomical location determines the distribution and function of dendritic cells and other 
APCs in the respiratory tract. J Immunol 175:1609-1618.
de Heer, H.J., H. Hammad, M. Kool, and B.N. Lambrecht. 2005. Dendritic cell subsets and immune regulation 12. 
in the lung. Semin Immunol 17:295-303.
Sung, S.S., S.M. Fu, C.E. Rose, Jr., F. Gaskin, S.T. Ju, and S.R. Beaty. 2006. A major lung CD103 (alphaE)-13. 
beta7 integrin-positive epithelial dendritic cell population expressing Langerin and tight junction proteins. J 
Immunol 176:2161-2172.
Wikstrom, M.E., and P.A. Stumbles. 2007. Mouse respiratory tract dendritic cell subsets and the immunological 14. 
fate of inhaled antigens. Immunol Cell Biol 85:182-188.
del Rio, M.-L., J.-I. Rodriguez-Barbosa, E. Kremmer, and R. Forster. 2007. CD103- and CD103+ bronchial 15. 
lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and 
CD8+ T cells. J Immunol 178:6861-6866.
Shortman, K., and S.H. Naik. 2007. Steady-state and inflammatory dendritic-cell development. 16. Nat Rev 
Immunol 7:19-30.
Sertl, K., T. Takemura, E. Tschachler, V.J. Ferrans, M.A. Kaliner, and E.M. Shevach. 1986. Dendritic cells with 17. 
antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura. J. Exp. Med. 
163:436-451.
Lambrecht, B.N., B. Salomon, D. Klatzmann, and R.A. Pauwels. 1998. Dendritic cells are required for the 18. 
development of chronic eosinophilic airway inflammation in response to inhaled antigen in sensitized mice. 
J. Immunol. 160:4090-4097.
van Rijt, L.S., S. Jung, A. Kleinjan, N. Vos, M. Willart, C. Duez, H.C. Hoogsteden, and B.N. Lambrecht. 2005. 19. 
In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features 
of asthma. J Exp Med 201:981-991.
van Rijt, L.S., J.B. Prins, V.C. deVries, P.J. Leenen, K. Thielemans, H.C. Hoogsteden, and B.N. Lambrecht. 2002. 20. 
Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD31hi Ly-6Cneg 
hematopoietic precursors. Blood 100:3663-3671.
Lambrecht, B.N. 2006. Alveolar macrophage in the driver’s seat. 21. Immunity 24:366-368.
Asselin-Paturel, C., G. Brizard, J.J. Pin, F. Briere, and G. Trinchieri. 2003. Mouse strain differences in 22. 
plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J Immunol 
171:6466-6477.
Blasius, A.L., E. Giurisato, M. Cella, R.D. Schreiber, A.S. Shaw, and M. Colonna. 2006. Bone marrow stromal 23. 
cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell 
49DC  subsets in influenza virus infection
Ch
ap
te
r 
2
surface antigen following IFN stimulation. J Immunol 177:3260-3265.
De Heer, H.J., H. Hammad, T. Soullie, D. Hijdra, N. Vos, M.A. Willart, H.C. Hoogsteden, and B.N. Lambrecht. 24. 
2004. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled 
antigen. J Exp Med 200:89-98.
Smit, J.J., B.D. Rudd, and N.W. Lukacs. 2006. Plasmacytoid dendritic cells inhibit pulmonary immunopathology 25. 
and promote clearance of respiratory syncytial virus. J Exp Med 203:1153-1159.
Wang, H., N. Peters, and J. Schwarze. 2006. Plasmacytoid dendritic cells limit viral replication, pulmonary 26. 
inflammation, and airway hyperresponsiveness in respiratory syncytial virus infection. J Immunol 177:6263-
6270.
Hamilton-Easton, A., and M. Eichelberger. 1995. Virus-specific antigen presentation by different subsets of 27. 
cells from lung and mediastinal lymph node tissues of influenza virus-infected mice. J.Virol. 69:6359-6366.
Yamamoto, N., S. Suzuki, A. Shirai, M. Suzuki, M. Nakazawa, Y. Nagashima, and T. Okubo. 2000. Dendritic 28. 
cells are associated with augmentation of antigen sensitization by influenza A virus infection in mice. Eur. J. 
Immunol. 30:316-326.
Brimnes, M.K., L. Bonifaz, R.M. Steinman, and T.M. Moran. 2003. Influenza virus-induced dendritic cell 29. 
maturation is associated with the induction of strong T cell immunity to a coadministered, mormally 
nonimmunogenic protein. J. Exp. Med. 198:133-144.
Belz, G.T., C.M. Smith, L. Kleinert, P. Reading, A. Brooks, K. Shortman, F.R. Carbone, and W.R. Heath. 2004. 30. 
Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen 
presentation after lung infection with virus. Proc Natl Acad Sci U S A 101:8670-8675.
Belz, G.T., L. Zhang, M.D. Lay, F. Kupresanin, and M.P. Davenport. 2007. Killer T cells regulate antigen 31. 
presentation for early expansion of memory, but not naive, CD8+ T cell. Proc Natl Acad Sci U S A 104:6341-
6346.
Belz, G.T., S. Bedoui, F. Kupresanin, F.R. Carbone, and W.R. Heath. 2007. Minimal activation of memory 32. 
CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat Immunol 
8:1060-1066.
Bender, A., L.K. Bui, M.A.V. Feldman, M. Larsson, and N. Bhardwaj. 1995. Inactivated influenza virus, when 33. 
presented on dendritic cells, elicits human CD8(+) cytolytic T cell responses. J. Exp. Med. 182:1663-1671.
Fonteneau, J.F., M. Gilliet, M. Larsson, I. Dasilva, C. Munz, Y.J. Liu, and N. Bhardwaj. 2003. Activation of 34. 
influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive 
immunity. Blood 
Dhodapkar, M.V., R.M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S.M. Donahoe, P.R. Dunbar, V. 35. 
Cerundolo, D.F. Nixon, and N. Bhardwaj. 1999. Rapid generation of broad T-cell immunity in humans after a 
single injection of mature dendritic cells. J Clin Invest 104:173-180.
Bennett, C.L., E. van Rijn, S. Jung, K. Inaba, R.M. Steinman, M.L. Kapsenberg, and B.E. Clausen. 2005. 36. 
Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell 
Biol 169:569-576.
Jung, S., D. Unutmaz, P. Wong, G. Sano, K. De los Santos, T. Sparwasser, S. Wu, S. Vuthoori, K. Ko, F. Zavala, 37. 
E.G. Pamer, D.R. Littman, and R.A. Lang. 2002. In vivo depletion of CD11c(+) dendritic cells abrogates 
priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17:211-220.
Vermaelen, K., and R. Pauwels. 2004. Accurate and simple discrimination of mouse pulmonary dendritic cell 38. 
and macrophage populations by flow cytometry: methodology and new insights. Cytometry A 61A:170-177.
Van Rijt, L.S., H. Kuipers, N. Vos, D. Hijdra, H.C. Hoogsteden, and B.N. Lambrecht. 2004. A rapid flow 39. 
cytometric method for determining the cellular composition of bronchoalveolar lavage fluid cells in mouse 
models of asthma. J Immunol Methods 288:111-121.
Topham, D.J., M.R. Castrucci, F.S. Wingo, G.T. Belz, and P.C. Doherty. 2001. The role of antigen in the 40. 
localization of naive, acutely activated, and memory CD8(+) T cells to the lung during influenza pneumonia. 
J Immunol 167:6983-6990.
Thomas, P.G., S.A. Brown, W. Yue, J. So, R.J. Webby, and P.C. Doherty. 2006. An unexpected antibody response 41. 
to an engineered influenza virus modifies CD8+ T cell responses. Proc Natl Acad Sci U S A 103:2764-2769.
Kreijtz, J.H., R. Bodewes, G. van Amerongen, T. Kuiken, R.A. Fouchier, A.D. Osterhaus, and G.F. Rimmelzwaan. 42. 
2007. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a 
heterosubtypic virus strain in mice. Vaccine 25:612-620.
Sapoznikov, A., J.A. Fischer, T. Zaft, R. Krauthgamer, A. Dzionek, and S. Jung. 2007. Organ-dependent 43. in vivo 
50
priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. J Exp Med 204:1923-1933.
Asselin-Paturel, C., A. Boonstra, M. Dalod, I. Durand, N. Yessaad, C. Dezutter-Dambuyant, A. Vicari, A. 44. 
O’Garra, C. Biron, F. Briere, and G. Trinchieri. 2001. Mouse type I IFN-producing cells are immature APCs 
with plasmacytoid morphology. Nat. Immunol. 2:1144-1150.
Naik, S.H., D. Metcalf, A. van Nieuwenhuijze, I. Wicks, L. Wu, M. O’Keeffe, and K. Shortman. 2006. Intrasplenic 45. 
steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 7:663-671.
Blusse van Oud Alblas, A., B. van der Linden-Schrever, and R. van Furth. 1981. Origin and kinetics of 46. 
pulmonary macrophages during an inflammatory reaction induced by intravenous administration of heat-
killed bacillus Calmette-Guerin. J Exp Med 154:235-252.
Dudziak, D., A.O. Kamphorst, G.F. Heidkamp, V.R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. 47. 
Liu, H.W. Lee, C.G. Park, R.M. Steinman, and M.C. Nussenzweig. 2007. Differential antigen processing by 
dendritic cell subsets in vivo. Science 315:107-111.
Allan, R.S., J. Waithman, S. Bedoui, C.M. Jones, J.A. Villadangos, Y. Zhan, A.M. Lew, K. Shortman, W.R. 48. 
Heath, and F.R. Carbone. 2006. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic 
cell population for efficient CTL priming. Immunity 25:153-162.
Schnorrer, P., G.M. Behrens, N.S. Wilson, J.L. Pooley, C.M. Smith, D. El-Sukkari, G. Davey, F. Kupresanin, 49. 
M. Li, E. Maraskovsky, G.T. Belz, F.R. Carbone, K. Shortman, W.R. Heath, and J.A. Villadangos. 2006. The 
dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad 
Sci U S A 103:10729-10734.
Vermaelen, K.Y., I. Carro-Muino, B.N. Lambrecht, and R.A. Pauwels. 2001. Specific migratory dendritic cells 50. 
rapidly transport antigen from the airways to the thoracic lymph nodes. J.Exp.Med. 193:51-60.
Beaty, S.R., C.E. Rose, Jr., and S.S. Sung. 2007. Diverse and potent chemokine production by lung CD11bhi 51. 
dendritic cells in homeostasis and in allergic lung inflammation. J. Immunol. 178:1882-1895.
Serbina, N.V., T.P. Salazar-Mather, C.A. Biron, W.A. Kuziel, and E.G. Pamer. 2003. TNF/iNOS-producing 52. 
dendritic cells mediate innate immune defense against bacterial infection. Immunity 19:59-70.
Rimmelzwaan, G.F., M.M. Baars, P. de Lijster, R.A. Fouchier, and A.D. Osterhaus. 1999. Inhibition of influenza 53. 
virus replication by nitric oxide. J Virol 73:8880-8883.
Diebold, S.S., M. Montoya, H. Unger, L. Alexopoulou, P. Roy, L.E. Haswell, A. Al-Shamkhani, R. Flavell, P. 54. 
Borrow, and C.R. Sousa. 2003. Viral infection switches non-plasmacytoid dendritic cells into high interferon 
producers. Nature 
Stoecklinger, A., I. Grieshuber, S. Scheiblhofer, R. Weiss, U. Ritter, A. Kissenpfennig, B. Malissen, N. Romani, F. 55. 
Koch, F. Ferreira, J. Thalhamer, and P. Hammerl. 2007. Epidermal langerhans cells are dispensable for humoral 
and cell-mediated immunity elicited by gene gun immunization. J Immunol 179:886-893.
Kissenpfennig, A., S. Henri, B. Dubois, C. Laplace-Builhe, P. Perrin, N. Romani, C.H. Tripp, P. Douillard, L. 56. 
Leserman, D. Kaiserlian, S. Saeland, J. Davoust, and B. Malissen. 2005. Dynamics and function of Langerhans 
cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. 
Immunity 22:643-654.
Cella, M., F. Facchetti, A. Lanzavecchia, and M. Colonna. 2000. Plasmacytoid dendritic cells activated by 57. 
influenza virus and CD40L drive a potent TH1 polarization. Nat. Immunol. 1:305-310.
Soumelis, V., and Y.J. Liu. 2006. From plasmacytoid to dendritic cell: morphological and functional switches 58. 
during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol 36:2286-2292.
Jego, G., A.K. Palucka, J.P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau. 2003. Plasmacytoid dendritic 59. 
cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19:225-234.
Rimmelzwaan, G.F., M. Baars, E.C. Claas, and A.D. Osterhaus. 1998. Comparison of RNA hybridization, 60. 
hemaglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring 
influenza virus replication in vitro. J Virol Methods 74:57-66.
Lambrecht, B.N., R.A. Pauwels, and B. Fazekas De St Groth. 2000. Induction of rapid T cell activation, 61. 
division, and recirculation by intratracheal injection of dendritic cells in a TCR transgenic model. J. Immunol. 
164:2937-2946.
Haanen, J.B., M.C. Wolkers, A.M. Kruisbeek, and T.N. Schumacher. 1999. Selective expansion of cross-reactive 62. 
CD8 positive memory T cells by viral variants. J Exp Med 190:1319-1328.
Masurel, N., P. Ophof, and P. de Jong. 1981. Antibody response to immunization with ilfluenza A/USSR/77 63. 
(H1N1) virus in young individuals primed or unprimed for A/New Jersey/76 (H1N1) virus. J Hyg 201-209.
51DC  subsets in influenza virus infection
Ch
ap
te
r 
2
Supplementary figures
Mo
ck
da
y 4
da
y 1
0
da
y 2
4
0
5
10
15
20
25
ab
s 
no
 B
 c
el
ls
 (x
10
4 )
Mo
ck
da
y 4
da
y 1
0
da
y 2
4
0
5
10
15
ab
s 
no
 C
D
8+
 T
 c
el
ls
 (x
10
3
)
Mo
ck
da
y 1
 
da
y 4
da
y 1
0
0
10
20
30
40
ab
s 
no
 n
eu
tr
op
hi
ls
 (x
10
4 )
A B C
*
*
*
**
*
Supplementary figure 1: Cellular composition of BAL fluid. 
(A) Number of CD11b+ Gr1+ neutrophils (B) Number of CD19+ B cells (C) Number of CD8+ T cells. The values are 
representative of 5 mice/group and expressed as mean ± SEM.  Similar results were obtained from several separate 
experiments. *p<0,05 **p<0,01
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Supplementary figure 2: Gating strategies in 8 color flowcytometric analysis of lung samples.
 (A) cDCs were gated as live cells, CD45+ and low fluorescent. Next, CD11b+ and CD11b- fractions were determined 
and within these populations the MHCII+CD11c+ DCs were gated. (B) pDCs were gated as live cells, CD45+ in the 
lymphocyte gate. Next they were gated as CD11b-MHCIIint cells expressing CD11cint and high mPDCA-1. (C) Alveolar 
macrophages were determined in BAL fluid as highly autofluorescent cells, expressing high levels of CD11c. Next, the 
CD11b- fraction was gated for F4/80 pos cells.
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ABSTRACT
Natural killer cells are innate effector cells known for their potential to produce 
interferon-g and kill tumour and virus-infected cells. Recently, B220+CD11cintNK1.1+ 
NK cells were found to also have antigen presenting capacity like dendritic cells (DC), 
hence their name interferon producing killer DC (IKDC). Shortly after discovery, it has 
already been questioned if IKDC really represent a separate subset of NK cells, or merely 
represent a state of activation. Despite similarities with DCs, in vivo evidence that they 
behave as bona fide APCs is lacking. Here, using a model of influenza infection, we found 
recruitment of both conventional B220- NK cells and IKDCs to the lung. To study antigen 
presenting capacity of NK cell subsets and compare it to cDCs, all cell subsets were sorted 
from lungs of infected mice and co-cultured ex vivo with antigen specific T cells. Both 
IKDCs and conventional NK cells as well as cDCs presented virus-encoded antigen to CD8 
T cells, whereas only cDCs presented to CD4 T cells. The absence of CD4 responses was 
predominantly due to a deficiency in MHCII processing, as preprocessed peptide antigen 
was presented equally well by cDCs and IKDCs. In vivo, the depletion of NK1.1-positive 
NK cells and IKDCs reduced the expansion of viral nucleoprotein-specific CD8 T cells in 
the lung and spleen, but did not affect viral clearance from the lung.  In conclusion, we 
found evidence for APC function of lung NK cells during influenza infection, but this is a 
feature not exclusive to the IKDC subset.  
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INTRODUCTION 
Influenza type A is a cytolytic virus that causes acute respiratory infection of which 
the clinical outcome can vary greatly. The way in which the innate and adaptive 
immune system initially recognizes and deals with replicating virus could be 
decisive in determining outcome of infection, as this might heavily influence the 
kinetics of viral clearance (1-3).  In immediate response to viral infection, innate 
defence mechanisms consist of high level production of type I interferons by 
infected epithelial cells, alveolar macrophages and natural interferon producing 
cells, as well as recruitment of neutrophils and NK cells (4),(5, 6). NK cells can 
kill virus-infected cells without prior antigen stimulation (7-9) in a process that is 
controlled by inhibitory and activating receptors, of which the activating natural 
killer cell receptor (Ncr1) gene product is most crucial during influenza infection 
(9-11). How exactly this innate immune response influences or enhances initiation 
of adaptive immunity is poorly understood.
 By expressing a wide array of microbial pattern recognition receptors 
shared with cells of the innate immune response and at the same time displaying 
the potential to process and present antigen to naive T cells, lung DCs bridge innate 
and adaptive immunity (12). During influenza infection, both conventional (cDC) 
and plasmacytoid (p)DCs exert different functions, but both are necessary to induce 
an immune response that clears the virus from the lungs and prevents re-infection 
(13). Recently it has been proposed that new member in the mouse DC family 
might display both innate immune functions of NK cells, as well as the potential 
to process and present antigen to naïve T cells, the so-called interferon producing 
killer DC, or IKDC (14, 15). Phenotypically IKDCs are defined as non-T (CD3-), 
non-B (CD19-) cells, with expression of intermediate levels of CD11c, B220, and 
MHC class II, and high-level expression of NK-specific markers NK1.1 and NKp46 
controlled by the Ncr1-locus (14-16). Functionally, IKDCs have the capacity to 
kill NK-sensitive target cells without prior activation, and induce proliferation of 
naïve T cells when pulsed with antigenic peptides. By contrast, conventional NK 
cells that lack expression of B220 and MHCII have not been identified as antigen 
presenting cells in the mouse(17). Although the existence of the IKDC population 
would make evolutionary sense, it has been controversial whether IKDCs really 
represent a separate DC lineage or nothing else but activated NK cells, endowed 
with antigen presenting capacity (18). The latter view is supported by the fact that 
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human NK cells have long been known to have APC-like activity (19, 20). The 
developmental pathways between NK cells and IKDCs also overlap as both rely on 
the IL-2Rb, IL-5Rb and common g chain (and thus a functional IL-15R complex) 
and IL-15 for development, whereas cDCs and pDCs develop in the absence of a 
functional IL-15R (15, 16).  Furthermore there was some doubt whether resting or 
CpG activated splenic IKDCs could present protein antigen or relevant pathogens 
(as opposed to pre-processed peptide) to CD8 and CD4 T cells ex vivo (21). 
Therefore, some authors suggest that IKDCs are functionally and developmentally 
closer to NK cells than to the two best-known DC family members.
 Here, we have studied the antigen presenting capacities of conventional 
NK cells, IKDCs and cDCs during influenza infection. Subsets of conventional 
NK and IKDCs were sorted from the lungs of infected mice to study their APC 
potential, in direct comparison with conventional DCs.  We found clear evidence 
for recruitment of NK subsets to lungs of infected mice and both conventional 
and IKDC subsets were able to present virus-encoded antigen to CD8 cells, but 
not CD4 T cells.  In support, NK1.1 depletion led to a reduced expansion of 
virus specific CD8 T cells in the spleen and lung.  However, viral clearance was 
unaffected.  These data support an APC function for NK cells, which however is 
not unique to the IKDC subset.
RESULTS
Surface phenotype analysis of lung DC subsets and NK cells following 
influenza virus infection
There is considerable overlap in the level of expression of phenotypical markers 
that have been used to discriminate putative IKDCs from pDCs, cDCs and NK 
cells.  In an attempt to make a head to head comparison of these various subsets in 
lungs in steady state conditions (mock infected mice) or during influenza infection, 
we have employed 10-colour flow cytometry to rigorously define phenotypes and 
activation status. We first gated on live cells in the lung and subsequently gated out 
the CD19+ B and CD3+ T cells (figure 1A, left plot), while discriminating between 
B220+ and B220- cells.  Conventional DCs (cDC) are described as being low for 
B220, while expressing high levels of CD11c and MHCII. As previously described 
by others, and us, in steady state conditions (mock) these cells can be further 
57IKDC in influenza
Ch
ap
te
r 
3
Figure 1: Identification of NK and DC subsets cell in lung tissue
(A) 10-color flowcytometric analysis of lung tissue. A CD3/CD19 negative population was gated from live, low 
autofluorescent cells in the lung. The B220 high population was further subdivided based on CD11c, 120G8, CD11b 
and NK1.1. After influenza virus infection, three populations could be clearly demarkated.CD11cinterm120G8lowNK1.1hi 
IKDCs, CD11cinterm120G8hiNK1.1loCD11blo pDCs and CD11chi120G8hiCD11bhiMHCIIhi iDCs. The iDC population was 
completely absent in steady state condition.  In the B220 low population cDCs were gated as MHIIhiCD11chi and 
NK cells as a NK1.1hi population expressing intermediate levels of CD11b. (B) Histograms demonstrating CD122 
expression on NK cells, IKDCs and cDCs. The grey histogram represents isotype control, black histogram represents 
CD122 expression.  Representative of 3 experiments.
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discriminated into a CD11b+ and a CD11b- subpopulation lacking expression of 
120G8 as depicted in the lower panels of figure 1A (13, 28). The CD3-CD19-B220- 
population also contained the conventional NK1.1+ NK cells.  When selecting for 
CD3-CD19-B220+ cells, we found two populations of CD11cint cells in steady state 
conditions, which can be further discriminated into pDCs by expression of the 
pDC marker bone marrow stromal antigen-2 recognized by the moAb 120G8. The 
120G8+CD11cint population represents NK1.1-CD11b- pDCs with low forward and 
side scatter, whereas the 120G8-CD11cint population represents NK1.1hiCD11bint 
IKDCs, also of small size and scatter (14). In influenza X-31 infected lungs, there 
was a striking difference in the characteristics of isolated populations found at 4 
days post infection.  Firstly, within the B220-MHCIIhiCD11chi cDC, there was a loss 
of the CD11b- subset, as recently reported, and the remaining CD11bhi DCs co-
expressed 120G8 (a pDC marker shown to be induced by interferon production) 
(29) (13). Even more strikingly, the B220+ cells now also contained a subset of cells 
that highly expressed CD11c (like cDCs) as well as 120G8 (like pDCs).  Further 
analysis of this population revealed that it expressed very high levels of CD11b 
and intermediate levels of NK1.1, although a subset of these cells was as high in 
expression of NK1.1 as IKDCs and NK cells.  These cells were however larger 
and expressed very high levels of MHCII, most likely resembling inflammatory 
DCs, recently surged from monocytes (13, 30). Figure 1B demonstrates that the 
expression of the IL-2-IL-15 receptor b chain (CD122) was only expressed on 
NK cells and IKDCs, but not on pDCs or cDCs, as previously described (15).  In 
addition, IKDCs in the lungs expressed NKG2D and PDL1 (also known as B7H-1)
(data not shown).
During influenza infection, both lung IKDCs and B220- NK cells lyse NK-
sensitive targets
The main function of NK cells is known to be cell lysis without prior activation in a 
process requiring granzyme A and B. We compared expression of these molecules 
by qPCR on lung derived NK cell subsets and cDCs, and found higher expression 
levels of both Granzym A and B on IKDCs than on regular B220- NK cells. On 
cDCs no expression was detected (figure 2A). Next, the functional capacity to lyse 
NK-sensitive YAC target cells was studied by using a CFSE-labeled YAC assay as 
described previously (25). In line with granzyme expression and expression of 
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activating NK receptors, both IKDCs and B220- NK cells sorted from infected lung 
tissue efficiently lysed YAC-1 target cells (figure 2B), to a degree that is seen when 
using splenic NK cells as effector cells, supporting the idea that lung CD3-CD19-
B220+CD11cintNK1.1+ cells also functionally behave like IKDCs (15, 21).
Kinetics and maturation state of IKDCs, B220- NK cells and cDCs in lung 
following influenza virus infection
As influenza X-31 infection is a mild infection localized in the respiratory tract, 
we studied the effect of infection on the number and maturation status of IKDCs 
in the respiratory tract (lung, bronchoalveolar compartment (BALf), mediastinal 
LN (MLN) and the spleen), using the multi-parameter gating strategy as above.  A 
kinetic analysis at various days post infection (dpi) revealed that IKDCs, B220-NK 
cells and cDCs accumulated in the lungs with different kinetics and to different 
extents; IKDCs and cDCs peaking at 7dpi whereas NK cells were increased from 
day 1 to 7 post infection compared with mock infected mice (data shown for 
digested lung tissue).  For clarity reasons we lumped CD11b+ and CD11b- cDCs 
together, but we have recently provided detail on this (13). We next defined the co-
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Figure 2: IKDCs and B220- NK cells induce cell lysis
(A) Expression of Granzyme A and B on sorted cell subsets at 4 dpi. Bars represent the values of expression relative to 
NTC. (B) Percentage YAC-1 cell target lysis after co-culture with different effector DC and NK cell subsets. IKDCs, B220- 
NK cells and DCs were sorted from lung tissue at 4 dpi following gating strategies depicted in figure 2 and compared 
with enriched NK cells from spleen tissue. Cells were incubated with CFSE-labeled NK-sensitive YAC-1 target cells. 
Lysis at each effector:target (E:T) ratio was determined as described in materials and methods. Representative of 2 
experiments.
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stimulatory molecule expression on these various populations at 4 dpi. Whereas 
we could find an increased number of IKDCs in all compartments (figure 3A 
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depicts only the digested lung samples), the increase in expression of the maturation 
marker CD86 (Fig 3B) and expression of MHC class II (figure 3C) molecules was 
restricted to the site of primary infection being lung and BALf (figures depict lung 
tissue) and occurred on both IKDCs, B220-NK cells and cDCs, albeit to different 
degrees.  Notably there were no signs of cDC, NK or IKDC activation in spleen or 
MLN (data not shown).  
 An increase in IKDCs could be due to increased chemoattraction of IKDCs 
to the lung, in a process that might be controlled by CXCR3 and/or CCR2 (31). 
We therefore examined expression levels of the CXCR3 ligands CXCL10 (IP-10), 
CXCL11 (ITAC), as well as the CCR2 ligands CCL2 (MCP-1) on a genome-wide 
expression micro array performed on whole lung homogenate from mock-infected 
or X-31 infected mice at various hours post infection (hpi) (Fig 3D, full microarray 
data to be published elsewhere).  Analysis revealed that these chemokines were 
clearly upregulated with similar kinetics as gene products associated with NK and/
or IKDC function such as Ncr1, granzyme A and B, klrk1, Nkg7.  Alternatively, 
IKDC accumulation could be due to increased proliferation or survival inside the 
lung, possibly due to the presence of homeostatic cytokines of the IL-2 family that 
share the gc chain for signaling (IL-2, IL-15, IL-21). 
Antigen presenting capacity of sorted IKDCs, B220-NK cells and cDCs from 
infected lungs 
After observing a clear increase in absolute number and maturation state (MHCII 
and CD86) of IKDCs in lung tissue at 4 dpi, we decided to sort IKDCs from infected 
mice and perform a head to head comparison with their two closest family members, 
cDCs and B220- NK cells for the capacity to present to CD8 or CD4 T cells.  To study 
the antigen presenting capacity of the different cell subsets we infected mice either 
with an influenza virus containing the OVA MHCI (SIINFEKL) or MHCII OVA323-
339 epitope. At 4 dpi DC and NK cell subsets were sorted with a purity exceeding 
98% from the lung tissue and put in co-culture with either CFSE-labeled OVA 
specific CD8+ T cells (OT-1) or CD4+ T cells (OT-2), taken from the respective TCR 
transgenic animals. As a negative control, co-cultures were set up with influenza 
virus infected cDCs in which the opposite OVA epitope was expressed (for example: 
a virus containing the MHCII OVA epitope for presentation to OT-1 cells). To test 
if any lung cell exposed to the innate cytokine response would be able to induce 
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proliferation of OT-1 T cells, additional cocultures were set up with CD45- lung 
epitelial cells as APCs. Four days later, CFSE dilution of T cells was measured 
by flowcytometry, and expressed as the % of cells that had divided at least once. 
As shown in Figure 4A, cDCs induced strong CD4 T cell proliferation ex vivo 
following influenza infection (48% recruited into cell division), whereas IKDCs 
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only induced the proliferation in 3% and B220- NK cells in 5% of co-cultured CD4 
T cells. In the supernatant of the co-culture we determined levels of IL-2 and IFN-g 
(figure 4B) and according to the T cell division we found high levels of IL-2 in the 
co-culture with cDCs.  High levels of IFN-g were induced in the co-culture with 
cDC and B220- NK cells but not with IKDCs. Next, we studied the capacity to induce 
CD8 T cell proliferation (figure 4C). Conventional DCs induced the proliferation 
of up to 95% of co-cultured CD8+ Ag specific T cells.  In contrast to the lack of 
induction of CD4 responses, IKDCs presented influenza derived OVA epitopes to 
CD8+ T cells (53% recuited into cell division), however to a degree similar to B220-
NK cells (62 % recuited into cell division). Lung epithelial cells did not induce any 
T cell divisions.  Cytokine profiles in figure 4D supported these data; high levels 
of both IL-2 and IFN-g were measured in the cDC co-culture, whereas similar 
(yet lower) levels were found in cultures with IKDCs and NK cells, and epithelial 
cells failed to induce IL-2 or IFN-g.The cytokine production showed a clear dose 
dependency in all APC populations, which were put into co-culture with several 
concentrations of OT-1 T cells.  The absence of CD4 T cell response induction in 
the face of clear CD8 activation could signify a defect in processing of viral antigen 
for MHCII pathway or an absence of co-stimulatory molecules on NK subsets. To 
address if the MHCII complex and co-stimulation on IKDCs is at least functional, 
we added pre-processed MHCII-restricted OVA323-332 peptide to the co-culture of 
IKDCs and OT-II cells, which induced efficient proliferation in up to 50% of CD4 
cells, similar to the degree of division seen in T cells stimulated with cDCs (67%), 
indicating that IKDCs do posses a functional MHCII complex.  Likewise, addition 
of MHCI-restricted OVA peptide led to identical T cell proliferation induced 
Figure 4: Antigen presenting capacity of lung cDCs and NK cell subsets
Lung populations were sorted following the gating strategies in figure 1. (A) CFSE-labelled OT-2 (CD4+) - T cell 
proliferation 4 days after co-culture with cDCs, IKDCs and B220- NK cells sorted from lung tissue of mice infected with 
PR-8 containing the OVA-CD4+ epitope. Negative control sample indicates co-culture of OTII cells with cDCs derived 
from a mouse infected with a MHCI-OVA epitope containing virus. Histogram represents average % of cells divided, 
from 3 seperately performed experiments. Lower left plots indicate T cell proliferation after addition of OT-2 peptide 
to the co-cultures. (B) Histogram represent IL-2 and IFN-g levels in supernatant of OTII co-cultures (C) Panel shows 
the same data for CFSE-labelled OT-1 (CD8+) - T cell proliferation 4 days after co-culture with cDCs, IKDCs, B220- NK 
cells and CD45-negative epithelial cells sorted from lung tissue of mice infected with WSN containing the OVA-
CD8+ epitope. Negative controls in this setting are co-culture of OTI cells with cDCs derived from a mouse infected 
with a MHCII-OVA epitope containing virus. Numbers in top left corners of all plots represent the percentage of 
cells recruited into cell division and the histogram shows average % cell divisions of 3 separate experiments. (D) 
Histograms represent IL-2 and IFN-g levels in supernatant of OTI co-cultures with different ratios of DCs versus OTI T 
cells.  (E) Expression of TAP-1, Sec61a1, Cathepsin S and invariant chain on sorted cell subsets at 4 dpi. Bars represent 
the values of expression relative to NTC. (D) Percentage of cells that have nucleoprotein (NP) positivity, measured by 
flowcytometry, and indicating replicative infection. Bars represent an average of at least 5 mice/group +/- SEM.
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by IKDCs and cDCs. It has been proposed that specializations of DCs to either 
cross-present to CD8 cells or to CD4 cells is a function of particular DC subsets 
caused by the expression of specific enzymes involved in antigen processing in 
particular DC subsets, or differential expression of antigen-uptake receptors (32, 
33). To study antigen-processing capacity of the various isolated NK-like cell 
populations, quantitative PCRs were performed on the sorted cell subsets (figure 
4E). Class II processing and loading molecules (cathepsin S and invariant chain) 
were expressed in high levels by cDCs and to a much lesser extent in IKDCs or 
B220-NK cells. MHCI pathway molecules Sec61a1 (an endoplasmatic reticulum 
membrane protein translocator involved in crosspresentation to CD8 T cells) and 
TAP-1 (ATP-binding cassette transporter associated with MHCI loading) were 
expressed on cDCs and on both IKDC and B220-NK cells. Differences in APC 
capacity might also reflect different degrees by which these cells were infected 
by influenza virus. To address this point, we studied the degree of infection by 
staining for nucleoprotein (NP) in the separate cell subsets at 4 dpi (13). Whereas 
15% of cDCs and B220- NK cell isolated from the lung were infected, we found that 
only 5% of IKDCs were NP positive (figure 4F). 
Depletion of NK1.1 positive cells during influenza virus infection reduces 
the innate and adaptive immune response to influenza
The described experiments suggested that IKDCs and B220- NK cells had APC 
potential for CD8 cells ex vivo. To study the role of NK1.1+ cells during infection 
in vivo we injected the NK1.1-specific depleting antibody PK136 before and 
throughout influenza infection or mock infection (34). Both in mock infected and 
infected mice, intra-peritoneal (i.p.) injection of the antibody efficiently depleted 
NKG2D+ B220-NK cells and IKDCs from the lung tissue (figure 5A) when 
compared to injection with isotype Ig diluted in PBS, although depletion was more 
absolute in mock infected mice.  On the contrast, cDC numbers were unaffected 
by treatment with NK1.1.  Previously an enhancing effect of NK cells on the state 
of maturation and antigen-presenting capacity of cDCs has been suggested (35-
37).  To exclude any confounding effects of NK1.1 depletion on cDC functions, 
we additionally compared the antigen presenting capacity of sorted cDCs after 
infection with influenza virus containing the OVA MHCI epitope, in mice treated 
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Figure 5: Depletion of NK1.1+ cells during in vivo influenza virus infection affects infection parameters 
(A) 2 days after injection of PK136 (NK1.1 depleting antibody), mice were infected with X31 virus. Two days later, 
depletion of NK subsets and cDCs was checked in lung tissue by using the gating strategy in Fig 1. (B) IFN-g was 
measured in BALf of infected mice versus mock-infected mice with or without NK1.1+ cell depletion. Bars represent 
mean values of IFN-g +/- SEM. At least 5 mice per group were used, * p<0,05. (C) Viral titers were measured in lung 
tissue of at least 5 mice per group and expressed as mean TCID50 +/- SEM. * p< 0,05. (D) Absolute numbers of TM 
specific CD8+ T cells were measured in spleen and lung tissue at 8 dpi and represented as mean values +/- SEM, of at 
least 5 mice/group. (E) Hemagluttinin specific antibodies in serum were measured at 8 dpi and depicted as geometric 
mean titer +/- SEM. * p<0,05. (F) Weight loss of mice during infection depicted as % of initial weight. Values indicate 
mean of at least 5 mice per group +/- SEM.*p<0,05.
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or not with PK136. At 4 dpi cDCs were sorted from both groups and expressed 
similar levels of co-stimulatory molecules (CD86) and MHCII and induced the 
same amount of T cell proliferation (supplementary Fig 1). We next addressed the 
impact of NK1.1 depletion on induction of antiviral innate and adaptive immunity 
to a mild X-31 pulmonary influenza infection. During the early innate response 
to influenza, IFN-g is found in high levels at the site of infection (lung tissue and 
BAL fluid) (13) and NK cells are the most prominent source of this cytokine (6, 
11).  Not surprisingly, we found a significant decrease of IFN-g at 4 dpi in mice 
depleted of NK1.1 cells. At 8 dpi this mild influenza X-31 infection has been 
cleared from the lungs and therefore IFN-g levels start decreasing at this time 
point (Figure 5B). Viral titers in mice lacking NK1.1 cells were increased 5 fold 
at 4 dpi compared with mice treated with isotype control antibody. Nevertheless 
virus was efficiently cleared at 8 dpi (figure 5C). Most importantly, to address the 
contribution of NK1.1 positive cells on induction of adaptive CTL immunity, we 
measured the percentage of virus-specific CD8 T cells at day 8 post infection by 
using a PE labeled H-2Db tetramer with the NP366–374 epitope ASNENMETM 
(13). At day 8 we found decreased numbers of tetramer (TM) positive cells in 
both spleen and lung tissue (figure 5D). In addition to this we determined the 
hemagluttinin specific antibodies in serum at 8 dpi (figure 5E) and found increased 
levels following NK1.1 depletion, supporting the higher viral titers. Both at earlier 
and later time points, similar conclusions on tetramer positive cell induction and 
humoral immune responses were reached (Supplementary figure 2).  Surprisingly, 
NK1.1 depleted mice did not appear to have much more severe systemic morbidity 
as their weight loss did not exceed 10% of initial weight, in contrast with isotype 
treated mice, which lost significantly more weight during the peak of infection 
(Figure 5F).  As a final support for an antigen presenting capacity of NK cells in 
vivo, we also found colocalization of naïve OVA-specific CD8 T cells with NK cells 
in the draining nodes 48 h after infection with influenza-OVA virus but to a much 
lower extent with wild type influenza virus (supplementary figure 3).
DISCUSSION
NK cells are part of the innate immune system and among the first immune effector 
cells to arrive at inflammation sites (5, 11).  Here, we found rapid accumulation 
of cells with an IKDC phenotype in infected lungs.  The reason for this could be 
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enhanced recruitment of IKDCs to the lungs, or enhanced proliferation and/or 
survival of IKDCs in the infected lung.  Although little is known about chemokines 
and their receptors that govern directed migration of IKDCs, CCR2 and CXCR3 
are likely candidates based on a recent study (31) and similarities with NK cell 
migration(38).  Accordingly, we found an early yet persistent upregulation of 
the ligands CXCL10 and CXCL11 as well as CCR2 and CCL2 in virus-infected 
lungs.  We also found increased expression of IL-15 in the lungs, a critical cytokine 
involved in IKDC development, expansion and survival in steady state (29) (16) 
(21) and inflammatory conditions (31). Another likely explanation for the increased 
number of NK-like cells in the lungs following infection could be that cells are 
interconverting by differentiation, thereby upregulating markers on their surface. 
We do not exclude that IKDCs could be a highly differentiated NK cell but decided 
to study both NK cell subsets separately and compare them with cDCs in lung 
tissue.
 Although the predominant effector function of NK cells is the direct attack 
of virus-infected cells, as illustrated here by an increase in early viral titer in the 
lungs of NK1.1 depleted mice, increasing evidence suggests that they shape the 
quality and quantity of the ensuing adaptive immune response by either stimulating 
or suppressing the function of bona fide APCs like DCs (35-40). NK cells have 
extensive trafficking capabilities and are found within non-lymphoid and lymphoid 
tissues, sometimes in close proximity to naïve T cells, as also shown in this study 
(38, 41).  In vitro studies revealed that activated human NK cells and NK cell clones 
can process soluble antigen, up-regulate MHCII and co-stimulatory molecules, 
and thus stimulate naïve CD4 and CD8 T cell responses (19, 20).  The functional 
relevance of this has been questioned in vivo, as mouse NK cells were classically not 
found to have direct APC function (17, 18). Recently, it was proposed that IKDCs 
found in central lymphoid organs and tumours are the in vivo mouse correlates 
of human NK cells that display DC-like properties, such as expression of CD86, 
MHCII and potential to present pre-processed peptides to T cells (14, 15, 17). 
Although in the original description, these cells were proposed to be a separate and 
new subset of NK-like DCs, subsequently three different groups refuted this idea 
and proposed that IKDCs are nothing else but DC-like NK cells (16, 21, 29). 
 Regardless of these ‘family affairs’ between NK cells and DCs, the argument 
that NK cells might be endowed with APC potential made us embark on a detailed 
study in the mouse in which we evaluated the precise contribution of NK cells to 
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induction of adaptive immunity during influenza infection of the lung.  We repeated 
an experiment previously reported by Kos and Engleman in which depletion of 
NK1.1+ cells was shown to hamper the induction of virus-specific CD8 CTLs (34). 
This experiment had been performed in an era when it was impossible to identify 
virus-specific CD8 T cells with MHCI-peptide tetramers and multi-colour flow 
cytometry was not so advanced as to discriminate and sort multiple subsets of 
NK cells and DCs simultaneously.  In our hands, injection of an NK1.1 depleting 
antibody effectively depleted the NKG2D+ conventional B220-NK cells, as well as 
IKDCs, which led to a reduction of tetramer-positive NP-specific CD8 T cells upon 
viral infection, as measured at several time points post infection.  Although our data 
on reduced CTL frequency support the early work of Kos et al, the interpretation 
has been that NK cells promote the accessory function of DCs via secretion of 
IFN-g or direct cell-cell contact (34, 35). However several other explanations are 
plausible. By studying the expression of MHCII, CD86 and the potential of cDCs 
to present viral derived antigen to CD8 T cells, we found little evidence for altered 
DC accessory function when NK1.1-positive cells were depleted during influenza, 
lending little support to the former theory.  Alternatively, NK1.1 Ab treatment 
might have eliminated CD8 CTLs directly, as NK1.1 is expressed by some 10% of 
virus specific CD8 CTLs ((42) and our own unpublished data). We do not believe 
that direct killing of CTLs by NK1.1 antibody was responsible for the observed 
effect because as many as 50% of tetramer-positive CD8 cells were depleted. CD3-
positive NK T cells also express the NK1.1 marker, yet these cells were recently 
shown not to play a predominant role for antiviral immunity during influenza 
infection (43).  Our data on the antigen presenting capacities of NK cell subsets ex 
vivo, as well as the colocalization of NK cells and naïve CD8 T cells in the central 
lymphoid organs at early time points post infection favour the theory that CD8 
T cell responses were partially reduced because of the depletion of B220-NK cells 
and IKDCs, as direct actors in the process of antigen presentation to naive antigen-
specific CD8 T cells.  
 As recently suggested by others, we also found that during influenza 
infection the APC functions of NK cells are present within a subset of lung CD3-
CD19-NK1.1+ B220+CD11c+ cells that also express killing activity for classical NK 
targets (14, 15). However, this APC feature was not unique to IKDCs and similarly 
present in B220- conventional NK cells. Both subsets upregulated the expression 
of CD86 upon influenza infection and presented to CD8 T cells. This could be 
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a reflection of direct Ag presentation in case of direct infection of NK subsets by 
influenza virus or cross-presentation of virally infected lung epithelial cells.  At 
least for IKDCs we favour the latter explanation as we did not find real evidence of 
direct infection of IKDCs by influenza (low levels of viral nucleoprotein staining 
compared with cDCs (13, 21)), and as IKDCs highly expressed members of the 
ER retro translocation machinery Sec61a1 (involved in cross-presentation) and 
cathepsin S, also recently implicated to play a role in crosspriming (32, 33). How 
exactly IKDCs acquire antigen for cross-presentation however is unclear at present 
as we did not address their capacity to phagocytose virus infected cells, nor the 
causal relationship between killing of virus infected cells and subsequent processing 
of antigen derived from killed target cells. The division that was induced ex vivo in 
CD8 T cells by IKDCs was not accompanied by vigorous IFN-g production, in 
contrast to T cells stimulated with cDCs under identical conditions.  
 One factor that discriminates lung NK cell subsets is the higher level of 
expression of MHCII on IKDCs compared with B220- NK cells in infected lung 
samples.  It was therefore striking to see that IKDCs hardly presented influenza 
derived antigen to specific CD4 T cells, whereas cDCs readily did under these 
conditions. The most obvious explanation would be the much higher level of 
co-stimulatory molecules and MHC molecules on cDCs, and expression of the 
full enzymatic machinery to process antigen for the MHCII pathway in cDCs. 
Supporting this idea, we did find that addition of pre-processed MHCII peptide 
on IKDCs led to T cell divisions, albeit at reduced vigour compared with similarly 
pulsed cDCs. The apparent lack of mRNA expression of invariant chain by B220-
NK cells and IKDCs, compared with cDCs explains the incapacity to process for 
MHCII, as invariant chain is crucial for proper intracellular routing and loading 
of MHCII molecules by endosomal cargo (32, 33, 44).  Strikingly, the coculture 
of B220- NK cells and naïve CD4 T cells, did lead to a good production of IFN-g. 
The fact that this was not accompanied by CD4 T cell division, makes it likely that 
this IFN-g response was NK-derived.  The idea that IKDCs have MHC processing 
capacity has been questioned by other studies showing a very weak potential of 
these cells to present antigen to CD4 T cells ex vivo following expansion in Gleevec/
IL-2 and maturation by IL-15 (31), or following exposure in vitro to soluble protein 
antigens or pathogens (21).   It is possible that IL-15 present in the lungs of influenza 
infected mice (as detected from our whole lung mRNA array data) shuts down part 
of the APC function of IKDCs for CD4 T cells, as recently demonstrated in vitro 
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(31). 
 At first sight our data on the APC capabilities of IKDCs are at odds with 
recent papers studying this subject. In vitro work in the human immune system 
illustrated how activated NK cells expressing MHCII and co-stimulatory molecules 
could process influenza hemaglutinin (HA) protein and virus infected targets for 
presentation to HA-specific CD8+ and CD4+ T cell clones (20).  There could be 
major differences between in vitro activated human NK cells and ex vivo lung 
derived murine NK cells that have been part of an innate immune response to live 
influenza infection. In one of the papers refuting the idea that IKDCs represent 
a subset of DCs it was shown that splenic IKDCs were unable to present viral 
antigens to influenza specific T cells following in vitro influenza infection, even 
after CpG stimulation (21).  This could reflect the need for a cell population or 
cytokine response in vivo that licences NK cell subsets to become APCs at the site 
of infection.  Clearly, finding such a stimulus could be very instructive in finding 
ways to improve mucosal vaccines.
 In conclusion we have demonstrated that influenza virus infecting the 
lung tissue seriously affects the phenotypical appearance of cells, which makes 
multi-color flowcytometry necessary to distinguish multiple cell subsets. We 
found in vivo and ex vivo evidence for antigen presenting capacities within IKDCs 
and conventional NK cells during influenza infection. All together, clearance of 
influenza virus from the lungs is therefore yet another example of the delicate 
crosstalk between innate and adaptive immune response that emerged through 
evolution to safeguard the host from infectious threats while avoiding immune 
pathology to the host. 
MATERIALS AND METHODS
Influenza virus infection
C57BL/6 mice (6-8 weeks) were purchased from Harlan (Zeist, The Netherlands). Influenza virus X-31 
(MRC, Cambridge, England) was inoculated in the allantoic cavity of embryonated chicken eggs. Infectious 
virus titers were determined in Madin-Darby Canine Kidney (MDCK) cells. Lungs were homogenized and 
ten-fold serial dilutions of these samples were used in eight-fold to determine the virus titers in MDCK cells 
as described previously(22). All experiments were approved by an independent animal ethics committee at 
Erasmus MC Rotterdam, the Netherlands.
NK1.1 cell depletion
Naive C57BL/6 mice were treated i.p. with 200mg of anti-NK1.1 mAb (PK136) on day -2 followed by 
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infection with influenza X-31 at day 0. Subsequent i.p. injections of 100mg anti-NK1.1. were given at day 0, 
1, 2, 3, 4, 5 and 7 post infection. As a control mice were treated with isotype IgG from mouse serum (Sigma-
Aldrich)
Flow cytometry and cell sorting
For detection and phenotyping of DC subsets in organs, cell suspensions of lung, MLN and spleen were 
prepared as described previously(23). Cells were subsequently stained with moAbs directed against 120G8 
FITC (kindly provided by C.Asselin-Paturel), CD11b PE, MHCII PECy5, B220 PECy7, NKG2D PECy7, 
CD122 Pacific Orange (eBioscience), CD11c PETxR(Caltag), NK1.1 APC, CD3 APC Cy7, CD19 APC 
Cy7 (BD Biosciences), and a live/dead marker (DAPI) in Violet. Acquisition of 9-10 color samples was 
done on a LSRII cytometer. For measurement or viral nucleoprotein (NP) in cells FITC labeld anti-NP 
Ab (DakoCytomation) was used. Virus-specific CTL were detected by tetramer-staining with following 
antibodies: CD3e-PerCP, CD8b.2-FITC (PharMingen, San Diego, United States), ToPro 3-APC (Molecular 
Probes,Eugene, United States) and PE labeled H-2Db tetramer with the NP366–374 epitope ASNENMETM 
(Sanquin Research, Amsterdam, The Netherlands). Final analysis and graphical output were performed 
using FlowJo software (Treestar, Costa Mesa, CA). 
Flow cytometry-based cytotoxicity assay
Effector cells from infected lungs were sorted on a FacsARIA cytometer and as a positive control spleen NK 
cells (isolated from infected spleens of the same mice of which lungs had been obtained) were enriched by 
MACS cell sorting with DX-5  antibodies according to manufacturer’s protocol (Miltenyi Biotec GmbH). All 
effector cells were labeled with CFSE (24) and plated in serial dilution. Target cells (YAC-1) were harvested 
in exponential growth phase, washed and plated 2000 target cells/well. As a positive control 2% triton was 
added to a number of wells containing only YAC-1 cells. Cells were centrifuged for 1 minute at 335g to 
facilitate cell-cell contact, and incubated for 4 hours at 37˚C. At the end of the incubation time samples were 
put in an ice water bath and Micro Beads were added to allow a constant number of measuring on the LSRII 
Flowcytometer (BD Bioscience, USA). Prior to measuring, DAPI was added for labeling of dead cells. All 
samples were analysed using FlowJo software (Treestar, Costa Mesa, CA) as described previously (25).
Antigen presentation assays
For antigen presentation assays of lung DC subsets, mice were infected with WSN influenza virus encoding 
OVA257-264 Kb restricted MHC I epitope in the neuraminidase (26) and PR-8 influenza virus encoding 
OVA323-339 MHC II epitope in hemagglutinin of the virus (27). The OVA viruses were kindly provided by 
Dr. R.Webby (St. Jude Children’s Hospital, Memphis, Tennessee, USA). OT-1 and OT-2 transgenic T cells 
were isolated from spleens and LN of respective mice, enriched by MACS cell sorting with anti-CD8 or 
–CD4 antibodies according to manufacturer’s protocol (Miltenyi Biotec GmbH) and labeled with CFSE(24). 
Sorted DC subsets were co-cultured with T cells at 1/10 ratio for 4 days. T cell divisions were measured by 
flow cytometry and supernatants were collected and stored at -20˚C until ELISA for IFN-g and IL-2 (BD 
Biosciences) was performed in 96 wells ELISA plates (Greiner Bio-One).
Affymetrix GeneChip hybridization and analysis
Mice were infected with 105 influenza virus X-31 at day 0. At several time points after infection (6, 24, 48, 
96, 192 hours) mice were sacrificed, lungs were collected in RNAeasy and stored at -80˚C. Total lung RNA 
from influenza virus infected lungs was isolated using an RNeasy kit (Qiagen). RNA was biotin labeled and 
hybridized to mouse micro arrays (Affymetrix Mouse 430.2). 
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Real-time quantitative RT-PCR
Quantative RT-PCR for TAP-1, Sec61a1, Cathepsin S, invariant chain, Granzym A and Granzym B were 
performed on RNA from sorted DC subsets and NK cells. Frozen cell pellets were homogenized, RNA was 
isolated with RNAqueous micro kit (Ambion) and treated with DNaseI, according to the manufacturer’s 
protocol. RNA (100 ng) was reverse transcribed using SuperscriptII (Invitrogen) and random hexamers 
(Amersham Biosciences) for 50 min at 42 ˚ C. Quantitative PCR was performed with Taqman Universal PCR 
Mastermix (Applied Biosystems) and preformulated primers and probe mixes (‘Assay on Demand’, Applied 
Biosystems). PCR conditions were 2 min at 50˚C, 10 min at 95˚C, followed by 40 cycles of 15 s at 95˚C and 
60˚C for 1 min using an ABI PRISM 7300 (Applied Biosystems). PCR amplification of the housekeeping 
gene encoding ubiquitin C was performed during each run for each sample to allow normalization between 
samples. 
Statistical analysis
All experiments were performed using 5-10 animals per group. The difference between groups was 
calculated using the Mann-Whitney U test for unpaired data (GraphPad Prism version 4.0; GraphPad, San 
Diego, CA). Differences were considered significant when p<0,05.
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ABSTRACT
Tertiary lymphoid organs (TLO) are organized aggregates of B and T cells formed in 
post-embryonic life in response to chronic immune responses to infectious agents or 
self-antigens.  Although CD11c+ dendritic cells are consistently found in regions of TLO, 
their contribution to TLO organization has not been studied in detail.  Here, we found 
that CD11chi DCs are essential for the organisation of inducible bronchus-associated 
lymphoid tissue (iBALT), a form of TLO induced in the lungs following influenza virus 
infection.  Elimination of DCs after the virus had been cleared from the lung resulted in 
iBALT disintegration, and led to significantly reduced numbers of class switched plasma 
cells in the lung and bone marrow. DC depletion demonstrated a major contribution of 
iBALT to protective serum immune globulins. Dendritic cells isolated from the lungs of 
mice with iBALT no longer presented viral antigens to T cells, but rather were a source 
of homeostatic chemokines and cytokines known to organize TLO structures.  Finally, 
repetitive administration of DCs to the lungs of naïve mice was sufficient to induce BALT 
like structures.  Together our data reveal a previously unappreciated function of DCs in 
TLO homeostasis and humoral immunity. 
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INTRODUCTION
The organized accumulation of lymphocytes in lymphoid organs is a biological 
phenomenon used to optimize both homeostatic immune surveillance, as well 
as chronic responses to pathogenic stimuli (1). During embryonic development, 
circulating hemopoietic cells gather at predestined sites throughout the body, 
where they are subsequently arranged in T and B cell specific areas, characteristic 
of secondary lymphoid organs (SLO). In contrast, the body seems to harbour a 
limited second set of selected sites that support neo-formation of organised 
lymphoid aggregates in adult life. However, these are only revealed at times of local, 
chronic inflammation when so-called tertiary lymphoid organs (TLO) appear. As 
such, TLO was found in the liver of mice with chronic hepatitis (2), in the pancreas 
of mice with autoimmune diabetes (3), around blood vessels in chronic allograft 
rejection (4) and atherosclerosis (5), and in the brain in experimental allergic 
encephalitis (6).  In humans, TLO has been observed in the joint and lung of 
rheumatoid arthritis (7), around the airways of COPD patients (8, 9), and in the 
thyroid (9). Certain infectious diseases are also accompanied by formation of TLO. 
As an example, influenza virus infection of the respiratory tract leads to formation 
of inducible bronchus associated lymphoid tissue (iBALT) that supports T and 
B cell proliferation and productive immunoglobulin class switching in germinal 
centres (GC) (10, 11). 
 Although the development of secondary lymphoid organs (SLO) during 
embryogenesis requires the function of CD3-CD4+ lymphoid tissue-inducer cells 
(LTi), these are not a prerequisite for TLO induction (12). Like SLO, TLO are formed 
in a highly regulated manner controlled by production of homeostatic chemokines 
such as CXCL13 and CCL19/CCL21, partially in response to signalling from the 
heterotrimer lymphotoxin-a1b2 (LT-a1b2) acting on the LTb-receptor on stromal 
lymphoid tissue organizer cells (5, 7, 10, 12-14). The instruction of stromal cells leads 
to formation of specialized high endothelial venules and the organized production 
of chemokines leads to cellular organization of T cells and B cells in discrete area 
(14).  In all instances where TLO have been described, antigen presenting DCs 
have been found interspersed with T and B cell area, just as they do in SLO (10, 
12, 15-17). So far, the precise role of DCs in the functional organization of TLO 
has not been studied in great detail. Although DCs are mainly known for their 
function as antigen presenting cells to T and B cells (18), they are also a prominent 
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source of homeostatic and inflammatory chemokines that can attract T and B cells 
and thus may contribute to TLO homeostasis (19, 20).  Here, we have studied the 
precise contribution of DCs in the functional organization of inducible bronchus 
associated lymphoid tissue (iBALT) a specific form of TLO found in the lung after 
influenza virus infection (10, 11, 21).
RESULTS
Lung CD11c+ DCs localize to zones of iBALT after clearance of influenza 
virus
Mice were infected intranasally with a non-lethal strain of influenza A/HK-X-
31 (H3N2) that is cleared from the lungs at 8 days post infection (dpi) (22) and 
is accompanied by formation of iBALT as soon as 10 dpi (11).  At various dpi, 
the presence of CD11c+ DC subsets (CD11b+ and CD11b-)(23) was determined 
in dispersed lung cells. In mock-infected mice, a majority of DCs were CD11b-. 
However, up to at least 24 dpi the number and percentage of CD11b+CD11c+ DCs 
remained increased in influenza infected over mock infected mice (figure 1A and 
(22)). To precisely localize these CD11c+ cells in the lung, immunohistochemistry 
was performed 17 dpi (figure 1B). CD11c+ DCs were found within areas of B220+ 
B cell aggregates, as well as in regions containing more CD4 and CD8 T cells. In 
accordance to previous reports, these cell aggregates resembled iBALT as the B cell 
area contained follicular dendritic cells (FDC, recognized by the moAb FDC-M2) 
and PNA-positive germinal center (GC) B cells (see below).  Although iBALT was 
mainly present in close proximity to bronchi, these structures were also seen in the 
lung interstitium, as reported(21).
Lung DCs are necessary for maintenance of iBALT after viral clearance
Having observed the presence of DCs inside iBALT structures at 17 dpi, we next 
addressed whether CD11chi cells were necessary for preserving iBALT structures. A 
CD11c-diphteria toxin receptor (DTR) transgenic mouse model was used to deplete 
CD11c+ DCs from the lungs, as described previously (22, 24). By treating mice 
at 17 dpi with diphtheria toxin (DT) intra-tracheally, CD11c+ DCs were depleted 
from the lung (figure 2A) and draining mediastinal lymph nodes (ref (22) and 
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suppl figure 2), but not from the spleen or other SLO (data not shown). CD11cinterm 
plasmacytoid DCs were minimally affected by diphtheria toxin treatment (data 
not shown and (25)). One week after depletion of DCs (i.e. at 24 dpi), lungs were 
examined by immunohistochemistry. Whereas infected CD11c-DTR Tg mice 
treated with PBS (figure 2B, left upper photographs) or non-transgenic mice 
treated with DT (data not shown) still had extensive iBALT structures containing 
B220+ B cells and CD11c+ cells throughout the lung, these structures disintegrated 
after DT treatment of CD11c-DTR Tg mice (figure 2B lower photographs). Some 
B220+ B cells were still detected in the lung tissue, clustered into discrete regions, 
but density of B cells was strongly reduced and these regions no longer contained 
CD11c+ cells.
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Figure 1: The development of iBALT structures following influenza virus infection.
(A) Flowcytometric analysis of CD11b expression on DCs following infection. Numbers in the corners of the plots 
indicate % of MHCII+CD11c+ DCs. Histogram indicates absolute numbers of CD11b+ DCs, bars represent mean values 
of at least 5 mice/group and arrow bars indicate SEM, ** p<0,01 (B) Consecutive histological slides from snap frozen 
lung tissue at 17 days post infection (dpi). B220+ B cell structures could be identified, with CD11c+ DCs within the 
aggregates. Mainly CD4 T cells and some CD8 T cells were present in iBALT and follicular DCs (FDC) could be detected. 
Right panel shows schematic view of the depicted area. Bar represents 100mm.
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Figure 2: Depletion of CD11c+ DCs in a CD11c-DTR mouse model abrogates iBALT structures from the lung 
At 17 dpi mice were treated with DT i.t. and depletion was checked at 18 dpi and 24 dpi. At both time-points the 
majority of cDCs expressed CD11b. Boxes outline the DC populations, the numbers indicating mean values of % DCs 
(of cells alive) (B) one week after depletion of CD11c+ DCs dense B220-CD11c aggregates could not be detected in 
the lungs. Bar represents 100mm.
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DC depletion following viral clearance affects local humoral immune 
responses
The precise contribution of TLO to cellular and humoral immunity is currently 
unclear but it is thought to serve local immune responses to microbial derived 
antigens or to autoantigens (3, 9). Although a role for iBALT in mediating humoral 
immunity to influenza has been proposed, these studies were performed in mice 
lacking SLO through genetic manipulation (11). The breakdown of iBALT in 
DC-depleted mice, allowed us to study the functional contribution of these local 
structures to humoral immunity in mice with normal SLO.  GC B cells undergoing 
active immunoglobulin (Ig) class switching, are typically found within TLO (3, 
10). Presence of these GCs was demonstrated by staining consecutive slides for 
peanut agglutinin (PNA) and Ig isotypes (figure 3A). Next to IgM+ B cells, IgM, 
IgG and IgA secreting plasma cells could be detected at the periphery of the 
iBALT.  We next addressed if plasma cells were specific for influenza.  For this 
purpose we developed a novel staining technique, employing recombinant nuclear 
protein (NP) as a straining reagent to detect NP-specific B cells (see supplementary 
figure 1).  Double staining for NP-specificity with the plasma cell marker CD138 
confirmed that the majority of NP-specific cells within iBALT were plasma cells 
(supplementary figure 1A).  Strikingly, after local depletion of DCs by DT treatment 
at 17 dpi, these NP-specific plasma cells could no longer be detected on histology 
24 dpi (figure 3B). This indicated that besides an abrogation of iBALT aggregates, 
depletion of DCs seriously affected local immunity. To quantify these changes, 
multi-color flowcytometry was performed on dispersed lung cells taken 1 week 
after DC depletion. The numbers of total B220+CD19+ B cells (data not shown), 
and the number of B220+CD19+ IgM-IgD-CD95+ PNA-positive GC B lymphocytes 
were significantly decreased (figure 3C). Furthermore, local Ig levels in broncho-
alveolar lavage fluid (BALf) were measured. Whereas the levels of class-switch 
independent IgM remained unaffected by DT treatment, IgA levels were readily 
decreased (figure 3D). This points out the importance of iBALT structures and 
intact DC function for the local production of antibodies that rely on germinal 
centers for Ig class-switching. 
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Figure 3: Local humoral immunity is affected by DC depletion
(A) Local class switching in the lung is demonstrated on consecutive slides of lung tissue at 24 dpi which show IgM, 
IgG and IgA in proximity of PNA positive germinal centers. (B) Depletion of DCs affected presence of NP specific 
plasma cells. Bars represent 100mm. (C) Histogram represents the decreased number of B220+CD19+IgM-IgD-PNA+ 
cells per 100.000 lung cells one week after DC depletion (DT). (D) Levels of IgM and IgA measured in BALf of mice 
one week after DC depletion. Bars represent average values with an arrow bar indicating SEM. All results in this figure 
represent results of at least 5 mice/group and similar results were obtained from at least three separate experiments. 
* p<0,05 *** p<0,001
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Major contribution of iBALT to systemic humoral immunity
The contribution of iBALT plasma cells to systemic humoral immunity has not 
been studied in great detail. Serum hemagluttinin-inhibiting (HAI) antibodies, 
the gold standard correlate of protective systemic immunity to influenza, were 
determined at 24 dpi, one week after DCs and iBALT had been abolished by DT 
treatment. Surprisingly, the local depletion of DCs and iBALT led to significantly 
decreased HA specific antibodies in serum (figure 4A).  Although serum virus-
specific antibodies may derive from plasma cell production locally in the lung or 
draining lymph nodes, an important source of serum antibodies are long-lived bone 
marrow plasma cells (26).  To study this matter, CD19+CD138+ NP specific plasma 
cell numbers in bone marrow were determined by multi color flow cytometry, and 
found significantly decreased one week after lung DC depletion (24 dpi, figure 4B). 
These data suggest that even 17 days post infection, the formation of a pool of 
long lived plasma cells in the bone marrow still depends on continued input of 
B cells that have undergone class switching in the local TLO of the lung. As we 
found that DC depletion leaves the differentiation of NP specific plasma cells in 
lung draining lymph nodes intact (see supplementary figure 2), we conclude that 
iBALT contributes significantly to systemic humoral immunity. 
 To study the biological significance of the decrease in bone marrow plasma 
cells, we reinfected mice with the homologous virus, causing no systemic illness 
(data not shown).  Mice were infected at day 0 and a second time at day 31.  Although 
reinfection did not cause clinical illness, it strongly boosted serum HAI titers and 
local IgA responses in the BAL fluid, when compared with primo-infected mice. 
However, when iBALT structures were affected by DC depletion intermittently at 
17 dpi, reinfection led to lower titers of these antibodies.  However, reinfection in 
DC-depleted mice still elicited stronger humoral immunity when compared with 
primary infected mice. This was most likely due to the fact that DC depletion did 
not fully reduce the pool of long-lived plasma cells in the bone marrow down to 
the level of non-infected mice (Fig 4 B), nor did it fully abolish local IgA responses 
(figure 3D).
86
Figure 4: Abrogation of iBALT  affected systemic humoral responses
(A) Hemagluttinin (HA) agglutination inhibition titers measured in serum, indicating the titer of HA specific 
antibodies. Mice were treated with DT at 17 dpi, serum was obtained at 24 dpi. Bars indicate average values with 
SEM. (B) Number of CD11b-CD138+CD95+NP+ plasma cells in bone marrow per 100.000 bone marrow cells. All results 
in this figure represent results of at least 4 mice/group and similar results were obtained from at least three separate 
experiments. (C) Secondary homologous influenza virus infection 2 weeks after DC depletion (DT) or PBS. 4 days 
after secondary challenge IgA in BALf was measured (right plot) and 8 days after secondary challenge HA inhibiting 
serum titers were measured (left plot). Bars represent average values with an arrow bar indicating SEM. All results 
in this figure represent results of at least 5 mice/group and similar results were obtained from at least two separate 
experiments. * p<0,05, *** p<0,001, ns not significant.
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After viral clearance, lung CD11b+ DCs no longer present viral antigen yet 
express homeostatic chemokines 
Taken together, our data demonstrated a crucial role of DCs in maintenance of 
iBALT structures long after virus had been cleared from the lungs.  This could be 
due to ongoing presentation of viral antigen by DCs to nearby CD4+ or CD8+ T 
cells (see figure 1), which subsequently help in organizing the iBALT structure and 
local Ig class switching (12).  Previous reports have indeed suggested a possibility of 
prolonged persistence of viral or parasitic airborne antigen in pulmonary DCs (27, 
28). However, this scenario is less likely, as we studied antigen presentation of viral 
proteins by CD11b+ DCs at various dpi (figure 5A). To this end, we infected mice 
with a recombinant influenza X-31 strain in which the MHCII OVA323-339 epitope 
was inserted in the hemagglutinin gene of the virus. At 4 dpi and 17 dpi CD11b+ DCs 
(defined as B220-CD11c+CD11b+MHCII+120G8low) were purified from lung tissue, 
and co-cultured with CFSE-labeled OVA-specific CD4 T cells (OT-II), taken from 
OT-II transgenic animals. Four days later, CFSE dilution in T cells was measured by 
flow cytometry, and expressed as the % of cells that had divided at least once. Figure 
5A demonstrates that at 4 dpi lung CD11b+ DCs were capable of efficient OVA 
antigen presentation to CD4 T cells ex vivo. At 17 dpi however, sorted CD11b+ 
DCs could no longer induce CD4 T cell division, whereas addition of preprocessed 
OVA peptide showed that they still possessed antigen-presenting capacity for naïve 
T cells. In the negative control experiment, in which the co-culture was set up with 
OVA specific CD8 T cells (OT-1) at both time-points, DCs did not induce any cell 
division (data not shown). These data indicate that the function of DCs within 
iBALT at 17 dpi is not the presentation of viral antigen to surrounding T cells. 
 If DCs do not exert their antigen presenting capacity at the moment they are 
located in iBALT, what then is their function? Previous studies in influenza models 
indicated that chemokines are mainly produced by stromal cells during iBALT 
formation (7).  However, CD11c+Ly6Clo monocytic precursors to DCs have also 
been suggested to be a source of these chemokines (5) (23). To study the possible 
role of DCs as chemokine producers, we sorted CD11c+CD11b+ DCs from digested 
lung tissue at 17 dpi and compared these with populations sorted at 4 and 10 dpi. 
Total RNA was isolated and chemokine expression levels were determined by 
quantitative PCR. Importantly, at 17 dpi expression levels of CXCL12 (stromal cell 
derived factor 1), CXCL13 (B lymphocyte chemoattractant) and LTb were increased, 
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when compared with those at 4 and 10 dpi (figure 5B). These chemokines as well 
as LTb, for which recently a major role in aorta TLO formation was demonstrated 
(5), have been strongly implicated in controling both SLO and TLO development, 
by recruiting B cells and retaining plasma cells (7, 14, 29, 30). However, formation 
of iBALT seems to be only minimally affected by the loss of CXCL13 (7) suggesting 
that several chemokines might have redundant effects during iBALT formation. 
Adoptive transfer of DCs induces iBALT
So far, our studies demonstrated that endogenous lung DCs were located within 
iBALT and were necessary for maintenance of these structures, possibly by 
producing chemokines and cytokines controlling TLO homeostasis.  As a final 
experiment, we also questioned whether adoptive transfer of CD11b+DCs would 
be sufficient to induce iBALT. Therefore, GM-CSF cultured bone marrow DCs, 
which are an in vitro equivalent of in vivo inflammatory type CD11b+ DCs (31), 
were administered 5 times intra-tracheally (i.t.) to naïve mice, each with 2 week 
intervals. 2 days following the last DC injection lungs were immunohistochemically 
stained and examined for the presence of iBALT. Besides B220+ B cell aggregates 
containing CD11c+ DCs (figure 5C), germinal centers containing PNA-positive 
B cells were found, with some IgM or IgG antibody secreting plasma cells. 
These findings indicate that DCs may well exert their effects on TLO neogenesis 
directly. However, as we have previously shown that adoptive transfer of DCs to 
the lungs causes airway inflammation (32), it is also conceivable these effects on 
TLO neogenesis are induced via chronic inflammation. All together, our data for 
the first time support a crucial role for DCs in the control of iBALT formation 
in the lungs following influenza virus infection.  First, CD11b+CD11c+ DCs are 
found inside iBALT structures, and produce chemokines and cytokines that can 
retain B cells and organize TLO.  Secondly, depletion of CD11c+ DCs abolishes 
pre-exisiting iBALT structures and induces a concomitant reduction in systemic 
and local humoral immunity.  Finally, administration of just DCs to the lungs of 
naïve mice induces iBALT structures. It will be interesting to study if CD11c+ DCs 
would also have a critical role in SLO development and/or homeostasis following 
infections (33).  One study supports this notion, as c-Kit+ CD11c+ cells were found 
to be crucial for development of Peyer’s patches during embryogenesis (34). A big 
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Figure 5 DCs are capable of inducing iBALT due to chemokine expression
(A) Mice were infected with influenza virus containing OVA-class II epitope.  DC subsets were sorted from pooled 
infected lung tissue at 4 dpi and 17 dpi, and co-cultured with CFSE-labeled OVA specific CD4 T cells (OT-II) during 4 
days. Left panel demonstrates that at 4 dpi cDCs (B220-CD11c+MHCII+CD11b+120G8-) efficiently presented the OVA 
antigen to OT-II T cells, but at 17 dpi (right panel) both subsets had lost this capacity. However when peptide was 
added DC still showed to have APC function at 17 dpi. Boxes line the cells in division and the % of cells in division 
is indicated in the left corner. The experiments have been performed at least 2 times. (B) Relative expression of 
CXCL12, CXCL13 and Lymphotoxin-b on sorted CD11b+ DCs obtained from pooled lung tissues of 10 infected mice 
at various days post infection. Bars indicate relative expression. (C) Repetitive adoptive transfer of cultured GM-
CSF DCs induces iBALT.  DCs were gorown from the bone marow and injected five times with two week intervals. 
Consecutive histological slides show presence of iBALT aggregates. Bars represent 100mm.
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question that remains in the field of ectopic lymphoid tissue development is the 
precise character of the lymphoid tissue inducer cells that provide the initial trigger 
for TLO development to stromal organizer cells (12).  Although our paper does not 
answer this question, we provide clear evidence that DCs should be incorporated 
into any conceptual framework as to how these structures develop. 
MATERIALS AND METHODS
Mice
C57BL/6 mice (6-8 weeks) were purchased from Harlan (Zeist, The Netherlands). The generation and 
screening of CD11c-DTR Tg mice has been reported previously (35). Male Balb/c background CD11c-
DTR Tg (H2-Dd) were crossed to C57BL/6 (H2-Db) to obtain F1 progeny. CD11chi cells were depleted in 
CD11c-DTR x C57BL/6 Tg mice by i.t. injection of 50 ng DT, a dose previously determined by titration. All 
experiments were approved by an independent animal ethics committee of Erasmus MC Medical Center, 
Rotterdam, the Netherlands.
Influenza virus infection
Mice were i.n. infected with 105 TCID50 H3N2 influenza virus X-31 (MRC, Cambridge, England), diluted 
in 50 ml PBS. For antigen presentation assays of lung DCs, mice were infected with 105 X-31 influenza virus 
encoding OVA323-339 MHC II epitope in hemagglutinin of the virus (36). The OVA virus was kindly provided 
by Dr. R. Webby (St. Jude Children’s Hospital, Memphis, USA).
Histology
Lungs were inflated with OCT, snap-frozen in liquid nitrogen and stored at -80˚C. Frozen sections 
were fixed in acetone and endogenic peroxidase was blocked prior to immuno-histochemical 
staining. Immunohistochemical double staining was performed for B220 (BD, RA3-6B2) and CD11c 
(eBioscience,N418), CD8 (Serotec, KT-15) and CD4 (Ebioscience,RM4-5), IgG (BD, A85-1) and PNA 
(Sigma, L-6135), IgA (BD, 02262D) and PNA, IgM (BD,II-41) and KT3 (supernatant). FDC (BD, M2) was 
stained single. For detection of NP positive cells slides were incubated with recombinant NP (37) prior to 
FITC labelled anti-NP staining. 
Detection of antibodies in serum and BALF
For detection of HA-specific antibodies in serum, samples were treated with cholera filtrate and heat 
inactivated at 56°C. The serum samples were tested for the presence of anti-HA antibodies. For this purpose, 
a hemagglutination inhibition (HI) assay was used following a standard protocol of 1% turkey erythrocytes 
and 4 HAU of H3N2 influenza virus (37) in 96-wells plates (Greiner Bio-One). ELISA was performed on 
BALf for detection of IgA (BD Pharmingen) and IgM (Southern Biotec).
Adoptive transfer of GM-CSF cultured DCs 
Bone marrow cells were cultured for 9 days in DC culture medium (DC-TCM; RPMI 1640 containing 
glutamax-I (Invitrogen, Carlsbad, CA) supplemented with 5% (v/v) FCS (Sigma-Aldrich), 50mM 
2-mercaptoethanol (Sigma-Aldrich), 50 mg/ml gentamicin (Invitrogen) and 20 ng/ml recombinant mouse 
GM-CSF (a kind gift from Prof. K. Thielemans, Vrije Universiteit Brussel, Brussels, Belgium). Mice received 
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Flowcytometry and cell sorting
To check the depletion of cell subsets after treatment with DT and analyze tissues after depletion, single 
cell suspensions of lung and bone marrow were prepared as described previously (38). Extra-cellular 
staining for DCs was done by staining with 120G8 FITC (kindly provided by C.Asselin-Paturel), CD11b 
PE, MHCII PECy5, B220 PECy7(eBioscience), CD11c PETxR(Caltag), CD3 APC Cy7, CD19 APC Cy7 
(BD Biosciences), and a live/dead marker (DAPI) in Violet. PNA positive germinal centers in lung were 
detected with moAbs against IgD FITC, CD95 PE, IgM PECy7,B220 AF700 (BD Biosciences), CD19 PerCp 
Cy5.5 (eBioscience), biotinylated PNA (Sigma) and DAPI. For detection of NP specific plasma cells in bone 
marrow, cells were first stained extra-cellular with CD138 PE (BD Biosciences), CD19 PerCp Cy5.5, CD11b 
AF700 (eBioscience) and a Aqua Live/Dead marker (Invitrogen). Next Cytofix/Cytoperm (BD Bioscience) 
was added to fixate cells. Recombinant NP was diluted in perm buffer and added to each well; cells were 
incubated for 30 minutes and then washed with perm buffer. Intra cellular cells were stained with aNP 
FITC (Dakocytomation), IgM APC, biotinylated IgG2a/2b (BD Bioscience), and secondary streptavidin 
APC Cy7 (eBioscience). Acquisition of ten color samples was performed on a cytomter (LSR) equipped with 
FACSDiva software (both BDBiosciences). Final analysis and graphical output were performed using FlowJo 
software (Tree Star, Inc.). For sorting of DCs, mice were sacrificed at different time points after infection 
with X-31 influenza virus. Lungs of 10 animals were pooled and digested in a collagenase-DNAse solution 
for 1 hour at 37 ˚C to promote release of DCs. DCs were stained as above, cell sorting was performed on a 
FACSAria. The purity of sorted populations was > 98%. 
Antigen presentation assay
For the co-culture of sorted DC subsets with OVA specific CD4+ T cells, OT-2 transgenic T cells were 
isolated from spleen and MLN of a OT-2 mouse, enriched by MACS cell sorting with anti-CD4 antibodies 
according to the manufacturer’s protocol (Milteny Biotec), and labelled with CFSE (39). Sorted DC subsets 
were co-cultured with T cells in a v-bottom plate at a 1/10 ratio for 4 days. T cell divisions were measured 
by flow cytometry on a LSR cytometer equipped with FACSDiva software (both from BD Biosciences). 
Supernatant was stored at –20 ˚C.
Real-time quantitative RT-PCR
Quantative RT-PCR for CXCL12, CXCL13 and LT-b was performed on RNA obtained from sorted lung DC 
subsets. RNA was isolated with RNAqueous micro kit (Ambion) and treated with DNaseI, according to the 
manufacturer’s protocol. RNA (100 ng) was reverse transcribed using SuperscriptII (Invitrogen) and random 
hexamers  (Amersham Biosciences) for 50 min at 42 ˚C. Quantitative PCR was performed with Taqman 
Universal PCR Mastermix (Applied Biosystems) and preformulated primers and probe mixes (‘Assay on 
Demand’, Applied Biosystems). PCR conditions were 2 min at 50˚C, 10 min at 95˚C, followed by 40 cycles 
of 15 s at 95˚C and 60˚C for 1 min using an ABI PRISM 7300 (Applied Biosystems). PCR amplification 
of the housekeeping gene encoding ubiquitin C was performed during each run for each sample to allow 
normalization between samples. 
Statistical analysis
All experiments were performed using 5-10 animals per group. The difference between groups was calculated 
using the Mann-Whitney U test for unpaired data (GraphPad Prism version 4.0; GraphPad, San Diego, CA)
Differences were considered significant when p<0,05.
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Supplementary figures
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Supplementary figure 1: Detection of NP specific plasma cells in iBALT 
Use of an antibody to NP detected infected cells of the lungs shortly after infection (data not shown and 22). (A) At 24 
dpi staining with this antibody no longer detected NP-positive cells within iBALT, demonstrating that virus had been 
completely cleared from the lung and that NP antigen was not retained for prolonged periods in the FDC network. 
(B) Recombinant NP protein was used to reveal NP specific B cells; binding was demonstrated by using NP-specific 
antibody. (C) Double staining in which slides were coated with rNP, stained for NP positivity and then double stained 
with CD138 (plasma cell marker). Bars represent 100mm.
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Supplementary figure 2: Depletion of DCs from MLN does not affect local NP specific plasma cells
I.t. treatment of CD11-DTR Tg mice with DT depleted CD11c+ cells from lung and MLN. (A) FACS plots demonstrate 
depletion of CD11c+MHCII+ DCs in MLN 1 day after DT treatment at day 17 (B)Histology demonstrates intact NP 
specific plasma cell differentiation in MLN, 1 week after DT treatment (24 dpi). Bar represents 100 mm.
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ABSTRACT
Dendritic cells (DCs) are the most potent antigen presenting cells during influenza virus 
infection. Two main subsets of DCs are plasmacytoid DCs (pDC) and conventional DCs 
(cDC). Whereas in vivo studies have demonstrated that upon influenza virus infection 
CD8a+ cDCs efficiently present antigen to both CD4+ and CD8+ T cells, pDCs did not seem 
to contribute. As this antigen presenting capacity of pDCs in inflammatory conditions 
remains a controversial issue, we have performed a study to further investigate this 
point. We used a controlled in vitro system in which infection, antigen processing and 
antigen presentation of DC subsets was studied. Therefore both pDCs and the equivalent 
of in vivo cDCs were cultured in a Flt3-L/SCF bone-marrow culture. Infection patterns 
following influenza virus infection differed for both subsets and in accordance to our 
in vivo studies, cDCs were most efficient in presenting antigen to T cells. Nevertheless, 
pDCs did present endogenously processed antigen to naïve CD8+ T cells, especially 
after maturation by influenza virus infection. Antigen presentation of pDCs to CD4+ T 
cells remained problematic, probably due to a defective MHCII signaling pathway. In 
conclusion, this study demonstrates that pDCs in an appropriate (infectious) setting do 
have antigen presenting capacity. However, due to defective antigen processing they 
hardly present exogenous antigen to CD4+ T cells. All together their contribution to 
antigen presentation in vivo will be inferior to cDCs.
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INTRODUCTION
Influenza virus is a major pathogen causing acute respiratory illness, which can 
produce severe injury to the respiratory tract. Besides direct morbidity, respiratory 
viral infection can cause modulation of the airway immune response, leading 
to increased susceptibility to atopic sensitization and asthmatic disease. During 
induction of an adaptive immune response against influenza virus infection, 
activation of T lymphocytes by dendritic cells (DCs) is required. Costimulatory 
molecule expression on DCs is upregulated and they are recruited to the site of 
infection where an inflammatory environment is induced. These events lead to 
enhanced antigen presentation but possibly can also change the normal tolerogenic 
response to inhaled antigen into an immunogenic response.
 Generally, DCs are divided into plasmacytoid (p)DCs and conventional 
(c)DCs. Within the population of cDCs recent studies have described various 
subpopulations with a distinct division of labor, depending on anatomical 
location (1, 2). In the spleen a population of CD8a+ cDCs are specialized in cross-
presenting exogenous antigen to CD8+ T cells, whereas a population of CD8a- 
cDCs are specialized in CD4+ T cell presentation (3, 4). We and others (5, 6) have 
demonstrated that upon in vivo influenza virus infection, resident CD8a+ DCs are 
most efficient antigen presenting cells to both CD4+ and CD8+ T cells. Most authors 
who have previously studied the in vitro effect of viral infection on DCs have used 
GM-CSF cultured DCs. More recent studies have demonstrated that these GM-
CSF DCs are an in vitro equivalent of in vivo inflammatory type DCs (7). In order 
to compare antigen-presenting capacities of our in vitro cultured DCs to the in vivo 
CD8a+ DCs we sorted MHCII+CD11c+ DCs from a Flt3L/SCF culture, which are 
the equivalent of in vivo CD8a+ cDCs (8).
 PDCs are a more recent described member of the DC family and are 
specialized in producing high levels of type 1 interferon upon viral stimulation 
(9-14). It was previously assumed that pDCs play an important role in clearance of 
viral infection, but more recent studies have demonstrated that this is dependent 
on the type of viral infection (5, 9, 15). Yet, another role of pDCs has been 
described in immune regulation, by inducing the formation of regulatory T cells 
(10, 16-19). In our study pDCs were sorted from the same Flt3L/SCF culture to 
make a comparison with cDCs. Although the potential of pDCs to present peptide 
antigen or to stimulate allo-specific T cells during a mixed leukocyte reaction has 
100
been shown (13, 20), the relative strength of the antigen uptake and processing of 
pDCs versus cDCs for mounting effective T cell responses remains controversial, 
especially under inflammatory conditions. In our recently published in vivo studies 
(5) we were not able to show antigen presentation by pDCs but to confirm this 
finding we decided to use optimal in vitro infection conditions to study infection, 
antigen processing and antigen presentation of pDCs in comparison to cDCs. We 
now demonstrate that influenza virus differentially affect pDCs and cDCs in vitro. 
Differences in antigen presenting capacity between DC subsets following influenza 
virus infection might be related to deficient MHCII processing in pDCs.
RESULTS
The effect of influenza virus infection in vitro on conventional DCs and 
plasmacytoid DCs
To obtain highly purified populations of cDCs and pDCs, murine bone marrow 
cells were cultured in Flt3-L and SCF (8). After 9 days of culture, DCs were purified 
using high-speed cell sorting to over 98% purity. PDCs were sorted by expression 
of intermediate levels of CD11c, BST2 (recognized by the clone 120G8), B220 and 
lack of expression of CD11b. Conversely, cDCs were identified based on expression 
of CD11c, CD11b and lack of 120G8 and B220, as previously described (21). 
Following cell sorting, DCs were infected with influenza X-31 (H3N2) virus, using 
a MOI of 3, for 1 hour at 37˚C after which virus was washed away and cells were left 
overnight for infection at 37˚C. The next day DCs and supernatant were harvested 
and DCs were partly spotted on histological slides to perform a fluorescent 
nucleoprotein (NP) staining. This fluorescent staining nicely demonstrated infected 
cDCs by concentrated NP in the nucleus. In contrast, pDCs were not infected at 
all by this MOI and time-point (figure 1A). The grade of infection was confirmed 
by flow cytometry. Therefore cells were first stained extra-cellularly using DC 
markers, then fixed and permeabilized and subsequently NP was stained intra-
cellularly. Flowcytometric data confirmed our fluorescent staining on histology 
and demonstrated an infected percentage of cDCs of 19%, whereas pDCs failed to 
get infected (figure 1A, histograms)
 Next, levels of IFN-a on cell culture supernatant after overnight infection 
were determined. Previous studies described that pDCs produce high levels of 
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IFN-a following viral infection (11, 13, 14, 22-24). Our data confirmed these 
studies; whereas both cDCs and pDCs increased IFN-a production following 
infection, levels produced by pDCs were five times higher than cDCs (figure 1B). 
This illustrates that at least pDCs were viable in our assays.  
 Finally, we studied the effect of overnight infection on the phenotype of 
cDCs and pDCs. A comparison was made between mock and influenza virus 
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Figure 1: Infection and maturation of DC subsets by influenza virus infection in vitro.
Mice plasmacytoid and conventional DCs were cultured from bone marrow with Flt3-L. On day 9, cell populations 
were purified by FACS sorting. (A) Rate of infection of DC subsets after influenza X-31 virus infection (MOI=3) versus 
mock infection determined by aNP staining. Numbers stated in histograms indicate % of sorted cells. (B) IFN-a 
measured in supernatant of cultured DC populations after overnight infection with influenza virus or mock. (C) 
Upregulation of maturation markers on DC subsets following overnight infection with influenza virus or mock. A 
comparison was made to overnight CPG exposure. Demonstrated data are representative of at least 3 experiments.
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infected DCs. Addition of bacterial CPG motifs (an endosomal TLR9 agonist) to 
DCs is known for it’s effect on cell maturation, and was therefore used as a positive 
control. Both cDCs and pDCs upregulated the expression of surface molecules as 
CD40, CD80, CD86 and ICAM-1, in the presence of CPG and influenza virus when 
compared to mock infection (figure 1C).
Both cDCs and pDCs more efficiently cross-present exogenous protein 
antigen to CD8+ T cells following influenza infection, but pDCs only induce 
minor CD4+ T cell proliferation
Whereas cDCs are generally known to be efficient antigen presenting cells (APCs), 
several papers also describe pDCs as good APCs for CD4 and CD8 T cell responses 
(12, 25, 26). However, some of these studies just show presentation of antigenic 
peptides and not whole protein, bypassing the need for antigen presentation. 
Besides the antigenic stimulus, the purity of used pDCs for stimulation can also be 
a confusing factor. We have found that a slight contamination with cDCs (of 4–5%) 
can already significantly contribute to antigen presentation (data not shown), 
therefore highly purified pDC and cDC populations were used in our study.
 Being interested in the antigen presentation capacity of “bystander antigen” 
during infection, we used ovalbumin (OVA) as a model antigen. Presentation of 
exogenous antigen was compared to an antigen incorporated in the virus. For 
this we used recombinant influenza viruses with either an OVA MHI or MHCII 
construct built into respectively the neuraminidase or hemagluttinin of the viruses. 
As effector cells we used OVA specific CD4 (OTII) or CD8 (OTI) T cells. Sorted 
DCs were infected with influenza virus, an OVA-containing influenza virus, mock 
or exposed to CPG. One hour later, cells were washed, put into fresh DC culture 
medium and OVA, PBS or pre-processed OVA-peptide was added overnight. The 
next day cells were harvested and put into co-culture with either CFSE labeled 
Figure 2: Antigen presentation of DC subsets to CD8 and CD4 T cells.
Mice plasmacytoid and conventional DCs were cultured from bone marrow with Flt3-L. On day 9, cell populations 
were purified by FACS sorting. (A) Sorted cDC and pDC were infected overnight with influenza virus X-31, mock, 
influenza virus containing OVA-class I epitope or CPG was added. To study the antigen presentation of bystander 
antigen to CD8 T cells, OVA, PBS or OVA class I peptide was added to all conditions. The next day they were co-cultured 
with CFSE-labeled OVA specific CD8 T cells (OT-I) during 4 days. Left panel demonstrates T cell division induced by 
cDCs, right panel by pDCs. Numbers in the left corners indicate % of divided cells. (B) Experiment performed as 
described in A, but CD4 T cell response was studied by using OVA specific CD4 T cells (OT-II). The experiments have 
been performed at least 3 times.
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CD8 (OTI) or CD4 (OTII) OVA specific T cells. Co-cultures were left for 4 days 
and proliferation of T cells was measured by CFSE dilution on flowcytometry. As 
expected, cDCs efficiently presented antigen to CD8+ T cells (figure 2A left panel). 
Addition of either exogenous OVA antigen (OVA), OVA incorporated into the virus 
(X-31 OVA OT1) and OVA peptide to cDCs induced clear CD8+ T cell proliferation. 
PDCs were much less capable of inducing CD8+ T cell proliferation (figure 2A right 
panel). Whole OVA could be presented, but only after prior DC maturation by 
CPG or influenza virus infection. In case OVA was either incorporated into the 
virus or pre-processed (thereby circumventing antigen processing), pDCs became 
more efficient in presentation to CD8+ T cells.
 Figure 2B displays the induction of CD4+ T cell proliferation. CDCs again 
efficiently presented all forms of antigen to CD4+ T cells, nevertheless it was 
remarkably to see that exogenous OVA presentation to CD4+ T cells decreased after 
influenza virus infection or CPG treatment. As the presentation of (pre-processed) 
OVA class II peptide was not affected this might indicate that maturation of cDCs 
by these stimuli altered the processing of OVA. Regarding pDCs (figure 2B right 
panel); in contrast to their minor antigen presenting capacity of pDCs to CD8+ T 
cells, they presented very weakly to CD4+ T cells in all instances. Only pre-processed 
OVA class II peptide was efficiently presented after pDCs were either infected or 
stimulated with CPG motifs (figure 2B). 
Antigen processing for MHCII presentation
Following the antigen presentation studies described above, we hypothesized that 
perhaps pDCs had a problem in processing the OVA within the MHCII machinery. 
Loading of MHCII molecules occurs in an acidic endosomal compartment, rich in 
MHCII molecules, the so-called MHCII compartment. To follow if OVA would be 
targeted to these acidic compartments, OVA-DQ was used as a tracer. OVA-DQ is a 
quenched non-fluorescent protein that becomes fluorescent green when present in 
acidic endosomes and fluorescent red when it accumulates at high concentrations 
in these compartments. Unstimulated pDCs did not show any positive signal for 
either OVA-DQ green or red, showing an incapability of targeting the antigen to 
acidic endosomes or an inefficiency in acidifying the endosomes (figure 3 lower 
plots), whereas cDCs showed clear accumulation of OVA-DQ in these endosomes 
(over 50% of cDCs showing evidence of accumulation). The addition of CPG motifs 
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or influenza infection slightly increased processing of OVA-DQ in pDCs to about 
14%.
PDC and cDCs differentially espress enzymes involved in MHI and MHCII 
processing
Many of the proteins that regulate MHCI and MHCII processing pathways 
have been described and their expression has been documented in DCs (27). To 
evaluate if pDCs had intrinsic differences compared with cDCs in the expression 
of any of these proteins following infection, the mRNA levels were compared by 
q-RT-PCR. As an example of a protein regulating the MHCI processing we here 
show expression of the peptide loading complex consisting of TAP (Tap-1) and 
for MHCII processing the chaperone molecule H2-DMb1. After infection, the 
expression of Tap-1 on cDCs generally remained at the same level, but in contrast 
was dramatically increased on pDCs (figure 4A). This increase might contribute to 
the improved antigen presentation op pDCs to CD8 T cells after infection. Figure 
4B shows H2-DMb1 expression on cDCs, most evident is the decrease following 
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Figure 3: Antigen processing for MHCII presentation
Mice plasmacytoid and conventional DCs were cultured from bone marrow with Flt3-L. On day 9, cell populations 
were purified by FACS sorting and infected with influenza X-31, mock or CPG was added. OVA-DQ was added to 
cDC and pDC after one hour of infection. Eight hours later uptake and processing of OVA-DQ was measured by 
flowcytometry. Numbers in the corners indicate % of cells.
106
CPG treatment, which again correlates to depicted CD4 proliferation plots. 
Expression of H2-DMb1 on pDCs was clearly lower than on cDCs and only very 
slightly increased following infection or CPG treatment.
DISCUSSION
Infection of bone-marrow-derived DCs by influenza virus with triggering of the 
cytokine production (e.g., IL-6 and IL-12) and type 1 interferon production has 
been previously shown. Furthermore, efficient induction of CD8+ T cell responses 
in vitro appears to require direct infection of DC by live virus (28-32) although 
presentation of antigen from noninfectious sources through cross-presentation 
by DCs has been reported (33). Within the population of cDCs recent studies 
described differences in function between CD8a+ and CD8a- populations. These 
specialized functions are determined by a differential expression of antigen uptake 
receptors (34, 35) or by differential expression levels of the various enzymes and 
chaperone molecules associated with the antigen processing (27). Viral infection 
of the DCs can disturb these base-line conditions, by causing for example ligation 
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Figure 4: Enzymes involved in MHI and MHCII processing
Mice plasmacytoid and conventional DCs were cultured from bone marrow with Flt3-L. On day 9, cell populations 
were purifed by FACS sorting. DCs were infected overnight, mock infected or CPG was added. (A) RNA levels of Tap-1 
and (B) RNA levels of H2-DMb1.
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of pattern recognition receptors (like Toll like recepors), leading to upregulation of 
endocytic receptors, and for alteration of antigen processing signalling.
In this report, we have studied the responses of bone marrow cultured cDCs and 
pDCs to in vitro influenza virus infection. We have demonstrated that the pattern 
of infection between these subsets was not uniform and could thereby confirm 
previous studies on this point (36). Whereas a fraction of cDCs was infected by 
influenza virus and expressed high levels of influenza virus nucleocapsid protein at 
a MOI of 3, pDCs infected with a same MOI did not show any level of infection. Hao 
et al have shown a dose dependency of influenza virus infection (36), in purified 
respiratory tract DCs. It might be that the difficulty of infection of pDCs is due to 
the very high levels of interferon-a in the culture.
 PDCs were first considered to have a minor role in in antigen uptake (37) 
when compared to cDCs (16). However, more recent reports showed uptake of 
subcutaneously injected Ag by mouse lymph node pDCs and inhaled fluorescent 
OVA inside vacuoles of mediastinal lymphe node pDCs of naïve mice (16, 25). 
In this paper we show that highly purified bone-marrow derived pDCs do take 
up soluble (OVA-DQ) antigen following influenza virus infection. However, when 
comparing pDCs with cDCs obtained from the same Flt3L culture, cDCs were 
much more efficient in uptake of this soluble Ag.
 Next, we have addressed the controversial issue on the antigen presenting 
capacity of pDCs versus cDCs and especially focused on their capacities following 
in vitro infection with a high dosis of influenza virus. For presentation to CD4 T 
cells, pDCs were initially thought to present exogenous protein Ag only to already 
primed, but not naïve T cells (16, 38). Contrasting these early reports, more recently 
it was shown that lymphe node, but not splenic pDCs were able to present soluble 
Ag to naïve CD4 T cells in vivo, but only when the Ag was targeted to the BST2 
receptor via mPDCA-1 (25). In our study we found that when using BM-derived 
pDCs, they did not present exogenous Ag to CD4 T cells, whereas they readily 
did present pre-processed peptide, particularly when exposed to CPG motifs or 
influenza virus infection. The reason for the failure to present Ag to CD4 T cells 
might be the lack of expression of enzymes involved in MHCII processing (as the 
chaperone molecule H2-DMb1).
 Some authors have suggested that pDCs only present endogenous Ag to 
CD8 T cells, but fail to cross-present exogenous Ag (25, 39, 40). Our findings 
clearly confirm that purified pDCs can present an endogenously expressed Ag to 
108
naïve CD8 T cells, and the process is enhanced by maturation of pDCs by CPG 
or influenza virus. Regarding cross-presentation of exogenous Ag, we found that 
exogenous Ag was only presented under particular conditionsæafter pDCs had 
been matured. In all cases pDCs were weaker at presentation when compared with 
cDCs.  In conclusion, we have demonstrated that the major DC populations in 
vitro react differentially to influenza virus infection. As cDCs are already very 
efficient antigen presenters, influenza virus does not enhance this significantly. 
PDCs however, increased their antigen presenting capacity following infection, but 
only to CD8 T cells. A defective MHCII signaling pathway might be the cause of 
their deficient CD4 T cell presentation. Although the studies in this paper were 
performed purely in vitro, our findings might help to understand the role of DC 
subsets in the response to in vivo influenza virus infection. To further unravel the 
differential responses of DC subsets to influenza virus infection genomic tools will 
be used. Pathway analyses on in vitro infected DCs might provide novel insights in 
to functionality of distinct DC subsets.
MATERIALS AND METHODS
Mice
C57BL/6 mice (6-8 weeks) were purchased from Harlan (Zeist, The Netherlands).  OT-1 (C57BL/6 
background) Tg mice containing OVA-specific TCR CD8+ T cells (Hogquist K et al. Cell 1994) and OT-II 
(C57BL/6 background) Tg mice containing OVA-specific TCR CD4+ T cells (Barnden MJ Immunol Cell Biol 
1998) were bred at Erasmus MC. Mice were used when aged between 6-12 weeks. All experiments were approved 
by an independent animal ethics committee of Erasmus MC Medical Center, Rotterdam, the Netherlands.
Generation of BM DCs in hFlt3-L/SCF
Bone marrow (BM) cells were seeded in petridishes (106 cells/ml) in DC culture medium (DC-CM, RPMI 1640 
containing GlutaMAX-I (Invitrogen) supplemented with 5% FCS (HyClone), 50 mM 2-mercapthoethanol 
(Sigma) and 50 mg/ml gentamycin (Invitrogen) with 200 ng/ml human FMS-like trosin kinase 3 ligand 
(hFlt3-L, Amgen) and 50 ng/ml recombinant murine stem cell factor (rmSCF, PeproTech). At day 4, cells 
were harvested and re-plated (1x 106 cells/ml) in DC-CM supplemented with 200ng/ml hFlt3-L alone to 
obtain pDCs and cDCs.
Influenza virus infection
DCs were infected in vitro with influenza virus X-31(MRC, Cambridge, England), WSN influenza virus 
encoding OVA257-264 Kb restricted MHC I epitope in the neuraminidase (41) or X-31 influenza virus encoding 
OVA323-339 MHC II epitope in hemagglutinin of the virus (42). The OVA viruses were kindly provided by Dr. 
R. Webby (St. Jude Children’s Hospital, Memphis, USA). DCs were infected with an MOI=3 at 37 ˚C and 
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after 1 hour washed with PBS. DC-TCM was added for overnight infection at 37 ˚C with eventually OVA 
and/or CPG .
Flow Cytometry and cell sorting
Acquisition of 4 color samples for identification of maturation markers on DCs was done on a FACS Calibur 
(BD Biosciences) after staining with MHCII FITC, CD11c APC and CD40PE, CD80 PE, CD86 PE, ICAM-I 
PE. Proponium Iodide (PI) was used as a live/dead markere. FlowJo software (Tree Star Inc.) was used 
for analysis. For sorting of pDCs and cDCs, the BM Flt3-L/SCF culture was stained with moAbs against 
120G8-FITC (kindly provided by C.Asselin-Paturel), CD11c-APC, CD11b-PercP-Cy5.5 and B220-PECy7 
(eBioscience). Sorting of 120G8+CD11b-B220+CD11c+ pDCs and 120G8-CD11b+B220-CD11c+ cDCs was 
performed on a FACS Aria (BD Biosciences). 2.4G2 (anti Fc_RII/III) was used to reduce non-specific 
antibody binding in all stainings. In all flow cytometry experiments either propidium iodide (PI), TOPRO-
(Molecular-Probes) or DAPI (Molecular Probes) was used to discriminate between live and dead cells.
Analysis of T cell proliferation
OT-1 and OT-2 transgenic T cells were isolated from spleens and LNs of respective mice, enriched by 
MACS cell sorting with anti-CD8 or -CD4 antibodies according to manufacturer’s protocol (Miltenyi Biotec 
GmbH) and labelled with CFSE(43). Sorted DC subsets were co-cultured with T cells in v-bottom plates 
(Greiner Bio-One) at 1/10 ratio for 4 days. T cell divisions were measured by flow cytometry.
Antigen uptake and processing
To determine the antigen uptake and processing, sorted DC subsets after one hour of infection were plated 
at a concentration of 1*106 cells/ml with 10 mg/ml OVA-DQ. Uptake and processing of OVA-DQ was 
measured 8 hours after exposure.
Real-time quantitative RT-PCR
Quantative RT-PCR for H2DMb1, Cathepsin S and Tap1 was performed on RNA obtained sorted DC 
populations. RNA was isolated with RNAqueous micro kit (Ambion) and treated with DNaseI, according 
to the manufacturer’s protocol. RNA (100 ng) was reverse transcribed using SuperscriptII (Invitrogen) and 
random hexamers  (Amersham Biosciences) for 50 min at 42 ˚C. Quantitative PCR was performed with 
Taqman Universal PCR Mastermix (Applied Biosystems) and preformulated primers and probe mixes 
(‘Assay on Demand’, Applied Biosystems). PCR conditions were 2 min at 50˚C, 10 min at 95˚C, followed 
by 40 cycles of 15 s at 95˚C and 60˚C for 1 min using an ABI PRISM 7300 (Applied Biosystems). PCR 
amplification of the housekeeping gene encoding ubiquitin C was performed during each run for each 
sample to allow normalization between samples. 
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The studies described in this thesis focus on dendritic cell (DC) subsets present 
in the lung and elaborate on their distinct functions in the immune response 
to influenza virus infection. The DC subsets discussed in this final chapter are 
summarized in figure 1. 
β
α
Figure 1: Division of labor between dendritic cell subsets in the airways following influenza virus infection
The conducting airways are composed of airway epithelial cells, which act as a molecular sieve excluding inhaled 
antigens and pathogens. Underneath the epithelial layer several DC subsets are located. Langerin+CD11b-  DCs are 
situated in the basolateral space, and can extend their processes between epithelial cells directly into the airway 
lumen. These langerin+ DCs can migrate towards the draining MLN and directly present viral derived antigen to 
CD4+ and CD8+ T cells. IKDCs can directly kill virus-infected cells in the lung tissue and some migration to the MLN 
has been observed. Antigen is presented only to CD8+ T cells. PDCs migrate towards the MLN but are not capable of 
presenting antigen. Together with migrating langerin+CD11b- DCs they might be a source of viral antigen for resident 
CD8α+ DCs in the MLN, which can in their turn efficiently present it to CD8+ T cells. IDCs slightly migrate towards the 
MLN, but do not efficiently present antigen. Most importantly they are involved in the control of iBALT following the 
clearance of infection.
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Migration and antigen presentation by DC subsets in the lung
Several investigators have studied the involvement of antigen presenting cells in 
mediating protective immunity to influenza virus, such as DCs, macrophages and 
B cells (1-6). It was shown that a mouse-adapted strain of influenza virus induced 
the in vivo maturation of CD11c+ DCs in the lung of mice (7) and their migration 
to the mediastinal LNs (8-10).  In chapter 2 we describe that during influenza virus 
infection, the predominant source of CD11b- DCs arriving in the MLN originated 
from the network of highly dendritic-shaped langerin+CD103+ intra-epithelial DCs 
that lines the large conducting airways (11-13). The disappearance of this CD11b- 
population from the trachea was accompanied by a new influx of CD11b+ DCs 
into the trachea and interstitium. These freshly recruited CD11b+ DCs most likely 
represent inflammatory-type DCs (14, 15) a highly activated subset of cDCs found 
in the lungs upon respiratory infection (16). Data in chapter 4 have demonstrated 
that during influenza virus infection, these inflammatory DCs expressed B220 and 
120G8 in addition to high levels of CD11c and CD11b, considerably confusing 
the separation from pDC subsets if 10 colour multi-parameter flow cytometry is 
not used.  Some of these CD11b+ inflammatory DCs also migrated towards the 
draining MLN.
 Once arrived in the MLN, both CD11b-CD8α+ resident (i.e. non-migratory) 
DCs, and CD11b- and CD11b+ lung-derived migratory DCs upregulated co-
stimulatory molecules, and thus acquired the potential to present antigen. To 
test the antigen-presenting potential of the various DC subsets in the MLN 
we took advantage of influenza viruses encoding either the MHCI or MHCII 
immunodominant OVA epitope (17, 18). 4 days after infection with these viruses, 
DC subsets were sorted from MLN by flowcytometry and co-cultured ex-vivo 
with respectively OT-I or OT-II T cells. This allowed us to probe presentation of 
sorted lung DC subsets to naive OVA-specific CD8 and CD4 T cells directly. There 
was a clear division of labor between the DC subsets (chapter 2).  The CD11b- 
DCs stimulated CD4 and CD8 responses, whereas CD11b+ DCs were very poor 
at antigen presentation at all. This suggests that upon influenza virus infection, 
processing for and presentation on both MHCI and MHCII molecules can occur 
in a single cell CD11b- population in vivo in the lung, in contrast to what previously 
has been shown for spleen or lymph node (19-22). In accordance to findings by 
Belz et al. the resident CD8α+ DCs in the MLN efficiently presented viral antigen, 
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but exclusively to CD8 T cells (3), whereas pDCs did not present antigen to naïve 
T cells in the MLN at this time point (11). Despite the fact that both CD8α+ and 
CD8α-CD11b- DCs presented antigen to naïve T cells, the strength of viral NP 
staining was not abundant. This could be explained by the fact that the viral NP 
was digested in these subsets as part of an antigen-processing step, leading to a 
loss of immunoreactivity towards the NP-specific antibody. Alternatively, Belz et 
al. previously suggested that resident CD8α+ DCs acquired the antigen from other 
migratory APCs, proposed as the CD11b-CD8α- lung derived DCs, but this was not 
yet demonstrated (3). Our data on viral NP staining of DC subsets in MLN suggest 
that the CD11b+ DCs as well as the pDCs were abundantly positive for viral antigen 
in the MLN and therefore, could be the most important source for providing viral 
antigen to resident CD8α+ DCs.
 Finally, our data in chapter 3 have demonstrated presence of a novel 
subtype of antigen presenting cell during influenza virus infection. This 
B220+CD11cintermNK1.1+ interferon killer dendritic cell (IKDC) will be discussed 
further on in this discussion, but it should be mentioned that upon influenza virus 
infection this population was capable of presenting viral derived antigen to naïve 
CD8 T cells in the lung. However, this APC feature was not unique to IKDCs and 
similarly present in B220+ conventional NK cells. This antigen presenting function 
of NK cells supports earlier findings in human situations (23, 24).
Transgenic mouse models
Besides studying the antigen presenting capacities of isolated DCs ex vivo, there is 
another way to study the function of lung DC subsets in vivo. In chapter 2 we depleted 
DCs by using cell specific genetic targeting strategies employing the expression of 
the diphteria toxin receptor (DTR) under control of a specific promotor. In CD11c-
DTR transgenic mice, the CD11c promotor element drives the expression of the 
DTR. Murine cells are normally insensitive to DT treatment as they lack the DTR, 
leading to a conditional depletion of CD11c+ DCs in the airways of CD11c-DTR 
mice treated with DT intra-tracheally (25, 26). Another DTR transgenice mouse 
model we used was the langerin-DTR mouse, in which the expression of DTR is 
driven by the langerin promotor element and therefore langerin-expressing cells 
could be conditionally depleted (27). We have first carefully studied the depletion of 
DC subsets in the transgenic mice expressing DTR under DC-specific promoters. In 
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CD11c-DTR mice, there is a predominant depletion of lung CD11c+ DCs, of tracheal 
CD11b+CD11c+ DCs and of resident mediastinal LN CD8α+CD11c+ DCs after 
diptheria toxin (DT) treatment. Importantly, langerin+CD11b-CD11c+ migratory 
tracheal DCs are not depleted in these mice, and we consequently observed no 
decrease in mediastinal LN CD11b-CD8α- DCs.  In CD11c-DTR mice given DT, 
we noticed that generation of virus specific CD8+ CTLs as well as production of 
effector cytokines (IFN-α) by MLN cells was severely diminished. Based on our 
antigen presentation studies and on previous work of Belz et al, we propose that this 
is due to depletion of the resident CD8α+CD11c+ DCs or perhaps to the depletion 
of chemokine producing lung CD11b+ DCs. In CD11c-DTR mice, CD11c+ alveolar 
macrophages are also depleted, but it is unlikely that this contributed to a decrease 
in antiviral immunity as adoptive transfer of wild type DCs but not macrophages 
restored immunity.
 To more specifically address the role of migratory tracheal CD11b- DCs, 
we performed experiments in langerin-DTR mice (27).  Langerin was found to be 
present particularly on mucosal CD11b-CD103+ DCs in the lung (13), a population 
of cells that strictly relies on CCR7 to migrate to the mediastinal LN (28). In 
accordance, we also found increased numbers of langerin+CD103+CD11b-CD11c+ 
DCs in the mediastinal LN following influenza infection. Following intratracheal 
administration of DT, there was a selective depletion of CD11b-CD8α- migratory 
DCs in the trachea and MLN, while leaving the CD8α+ resident LN population or 
alveolar macrophages unaffected. In the absence of the migratory langerin+CD11b- 
DC population, influenza ran a particularly severe course. Strikingly, these data 
also suggest that the langerin+ DCs of the lung are much more immunogenic than 
their langerin+ Langerhans’ cell counterparts in the skin (27, 29, 30).
Inflammatory dendritic cells
We found a clear increase in CD11b+ inflammatory DCs (iDC) during influenza 
virus infection, but these DCs did not seem to present antigen in the MLN.  During 
our studies, the question therefore arose what might be their contribution to the 
immune response? Several possibilities were hypothesized; first, lung CD11b+ 
DCs have been shown to massively produce inflammatory chemokines and might 
therefore be crucial in attracking effector CD4 and CD8 cells that have been 
generated in the LN back to the lung and trachea, where they would mediate 
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effector function (31). Recently, Legge et al also suggested that these inflammatory 
type DCs might indeed be crucial for boosting effector CD8 responses in the lung, 
rather than priming of CD8 responses in naïve cells (32). Secondly, CD11b+ DCs 
might have direct innate antiviral activity by producing TNF and iNOS dependent 
NO, analogous to the situation seen with Listera monocytogenes infection (33, 
34), and thus might also contribute to the features of severe influenza such as lung 
damage and weight loss (16).  Thirdly, recruited CD11b+ DCs might also stimulate 
the innate antiviral activity through crosstalk with NK cells.  
 In chapter 5 we precisely localized these inflammatory CD11c+CD11b+ 
DCs in the lung by immunohistochemistry. CD11c+ DCs were found within areas 
of B220+ B cell aggregates, as well as in regions containing more CD4 and CD8 T 
cells. In accordance to previous reports, these cell aggregates resembled inducible 
bronchus associated lymphoid tissue (iBALT) as the B cell area contained follicular 
dendritic cells and PNA-positive germinal center (GC) B cells. IBALT is a form of 
so-called tertiary lymphoid organs (TLO), which are revealed at times of infectious 
diseases or during local, chronic inflammation (35-38). In all instances where 
TLO have been described, antigen presenting DCs have been found interspersed 
with T and B cell area, just as they do in secondary lymphoid organs (SLO) (39-
43). However, until now, the precise role of DCs in the functional organization of 
TLO was not studied in great detail. Having observed the presence of DCs inside 
iBALT structures at 17 dpi, we addressed whether CD11c+ cells were necessary for 
preserving iBALT structures. Again, the CD11c-DTR transgenic mouse model was 
used to deplete CD11c+ DCs from the lungs, as described above. CD11c+ DCs were 
depleted from the airways at day 17 dpi, which led to disintegration of iBALT one 
week after depletion of DCs (i.e. at 24 dpi). This disintegration resulted in effects on 
both local and systemic immunity. The local production of antibodies (relying on 
germinal centres for immune globulin class-switching) diminished, but also virus 
specific immune globulin levels in serum and even virus specific plasma cells in 
bone marrow were affected. Long lived bone marrow plasma cells are an important 
source of serum antibodies (44). Therefore these latter data suggest that even 17 
days post infection, the formation of a pool of long lived plasma cells in the bone 
marrow depends on continued input of B cells that have undergone class switching 
in the local TLO of the lung. When studying the way DCs controlled iBALT, this 
was not by presenting long-lived antigen but they rather seemed to be efficient 
producers of chemokines and cytokines that can retain B cells and organize TLO. 
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Whereas previous reports have suggested CD11c+Ly6Clo moncytic precursors 
to be a source of these chemokines (31, 35), we for the first time demonstrated 
production by sorted iDCs in chapter 4. Finally, administrating DCs to the lungs 
of naïve mice could induce iBALT structures. A big question which remains in 
the field of ectopic lymphoid tissue development is the precise character of the 
lymphoid tissue inducer cells, that provide the initial trigger for TLO development 
to stromal organizer cells (42).  Although our study does not answer this question, 
we provide clear evidence that DCs should be incorporated into any conceptual 
framework as to how these structures develop. 
Plasmacytoid dendritic cells
The precise role of plasmacytoid dendritic cells (pDC) in influenza virus infection 
remains undetermined from carefully studying the literature. Whereas they are 
main producers of type 1 interferon during both in vivo and in vitro influenza virus 
infection (45, 46) this role seems to be taken over by other (epithelial and alveolar 
macrophages) cells in case pDCs are depleted (11, 47, 48). Migration of pDCs to 
MLNs upon infection or inflammation has been demonstrated (11, 49, 50) but 
their contribution to antigen presentation at this site seems to be negligible in vivo, 
as depletion of pDCs through specific antibodies prior to infection did not affect 
viral clearance or induction of virus specific CD8 T cells (chapter 2, (48)).  Recently 
however, it was shown that human pDCs did have the potential to cross-present 
viral influenza antigen to CD8 T cells in vitro (5). This concept is worked out in 
chapter 6 of this thesis, where we compared in vitro antigen presenting capacities 
of pDCs and compared it to cDCs following influenza virus infection. Whereas 
pDCs in vitro had a minor antigen presenting capacity to CD8 T cells following 
influenza virus infection, cDCs became much more efficient antigen presenting cells 
(APC). In contrast to earlier reports (49, 51) which demonstrated presentation of 
exogenous antigen to already primed T cells, we demonstrated that apparently due 
to a defective MHCII signaling pathway pDCs did not present exogenous antigen 
to naïve CD4 T cells. In vivo infection, it could still be that we failed to detect APC 
function in lymph node pDCs because we studied the wrong compartment at a 
wrong point in time.  However, it seems that upon influenza virus infection lung 
pDCs (besides the cDCs) mainly accumulate at the site of infection and do not 
direct their interest to the MLN (32). It remains to be shown whether in vivo lung 
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(as opposed to MLN) pDCs present viral derived antigen or not to CD4 or CD8 T 
cells. Also, it could be that pDCs play an important role in contributing to antibody 
production by B cells (11, 52).
Interferon-producing dendritic cells
There has recently been proposed a new member in the mouse DC family, the 
so-called interferon producing killer DC (IKDC) (53-55). This DC subset was 
described in chapter 4 and displays both innate immune functions of NK cells, as 
well as the potential to process and present antigen to naïve T cells (54). Functionally, 
IKDCs have the capacity to kill NK-sensitive target cells without prior activation, 
and induce proliferation of naïve T cells when pulsed with antigenic peptides. By 
contrast, conventional NK cells that lack expression of B220 and MHCII have 
not been identified as antigen presenting cells in the mouse (56). Although the 
existence of the IKDC population would make evolutionary sense, it has been 
controversial whether IKDCs really represent a separate DC lineage or nothing 
else but activated NK cells, endowed with antigen presenting capacity (57-59). The 
latter view is supported by the fact that human NK cells have long been known to 
have APC-like activity (23, 24). In our studies we used 10-color flowcytometry to 
clearly demonstrate the presence of IKDCs following influenza virus infection and 
to distinguish the population from other inflammatory cell types during influenza 
virus infection. These data demonstrated the complexity of defining cell populations 
during an inflammatory state. Phenotypical markers were easily upregulated during 
inflammation, making the use of multi-color flowcytometry indispensable. As 
described above we found evidence for antigen presenting capacities within both 
IKDCs and conventional NK cells during influenza infection.
General conclusion
All together the studies described in this thesis have demonstrated a division of 
labor between DC subsets during influenza virus infection. A critical question 
which might come up in the field of influenza immunology is why so much different 
DC subsets are involved in the immune response to influenza virus infection and 
if it makes sense to divide DCs into functional subsets. For this question we should 
go back in history and make a comparison to T cell biology. In the late 1980s, 
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a revolution occurred in the basis understanding of immunology. The discovery 
that CD4+ T helper cells were not a homogeneous population but could be divided 
into Th1 and Th2 subsets based on their cytokine profiles caused skeptic reactions. 
20 years later the field of T cell subset phenotype and function remains moving 
with the recently demonstrated existence of T regulatory and Th17 cells adding 
extra layers of complexity. Nevertheless this division of T cell subsets is by now 
generally accepted and of big use for the understanding of the immune system. 
The recent division of DCs into various subsets seems to follow the same route-the 
more knowledge we obtain on the function of DCs, the more we find out that these 
functions do not belong to one and the same DC population. Our studies show that 
DC functionality depends on the environment they reside. Viral infections, like 
influenza, will alter this environment and trigger DC populations to fulfil a specific 
role in the immune response. We have clearly shown that this specific role of DCs 
lies beyond just CTL induction. Either by inducing T cell responses, transporting 
antigen or affecting chemokine or cytokine levels, DC subsets contribute to various 
aspects of the immune response against influenza virus infection. Increasing our 
knowledge on functionality of DC subsets will be useful for the design of improved 
influenza vaccines and could increase understanding of why particular strains of 
influenza are more pathogenic than others. 
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Influenza virus
Influenza virus infectie staat in de volksmond beter bekend als “de griep” en wordt 
veroorzaakt door het influenza virus. Niet alleen is dit virus de oorzaak van enkele 
zeldzame pandemiëen uit het verleden, ook de jaarlijkse griep epidemie wordt 
veroorzaakt door varianten van het influenza virus. Deze jaarlijks terugkerende 
epidemiëen hebben een grote impact op de maatschappij, zowel vanuit klinisch als 
economisch perspecief, wat vaak wordt onderschat. 
 Sinds de identificatie van het virus in 1931 zijn er vele ontwikkelingen 
geweest om bescherming tegen het virus te bieden. Tot op heden wordt de voorkeur 
gegeven aan vaccinatie om een influenza virus infectie te voorkomen. Echter, de 
voortdurende genetische en antigene variatie van het virus maken een continu 
wereldwijd toezicht  (screening) op de ontwikkeling van het virus noodzakelijk. 
Zo wordt de variatie van het virus gevolgd en kan hierop geanticipeerd worden 
met de ontwikkeling van het jaarlijkse griep-vaccin. Deze continue screening 
vraagt veel van de betrokken partijen. Daarom is onderzoek naar verbetering van 
bestaande vaccinatie strategiëen, danwel het ontwikkelen van nieuwe strategiëen, 
momenteel een prioriteit in de gezondheidszorg geworden. Voor de ontwikkeling 
van een breed (cross-protectief) vaccin, dat de noodzaak van continue screening 
weg zou kunnen nemen, kan gedacht worden aan aanpassingen in de dosis van het 
vaccin, de manier van toediening, het gebruik van adjuvantia (toevoegingen) of 
zogenoemde “immuun modulatoren”. Naar welke vorm de voorkeur ook uit gaat, 
een uitgebreide en gedetaileerde kennis van de immuun respons tegen het virus is 
essentieel om ontwikkelingen te kunnen maken in het induceren van een gewenste, 
brede immuun respons tegen influenza virussen.
 De immuun respons van het lichaam tegen influenza virussen kan worden 
onderverdeeld in een aspecifiek (aangeboren) en adaptief (specifiek) deel. De 
aspecifieke respons in de long is een acute respons gericht tegen een breed scala 
aan pathogenen. Tijdens deze respons worden veel interferonen geproduceerd 
door zowel geïnfecteerde epitheliale cellen van de long, alveolaire macrofagen 
en door dendritische cellen (DCs). Daarnaast worden tijdens deze acute respons 
natural killer (NK) cellen en DCs aangetrokken naar de infectiehaard. Door deze 
eerste snelle respons heeft het immuun systeem tijd en signalen gehad om de 
(specifieke) adaptieve response op gang te krijgen. Deze adaptieve respons kan 
weer worden onderverdeeld in een B lymfocyten respons en een T lymfocyten 
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respons. B lymfocyten zijn cellen die antilichamen vormen welke virus partikels 
kunnen binden en daarmee infectie van nieuwe cellen kunnen voorkomen. De T 
lymfocyten respons is een cellulaire respons, waarin T lymfocyten het uiteindelijke 
effect bewerkstelligen. Eerst zal echter het virale antigeen gepresenteerd moeten 
worden aan T lymfocyten wat gebeurt door DCs. DCs pikken het virale antigeen op, 
transporteren het en presenteren het aan (naïve) T lymfocyten. Deze T lymfocten 
zullen na herkenning van het antigeen gaan expanderen in een cytotoxische 
T cel (CTL) kloon, welke vervolgens direct (via contact door de T cel receptor) 
geinfecteerde cellen herkennen en elimineren.
 De rol van DCs in zowel de aspecifieke en adaptieve immuun respons is in 
de literatuur beschreven. In dit proefschrift hebben we ons gericht op de functies 
van DCs tijdens influenza virus infectie;  verschillende subtypes DCs in de long 
zijn geïdentificeerd en we hebben getracht hun rolverdeling in de immuun respons 
tegen influenza virus bloot te leggen. Een kritische vraag die zou kunnen opkomen 
is wat nou precies de bijdrage is van een dergelijke onderverdeling aan de influenza 
immunologie. Voor het beantwoorden van deze vraag zouden we een vergelijking 
kunnen maken met ontwikkelingen in de T cel biologie. Eind 80-er jaren werd 
begonnen met het onderverdelen van CD4 T cellen in subtypes, wat aanvankelijk 
sceptische reacties opriep. Tegenwoordig is de onderverdeling van T cellen (in 
Th1,Th2,Treg en recentelijk Th17) algemeen aanvaard en is men zich bewust van 
het nut van deze onderverdeling voor het begrip van het immuun systeem. De 
recente onderverdeling van DCs in subtypes lijkt een zelfde weg te bewandelen; 
hoe meer kennis er wordt verkregen over DC functionaliteit in verschillende ziekte 
modellen, hoe duidelijker het wordt dat deze functies niet aan één en dezelfde DC 
populatie toebehoren.
Dendritische cellen
DCs zijn 25 jaar geleden voor het eerst beschreven door Steinman en zijn collega’s. 
Aanvankelijk werden ze beschreven als een antigeen presenterende cel populatie in 
de milt en lymfeklieren van de muis. De jaren daarop is er veel onderzoek verricht 
naar het fenotype (uiterlijke kenmerken) van deze cellen in verschillende weefsels 
en hun rol in verschillende ziekte modellen. Om de verschillende DC populaties 
in de longen te bestuderen hebben wij gebruik gemaakt van de muis als proefdier 
model, een proefdier dat veel gebruikt wordt in verschillende ziektemodellen. 
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 In de long worden DCs gevonden in de meeste compartimenten, zoals 
het long parenchym, alveoli, pleura, perivasculair en in de long vaten. Net als de 
onverderdeling van DCs in lymfoide organen, worden ook in de long verschillende 
subtypes beschreven. Er wordt een onderverdeling gemaakt in conventionele DCs 
(cDCs) welke het oppervlakte molecuul CD11c tot expressie brengen (dus CD11c+ 
zijn), en plasmacytoide DCs (pDCs). Plasmacytoide brengen de marker CD11c 
middelmatig (CD11cinterm)tot expressie en worden verder gekenmerkt door andere 
specifieke oppervlakte markers, zoals 120G8, PDCA-1, Siglec-H en B220. 
 cDCs in de long worden vervolgens verder onderverdeeld in subpopulaties 
zijnde CD11b+ en CD11b-. In de trachea en de grotere luchtwegen bestaat in “rust” 
een uitgebreid netwerk van intra-epitheliale DCs, welke CD11b- zijn. Deze DCs 
lijken met hun uitlopers sterk op langerhans cellen in de huid en brengen ook 
langerin en CD103 tot expressie.
Migratie en antigeen presentatie van DC populaties in de long
Bij een infectie met het influenza virus worden primair de bovenste luchtwegen 
geinfecteerd. Long cDCs worden door infectie matuur en zullen met het virale 
antigeen naar de lymfeklieren migreren, alwaar het antigeen wordt gepresenteerd 
aan T cellen. In hoofdstuk 2 beschrijven we dat de belangrijkste bron van cDCs 
welke in de lymfeklier aankomen en aldaar het antigeen presenteren, de langerhans-
achtige CD11b- DCs uit de bovenste grote luchtwegen zijn. Nadat deze CD11b- DCs 
gemigreerd zijn is er een nieuwe influx van DCs, welke zijn getriggerd door het 
influenza virus. Dit zijn CD11b+ DCs en worden inflammatoire DCs genoemd. 
 Het antigeen presenterend vermogen van de verschillende DC populaties 
in de lymfeklier werd bestudeerd door gebruik te maken van een recombinant 
virus, waar het ovalbumine (OVA) eiwit is ingebouwd. DC populaties werden 
na infectie met het recombinant OVA-influenza virus mechanisch gesorteerd 
uit lymfeklieren van de geïnfecteerde muizen. Vervolgens werden ze in kweek 
gezet met CD4 of CD8 T cellen specifiek gericht tegen het OVA antigeen. Indien 
een DC populatie de capaciteit zou hebben om viraal antigeen te presenteren, 
zouden de T cellen geactiveerd worden waardoor ze zouden gaan delen. De mate 
van T cel deling is daardoor een maat voor het antigeen presenterend vermogen 
van de DCs. Een duidelijke taakverdeling werd met deze methode aangetoond. 
CD11b- DCs stimuleerden zowel CD4 als CD8 T cellen, terwijl CD11b+ DCs in 
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alle gevallen slecht het antigeen konden presenteren. Dit duidt erop dat in een 
enkele CD11b- DC populatie  het virale antigeen kan worden opgepikt, verwerkt 
wordt en gepresenteerd wordt. Dit is in tegenspraak met wat eerder is aangetoond 
in de milt en lymfeklieren. CD11b- DCs kunnen verder worden onderverdeeld in 
CD8α+ en CD8α- DCs. CD8α+ DCs zijn resident in de lymfeklier en zullen het 
antigeen moeten verkrijgen van DCs afkomstig van het geïnfecteerde gebied. Door 
het aankleuren van viraal antigeen in DC subsets suggereren onze studies dat 
zowel pDCs als CD11b-CD8α- DCs uit de hogere luchtwegen het virale antigeen 
transporteren naar de lymfeklier.
Transgene muis modellen
Naast bovenstaande beschreven methode voor het aantonen van antigeen 
presenterend vermogen van DC subpopulaties, is er een manier om functionaliteit 
van DCs te bestuderen. We hebben daarvoor in hoofdstuk 2 gebruik gemaakt 
van transgene muismodellen. In deze muizen konden DCs specifiek worden 
gedepleteerd (verwijderd) door gebruik te maken van cel specifieke genetische 
target-strategiëen. Een receptor voor diphterie toxine (DTR) is in deze muizen 
geplaatst voor de CD11c promotor. Muizen zijn normaal gesproken niet gevoelig 
voor diptherie toxine (DT) omdat ze deze receptor niet hebben. In transgene 
CD11c-DTR muizen zal behandeling met DT echter leiden tot een specifieke 
depletie van CD11c+ cellen. Een andere transgene muis die we hebben gebruikt 
is de langerin-DTR muis, welke gebaseerd is op het zelfde principe, maar waarin 
specifiek depletie van langerin+ cellen wordt bewerkstelligd.
 Eerst zijn in de transgene muizen uitvoerige analyses gedaan naar de cel 
populaties die verdwijnen na lokale toedienening van DT (in de long). Vervolgens 
zijn de muizen zonder respectievelijk CD11c+ cellen of langerin+ cellen, geïnfecteerd 
met influenza virus. Het verloop van de infectie werd nauwkeurig gevolgd en de 
imuunrespons werd in kaart gebracht. In CD11c-DTR werden door DT toediening 
alle CD11c+ DCs gedepleteerd, maar bleven de CD11b-CD8α- DCs uit de hogere 
luchtwegen intact. Infectie van deze muizen verergerde de infectie aanzienlijk, wat 
ondermeer was af te lezen uit het toegenomen gewichtsverlies van de muizen na 
infectie. Immuun parameters waren aangetast: een verminderde virus specifieke 
CTL respons, minder cytokine productie en het virus dat minder snel geklaard 
werd uit de longen. Om te bewijzen dat dit alles het gevolg was van afwezige CD11c+ 
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DCs (en niet van bijvoorbeeld macrofagen welke ook CD11c tot expressie brengen), 
werd er ter controle een experiment uitgevoerd waarin na behandeling van DT (en 
CD11c+ DCs dus weg waren uit de long), CD11c+ DCs werden teruggegeven. Het 
teruggeven van deze DCs herstelde de imuunrespons en dit toonde de specifieke 
noodzaak van DCs in de imuunrespons aan.
 Zoals beschreven bleven in de CD11c-DTR muizen de CD11b-CD8α- DCs 
intact. Omdat onze eerdere (antigeen presentatie) studies een belangrijke rol voor 
deze cellen impliceerden, besloten we een model te gebruiken waarin specifiek deze 
populatie uit de long kon worden gedepleteerd. Daarvoor werden langerin-DTR 
muizen gebruikt. Analyses in deze muizen toonden een specifieke depletie aan van 
mucosale CD11b-CD8α-CD103+langerin+ DCs in de hogere luchtwegen, terwijl alle 
andere populaties intact bleven. Depletie van deze DCs gedurende influenza virus 
infectie verergerde het verloop van de infectie dramatisch, wat een duidelijke rol 
voor deze DCs in influenza virus infectie aantoont. 
Inflammatoire dendritische cellen
Zoals beschreven worden CD11b+ DCs in de long tijdens en na influenza virus 
infectie ook wel inflammatoire DCs genoemd. Deze DCs konden het antigeen 
niet efficiënt presenteren, dus was de vraag wat dan wel de bijdrage van deze DC 
populatie aan de immuunrespons tegen het influenza virus is. In hoofdstuk 4 
hebben we met behulp van immuunhistochemie de CD11b+ DCs gelocaliseerd die, 
nadat het influenza virus was geklaard, nog in grote getale in de long aanwezig 
waren. CD11c+CD11b+ DCs werden gevonden in gebieden van B en T cellen. In de 
literatuur worden dergelijke B en T cel aggregaten beschreven als iBALT (inducible 
bronchus associated lymphoid tissue). iBALT is een georganiseerd agregaat van B 
en T lymfocyten met DCs erin en heeft de structuur van een lymphoide orgaan. 
 iBALT valt onder de zogenoemde tertiaire lymphoide organen, welke 
worden geïnduceerd door infectie of locale chronische ontsteking. Hoewel DCs 
altijd aanwezig zijn in deze structuren was hun exacte rol tot nu toe nog niet 
bekend. In hoofdstuk 5 hebben wij aangetoond dat CD11b+ DCs in de long nadat 
influenza virus infectie geklaard is (17 dagen na infectie), zich bevinden in iBALT. 
Door depletie van deze DCs in CD11c-DTR muizen op 17 dagen na infectie vallen 
de lymphoide structuren uiteen. Dit heeft effecten op zowel de locale immuniteit 
als de systemische immuniteit. Naast het feit dat de B cellen in iBALT namelijk 
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lokaal antilichamen produceren, werden er na het uiteenvallen van iBALT ook 
systemische veranderingen aangetoond. Virus specifieke imuun globulines in 
serum namen af en ook virus specifieke plasma cellen in het beenmerg waren 
verminderd. Deze “long-lived” plasma cellen in het beenmerg zijn een belangrijke 
bron voor virus specifieke imuun globulines in het serum. Dit impliceert dat enkele 
weken nadat de infectie geklaard is, de formatie van “long-lived” plasma cellen 
in het beenmerg afhankelijk is van een continue input van B cellen uit iBALT. De 
vraag blijft natuurlijk hoe DCs iBALT nu precies controleren. Dit is niet door een 
continue antigeen presentatie aan omliggende lymfocyten, maar CD11b+ DCs zijn 
belangrijke producenten van chemokines en cytokines die B cellen op hun plek 
houden en iBALT organiseren.
Plasmacytoide dendritische cellen
pDCs staan in de literatuur bekend als belangrijke producenten van type 1 
interferonen. Hoewel wij deze functie bevestigd hebben tijdens influenza virus 
infectie, lijkt bij depletie van pDCs (door antilichamen) tijdens influenza virus 
infectie deze rol overgenomen te worden door andere cel types (als epitheliale 
cellen en alveolaire macrofagen). Verder migreren pDCs gedurende een influenza 
virus infectie naar de lymfeklier, maar hun contributie aan het presenteren van 
antigeen lijkt nihil (hoofstuk 2 en hoofdstuk 5), waarschijnlijk door een defect in 
de pDC machinerie dat het antigeen verwerkt. Dit alles leidt er toe dat depletie van 
pDCs tijdens influenza virus infectie het verloop van de infectie niet beïnvloedt. 
Een opmerkelijke bevinding was echter dat de hoeveelheden virus specifieke 
antilichamen in muizen waarin pDCs waren gedepleteerd tijdens infectie, lager 
zijn t.o.v. muizen die wel pDCs hadden. Dit wijst op een mogelijk interactie tussen 
pDCs en B cellen die nader onderzocht dient te worden.
Interferon-producerende dendritische cellen
Interferon producerende dendritische cellen (IKDCs) zijn een zeer recent 
beschreven subtype van DCs. In hoofdstuk 3 tonen wij voor de eerste keer deze 
DCs aan in de long tijdens influenza virus infectie en we hebben met uitgebreide 
flowcytometrie kleuringen de verschillen getoond tussen IKDC an andere celtypes 
tijdens influenza virus infectie. We hebben kunnen bevestigen dat deze IKDCs 
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zowel functies van NK cellen hebben (het direct doden van virus geïnfecteerde 
cellen) als DCs (antigeen presentatie). Echter moet worden opgemerkt dat ook 
“reguliere” NK cellen tijdens influenza virus infectie een antigeen presenterend 
vermogen verkrijgen.
Slot conclusie
De studies beschreven in dit proefschrift tonen de rolverdeling aan tussen DC 
subtypes in de long tijdens een influenza virus infectie. De studies demonstreren dat 
het onderverdelen van DCs in subtypes niet een vorm van “postzegels verzamelen” 
is, maar een onderverdeling naar functionaliteit. Functionaliteit van DCs lijkt 
afhankelijk te zijn van de omgeving waarin ze verkeren. Virale infecties door 
bijvoorbeeld het influenza virus, zullen deze omgeving veranderen en DCs prikkelen 
om bepaalde specifieke functies te verrichten, zoals antigeen presentatie, transport 
van antigeen of productie van chemokines en cytokines. De verworven kennis over 
DC functionaliteit zal toepasbaar zijn bij het ontwikkelen van verbeterde influenza 
vaccins, maar draagt tevens bij aan het inzicht in pathogeniteit van verschillende 
influenza virussen.
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